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Abstract 
Artemisinin-derived endoperoxide drugs find widespread employment as frontline 
treatment against malaria. Although evidence of their potential to express toxicity within a 
clinical setting remains limited, outcomes derived from animal studies attest their ability to 
induce neurological and developmental toxicity in mammalian systems. Activity is further 
demonstrated in vitro within rapidly proliferating human cells – most notably those 
belonging to immortalised, cancer-derived lines – with significant cytotoxic effects being 
observed upon drug treatment across a range of settings. It is believed that these find their 
origin through a mechanism dependent upon Fe(II)-mediated reduction of the 
endoperoxide bridge functionality, culminating in molecular bioactivation and the 
subsequent formation of carbon-centred free radical species which in turn, owing to their 
great reactivity, impart deleterious effects upon cellular functioning. Evidence suggests that 
dysfunction of the mitochondrion and the formation of reactive oxygen species (ROS) are 
key stages in the route through which artemisinin derivatives are able to induce death.  
The characteristics of artesunate-stimulated impact upon mitochondrial functioning are 
examined. It is demonstrated that culturing of cells in the presence of galactose enhances 
cytotoxic potential within the HeLa line. The magnitude of this variation in sensitivity is 
indicative that targeting of the mitochondrion affords a route through which activity is 
mediated. Falls in cell viability are further preceded by declines in ATP production, 
providing evidence that disruption of oxidative phosphorylation occurs as an early event in 
the route towards death. Studies performed on mitochondrial bioenergetic function using 
the Seahorse XF analyser indicate that artesunate imparts dose-dependent and time-
dependent decreases in respiratory reserve capacity and oxidative phosphorylation 
coupling efficiency, whilst stimulating a switch towards glycolytic energy production.  
Attempts to delineate the root causes of these effects are focused upon examining the 
relationship between oxidative stress, Fe(II) content and mitochondrial performance. The 
mitochondrially-localised antioxidant tiron and the lysosomal Fe(II) chelator 
desferrioxamine are shown to induce substantial cytoprotective effects against artesunate 
within the HeLa line. Evidence derived from Seahorse XF analysis indicates strongly that 
these outcomes are related to the capacity of both compounds to abrogate drug impact 
upon the functions of the mitochondrion. It can thus be posited that mitochondrial damage 
has its origins in the emergence of oxidative stress, with Fe(II) content acting as key 
determinant in its progression. The outcomes of further examinations performed within the 
ρ0 HeLa line suggest an origin for ROS emergence independent of the respiratory chain. 
In order to test the hypothesis that artemisinin derivatives might induce direct peroxidation 
of the mitochondrial phospholipid cardiolipin, the impact of a cytochrome c peroxidase 
inhibitor TPP-IOA is examined on the response of HeLa and HL-60 cells towards artesunate 
treatment. Results indicate that the inhibitor has variable effects upon cardiolipin oxidation 
state and subsequent cell survival, leaving doubt as to the true validity of such a 
connection. As a further study, the cytotoxic capacities of a range of novel artemisinin-
derived anticancer agents and wholly synthetic tetraoxane and trioxolane antimalarials are 
given assessment.  
In conclusion, it can be stated that the outcomes of the studies performed in this thesis 
emphasise the importance of mitochondrial liability towards the progression of artemisinin-
induced cell death. Further insights into the mechanistic routes through which drug 
administration contributes, via oxidative stress and free Fe(II) content, to the defective 
functioning of the organelle have been achieved. 
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1.1. Introduction  
 
Artemisinin-derived endoperoxide drugs are routinely employed as frontline treatment in 
the fight against malaria. Their use in combination regimens provides highly effective 
therapy against parasite strains displaying resistance to other drug classes (WHO, 2010). 
Despite their high therapeutic efficacy and excellent safety profile within a clinical setting, 
concerns regarding their administration have emerged as a consequence of evidence 
outlining their ability to induce toxicity across animal models (Efferth et al., 2010). It has 
now become established that these compounds possess significant levels of activity against 
proliferating mammalian cells, such as those found within cancer cell lines (Firestone et al., 
2009). Research has demonstrated that such effects occur as a consequence of an ability to 
induce the formation of reactive oxygen species (ROS) and apoptotic cell death through a 
mechanism held to be dependent upon mitochondrial dysfunction (Mercer et al., 2011; 
Mercer et al., 2007). Within this chapter, current understanding as to the route through 
which these drugs are believed to impact upon cell function shall be given detailed review, 
in order to provide background and context for the studies into the mechanistic aspects of 
their activity which shall be presented in this thesis. 
1.2. Discovery of Artemisinin  
 
Artemisinin (1), known alternatively as qinghaosu, is a sesquiterpene lactone compound 
characterised by the presence of an endoperoxide bridge functionality. Occurring naturally 
within the leaves of the wormwood Artemisia annua, it has for millennia been used in 
Chinese folk medicine for the treatment of fevers and other maladies (Cui et al., 2009).  Its 
employment against malaria has been described in literature dating back to the fourth 
century AD, with the purported efficacy of Artemisia annua preparations being attested in 
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numerous medical manuscripts. The earliest modern, scientific assessments into the clinical 
antimalarial effectiveness of the plant were performed during the late 1960s as part of a 
scheme by the Chinese government to develop novel modes of treatment for the disease. 
Having emerged as the lead amongst an array of other traditional therapies examined, by 
1972 work performed by the group of Tu YouYou had led to the identification, 
characterisation and isolation of artemisinin as the active antiparasitic compound (Tu, 
2011). Purified directly from leaves at a low initial yield, its promising activity in early in vivo 
investigations led to its eventual employment in a clinical setting. 
1.3. Artemisinin the Antimalarial 
 
1.3.1. Disease Profile of Malaria 
 
Malaria is a disease which occurs as a consequence of infection by protozoal parasites of 
the genus Plasmodium. Carried and transmitted by mosquitoes, it constitutes a major 
health risk across the tropical and subtropical regions throughout which it is endemic. It is 
estimated that in excess of 200 million cases are reported annually worldwide, with roughly 
half a million of these culminating in fatality (WHO, 2010). Instances of malaria are 
classified as either severe or uncomplicated, with progression of the disease dictated 
through factors related both to the general health status of the patient and to the identity 
of the parasite responsible for the infection. Severe malaria is associated overwhelmingly 
with the species P. falciparum, which constitutes the most prevalent Plasmodium form. P. 
malariae, P. ovale, P. knowlesi and P. vivax are encountered with smaller frequency, and 
result generally in a milder, uncomplicated variety of the illness. 
Typically, the anopheles mosquito functions as the transmission vector for Plasmodium. 
Entry into man results from the bite of the female as it takes up a blood meal, injecting the 
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parasite within its saliva. Development of the condition occurs alongside the changes 
associated with the parasitic life cycle following transferral to the bloodstream. At the 
earliest phase, infective sporozoites locate to hepatocytes, where they reproduce asexually 
to form merozoites. The release of these merozoites precedes their entry into ethyrocytes, 
where they commence a multiplication process culminating in the destruction of the cell 
and a continuation of the cycle of infection and reproduction. Symptoms of malaria are 
usually noted 7 – 14 days following initial infection, passing first through stages of general 
malaise and illness before developing into characteristic paroxysmal fevers. In instances of 
severe disease, complications including anaemia, cerebral malaria and renal failure – any of 
which may be fatal – are often observed within the patient. 
 
1.3.2. Antimalarial Treatment   
 
Quinine, a naturally-occurring alkaloid prevalent in the bark of Cinchona, was the earliest 
antimalarial to find common use within the West. Its structure forms the basis of the class 
of synthetic agents referred to as quinolines, which contain the widely-employed 
antimalarials chloroquine, mefloquine and amodiaquine. Their common mechanism of 
action is believed to be centred upon disruption of the parasite feeding process within red 
blood cells (Foley et al., 1998). The degradation of haemoglobin is necessary for the 
obtaining of amino acids required for growth, although the toxicity of haem Fe(II) towards 
Plasmodium warrants the crystallisation of this species into non-toxic hemozoin. Quinolines 
act to prevent the formation of this hemozoin, causing parasite death through the eventual 
harmful accumulation of haem Fe(II) (Loria et al., 1999). 
The safety, efficacy and cost-effectiveness of chloroquine led to its emergence as frontline 
treatment against malaria. A growth in parasite resistance contributed to a fall in the 
effectiveness of both this and other quinoline compounds, prompting the development of 
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combination therapies centred upon drug classes with variant mechanisms of action (Hyde, 
2002). Favourable treatment outcomes have been witnessed upon the co-administration of 
antifolates such as sulphadoxine and pyrimethamine, and although resistance to this 
combination has itself developed, it continues to find use alongside other agents (WHO, 
2010). An alternative route through which treatment might be used in order to lower the 
threat of acquiring malaria is that of suppressive prophylaxis (Freedman, 2008).  Regimens 
incorporating drugs such as the tetracycline antibiotic doxycycline, which act upon the 
parasite erythrocytic phase, are administered over a period extending both prior to and 
following the risk of disease exposure. 
1.3.3. The Development of Artemisinin as Antimalarial Therapy 
 
Although artemisinin had been identified for its antimalarial efficacy by the early 1970s, 
knowledge of its discovery was slow to emerge from out of the closed Chinese state. 
Difficulties associated with the poor solubility of the isolated compound across water-based 
and organic-based systems spurred within China the development of the semi-synthetic 
derivatives which have since found widespread clinical use (Klayman, 1985). 
Functionalisation of dihydroartemisinin (DHA) (2), formed from lactone reduction of the 
natural product, led to the creation of the familiar drugs artemether (3), arteether (4) and 
artesunate (5) (Meshnick et al., 1996). Metabolism of these compounds in vivo occurs 
primarily through means of oxidation mediated by cytochrome P450 enzymes CYP 2B6 and 
CYP 3A4, serving to yield DHA as the active antiparasitic agent (Aweeka et al., 2008). Rapid 
rates of clearance are apparent within man, with elimination occurring at half-lives typically 
of the order 2 – 5 hours (Benakis et al., 1997). Levels of plasma protein binding are 
observed to be elevated, with the bound drug fraction estimated to account for greater 
than 90% of that in general circulation (Sidhu et al., 1997). Administration of the drugs may 
proceed through oral, rectal or intramuscular routes.  Artesunate, furthermore, owing to its 
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enhanced water solubility, may be given intravenously within a sodium salt formulation. 
Capable of providing rapid action against severe P. Falciparum malaria when delivered in 
such a manner, it remains generally the preferred treatment option in instances where 
acute remedy is required (Newton et al., 2006). 
 Twenty years following the initial characterisation of artemisinin, reports into its properties 
had spread outside of China. During the mid-1990s, the first-generation derivatives were 
assessed in large-scale trials by European drug companies for their potential employment 
upon the global market (Faurant, 2011). Although they were shown to be highly effective in 
monotherapy, it was apparent that enhanced clinical efficacy and reduced sensitivity 
towards parasite resistance could be attained through their use in combination with other 
drugs. Numerous artemisinin combination therapy (ACT) regimens have since been 
developed, exploiting the varying modes of antimalarial action across several other 
therapeutic classes (Sinclair et al., 2009). Artesunate is recommended for use alongside 
either of the quinolines mefloquine or amodiaquine, and it may also be administered 
accompanied by the antifolate combination sulphadoxine-pyrimethamine (Eastman et al., 
2009). Artemether and lumefantrine, as well as dihydroartemisinin and piperaquine, have 
also found clinical employment. Such partnerships exploit the comparatively lengthy half-
lives of the compounds accompanying artemisinin in order to facilitate the advancement of 
dosing regimens which typically function to enable successful therapeutic resolution 
following three-day treatment courses (Nosten et al., 2007). 
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ACT is now considered the first line of treatment against P. Falciparum malaria. Artemisinin 
derivatives have been found to exhibit a general absence of clinical toxicity in man, 
accompanied by a high level of efficacy against parasite strains displaying broad resistance 
towards other drug classes (Park et al., 1998; WHO, 2010). Whilst isolated reports of 
localised resistance have emerged in the literature, confinement of their use to 
combination strategies has prevented the emergence of significant spread.  
 
1.3.4. Mechanism of Artemisinin Antimalarial Action 
  
Although the precise mechanism through which artemisinin exerts its antiparasitic effects 
has not been definitively established, it is apparent that the presence of the endoperoxide 
bridge is a necessary feature for its activity (O'Neill et al., 2004). It has been demonstrated 
10 
 
conclusively, through studies performed with compounds such as deoxyartemisinin (6), that 
removal of this functionality deprives the compound of antimalarial properties (Klayman, 
1985). It is commonly held that sources of chelatable and haem-bound Fe(II) are 
responsible for activating the molecule through reduction of the bridge, inducing the 
structural changes which lend it biological action (Mercer, 2009). 
A number of potential routes through which artemisinin might induce the onset of parasite 
death have been identified. Research has demonstrated the ability to target several areas 
of Plasmodium function, ranging from the activities of enzymes such as the 
Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) PfATP6, to pathways related to the 
detoxification of haem (O'Neill et al., 2010b). Elevated oxidative stress and dysfunction of 
the mitochondrion have been observed additionally in several studies (Firestone et al., 
2009). It is currently uncertain as to whether antimalarial activity is mediated through 
impact upon a single target, or whether it arises as a consequence of simultaneous action 
upon several.  It is widely believed that the mechanism of drug action is dependent upon 
Fe(II) activation. The relationship between the chemistry of artemisinin bioactivation and 
therapeutic activity shall now be considered with reference to each of its postulated 
targets. Alternative, Fe(II)-independent theories as regards to drug action also exist within 
the literature. A consideration of these shall additionally be presented 
 
1.3.4.1. Endoperoxide Bioactivation and Carbon-Centred Radical Species 
 
The endoperoxide bridge is identified as the key pharmacophoric and toxicophoric group 
within artemisinin-derived compounds. It has traditionally been held that the formation of 
reactive carbon-centred radicals is of central importance towards antiparasitic activity. 
Studies into its chemistry have elucidated routes through which Fe(II)-mediated reduction 
induces bioactivation of the molecule and the formation of free radical species (Fig. 1.1.) 
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(Haynes et al., 1996; Wu et al., 1998). Interaction of Fe(II) with the bridge may commence 
through association between the metal ion and either of the two constituent oxygen 
atoms. Reaction with oxygen 1 has been shown to proceed via the oxyl radical intermediate 
(1a), before a rearrangement through C-C scission culminates in the generation of the 
primary carbon-centred radical (1b). Alternatively, it has been demonstrated that the initial 
interaction between Fe(II) and oxygen 2 grants formation of the oxyl radical (1d), which 
furnishes secondary carbon-centred radical species (1e) courtesy of 1,5 hydrogen-shift. In 
each instance, further progression to the stable products (1c) and (1f) is possible.  Many of 
the proposed intermediates in these mechanisms have been identified through electron 
paramagnetic resonance (EPR) studies employing spin-traps (O'Neill et al., 2000). 
 
 
Figure 1.1. Proposed mechanism carbon-centred radical formation through Fe(II)-
mediated endoperoxide bridge bioactivation. Adapted from Mercer et al., 2007. 
 
Although it was initially believed that haem Fe(II) within the parasitic food vacuole 
functioned as the reducing source for these degradations, the antagonistic effect of the 
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chelator desferrioxamine (DFO) towards antimalarial activity has suggested an additional 
activatory role for free Fe(II) (Stocks et al., 2007).  
 
1.3.4.2. Endoperoxide Bioactivation and the Open Peroxide Model 
 
As an alternative to the carbon radical theory, it has been postulated that endoperoxide 
bridge activation proceeds via a mechanism reliant upon ionic ring opening. According to 
this hypothesis, Fe(II) functions as a Lewis acid, donating an electron to either of the 
constituent oxygen atoms and initiating the splitting of the bridge (Fig. 1.2.) (Haynes et al., 
2007; Haynes et al., 1999; Olliaro et al., 2001). The resulting zwitterion (1g) may react with 
a water molecule, generating reactive hydroperoxide species (1h) capable of direct 
oxidation of protein residues. It is additionally forwarded that such an intermediate may 
participate in Fenton-style reactions to produce quantities of the hydroxyl radical OH•. 
Further decomposition routes culminate in the formation of the secondary carbon-centred 
radical (1e) and the deoxyartemisinin (1i). 
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Figure 1.2. Bioactivation of the endoperoxide bridge and subsequent radical formation in 
the open peroxide model. Adapted from O’Neill et al., 2010. 
 
Along with the carbon-centred radical species described previously, these decomposition 
products are hypothesised as being involved in the process of parasite killing. Their 
reactivity is believed to afford them the ability to alkylate biologically active molecules, 
inducing alterations in structure which render them and the pathways dependent upon 
them dysfunctional (O'Neill et al., 2010b).  
 
1.3.4.3. Artemisinin and Haem Targets 
 
The formation of haem-artemisinin adducts has been demonstrated to occur in biomimetic, 
in vitro and in vivo systems (Cazelles et al., 2001; Robert et al., 2005; Yang et al., 1994). 
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Structural modifications arising from drug alkylation are identified at the α, β and δ carbon 
atoms of the haem prosthetic group (Robert et al., 2001). Whilst this evidence attests to 
the capacity of artemisinin-derived radical species to form molecular conjugates, it does not 
provide indication that such modifications are of direct pharmacological relevance. 
Accordingly, whilst a link between haem adduction and the inhibition of hemozoin 
formation might appear feasible, conclusive evidence supporting such a hypothesis has yet 
to be produced. Adduct formation is further known to occur in parasite haemoproteins, 
including catalase and cytochrome c, although once again consequences as regards to drug 
activity remain undefined (Yang et al., 1994). 
 
1.3.4.4. Artemisinin and Thiol Targets 
 
An ability to induce the alkylation of thiol groups has been confirmed, prompting 
examination into interaction between artemisinin and cysteine-containing proteins (Wu et 
al., 2003). The adduction of albumin has been demonstrated, mediated through drug 
interaction with both cysteine and amino residues (Yang et al., 1993). Interference with the 
function of the papain cysteine proteases, employed by parasites for the purposes of 
haemoglobin degradation, has additionally been identified as a means through which 
antimalarial activity might be exerted (Liu et al., 2011b). 
 
1.3.4.5. PfATP6 and Artemisinin  
 
PfATP6, the parasitic analogue of the endoplasmic reticulum calcium ATPase SERCA, is 
recognised as a target for artemisinin. An ability to inhibit the activity of the enzyme was 
demonstrated through a study in which expression of the coding gene was amplified within 
frog eggs (Eckstein-Ludwig et al., 2003). Abrogation of drug inhibitory effects was achieved 
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through the co-administration of the iron chelator DFO, suggesting Fe(II) activation as a 
required mechanistic feature. The relevance of any artemisinin-induced impairment in 
PfATP6 function towards parasitic survival remains unclear. Whilst altered calcium 
homeostasis has been observed within Toxoplasma gondii, effects upon endoplasmic 
reticulum morphology have been shown to be considerably smaller than those induced 
through the more potent SERCA inhibitor thapsigargin (Jones-Brando et al., 2006; O'Neill et 
al., 2010b). More recent evidence has cast additional doubts over the ability of artemisinin 
to fully affect enzymatic function, ensuring that any potential role for it in explaining 
antimalarial efficacy remains controversial (Arnou et al., 2011). 
  
1.3.4.6. Artemisinin-Induced Oxidative Stress 
 
Increases in oxidative stress have been indentified upon artemisinin treatment. As shall be 
discussed later, it is well established that the formation of ROS is central to the mechanism 
of cytotoxicity in mammalian systems (Mercer et al., 2010). Varying hypotheses regarding 
means of onset and importance towards parasite killing have been posited. Following the 
initial observation of a link between drug administration and the emergence of lipid 
peroxidation, it has been suggested that such modifications might produce deleterious 
effects upon the parasite through inducing injury within the food vacuole (Berman et al., 
1997; del Pilar Crespo et al., 2008). A potential chemical explanation for this event has been 
ventured courtesy of a proposed mechanism reliant upon carbon-centred radical-mediated 
hydrogen abstraction at unsaturated lipid chains, culminating in the formation of peroxides 
upon interaction with oxygen (Fig. 1.3.) (O'Neill et al., 2004).  
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Figure 1.3. Peroxidation of lipids through artemisinin-derived radical species. Adapted 
from O’Neill et al., 2004. 
 
The open peroxide model of Fe(II) activation, discussed previously, also provides insight 
into a route through which the production of ROS might arise. Aside from involvement in 
the alkylation of amino acid residues, it is theorised that the hydroperoxide (1h) 
participates in Fenton reactions alongside Fe(II), generating the extremely reactive hydroxyl 
radical (O'Neill et al., 2010b).  
 
1.3.4.7. Radical-Independent Theories of Artemisinin Activity  
 
An alternative theory as to the mode of action of artemisinin has been presented, which 
eschews the conventional hypotheses regarding the importance of bioactivation and the 
generation of reactive radical species, and emphasises ability to induce enhanced oxidative 
stress levels through an Fe(II)-independent mechanism (Haynes et al., 2004). It holds that 
antiparasitic activity is derived from drug interference with the functioning of cofactors 
necessary for the maintenance of redox homeostasis. Specifically, this is believed to be 
mediated through a direct oxidation of the reduced flavins, such as FADH2, which are 
required for the regeneration of the antioxidant glutathione (Haynes et al., 2011). A 
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tentative chemical mechanism along which this might progress with artemether in a 
biomimetic setting is outlined in Figure 1.4. It is proposed that depletion of reduced 
antioxidant stock results in the inability of parasitic cells to detoxify ROS, causing eventual 
death. Evidence supporting this supposition is derived from biomimetic studies, which 
outline the capacity of artemisinin to induce the direct oxidation of the antimalarial drug 
leucomethylene blue (Haynes et al., 2010). It is noted that Fe(II) is not essential for any such 
reaction to occur, prompting the suggestion of alternative activation mechanisms. 
 
 
Figure 1.4.  Suggested mechanism through which direct, artemether-induced oxidation of 
the reduced cofactor FADH2 might occur within a biomimetic environment. Adapted from 
Haynes et al., 2010. 
 
In this model, the formation of carbon-centred radicals is not believed to be relevant 
towards the mechanism of drug activity. Fe(II)-mediated degradation of artemisinin is 
considered a side reaction, with its products possessing no pharmacological impact (Haynes 
et al., 2004). It is held that the enhancement of parasiticidal effects in the presence of Fe(II) 
derives from its participation in Fenton chemistry, and is a product of a growth in existing 
levels of ROS. Although chemical studies point to the feasibility of Fe(II)-independent routes 
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to artemisinin activity, evidence supporting the tenets of this hypothesis has yet to emerge 
in either in vitro or in vivo systems. 
 
1.3.4.8. Artemisinin and the Mitochondrion 
 
Morphological alterations to the parasitic mitochondrion have been observed upon drug 
administration, suggesting a function for the organelle either as a source of artemisinin 
activation or as a target for its effects (Golenser et al., 2006; Jiang et al., 1985). The 
mitochondrion itself is recognised as the primary site for the generation of ROS, and it has 
been demonstrated that its depolarisation occurs in both parasitic and yeast models upon 
artesunate and DHA treatment through a mechanism reliant upon oxidative damage and 
the presence of Fe(II) (Li et al., 2005; Wang et al., 2010). Whether the formation of ROS 
might itself have a mitochondrial origin remains a topic of controversy, with the reports 
conflicting as to the capability of the drugs to induce defective functioning within the 
constituent complexes of electron transport chain. Despite the lack of definitive evidence, 
impairment can be considered a theoretical possibility owing to the prevalence of 
haemoproteins and Fe(II)-S clusters within this system. Owing to inconsistent study 
outcomes, it has yet to be established conclusively if such events are an early occurrence in 
the induction of cell death, or if they arise instead downstream subsequent to initial 
functional defects occurring elsewhere (del Pilar Crespo et al., 2008). 
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1.4. The Activity of Artemisinin in Mammalian Cells 
 
Artemisinin and its derivatives are identified as possessing activity across a range of 
mammalian systems. Their ability to impart deleterious effects upon both cellular and 
broader physiological functioning has been attested over an array of studies both in vitro 
and in vivo. The potential for these compounds to exert cytotoxicity effects was first 
demonstrated in investigations assessing their activity against Ehrlich ascites tumour cells 
(Woerdenbag et al., 1993). Low micromolar IC50 values were noted for each drug examined, 
with the cytotoxicity of the semi-synthetic compounds DHA, artemether, arteether and 
artesunate each greater than that of their parent.  Further examination confirmed that such 
effects were, as with antimalarial properties, dependent upon the presence of the 
endoperoxide bridge (Beekman et al., 1997). Early hypotheses as to the mechanisms 
through which drugs effects were being exerted suggested that the inhibition of cell growth 
was of primary importance (Beekman et al., 1996). 
 
1.4.1. In-Vivo Artemisinin Toxicity 
 
1.4.1.1. Artemisinin and Neurotoxicity  
 
Neurotoxicity arising from artemisinin treatment has been noted to occur across animal 
models. Prolonged administration in dogs, rats, mice and monkeys is associated with the 
emergence of potentially fatal damage to the central nervous system (Brewer et al., 1994; 
Toovey, 2006). In vivo studies performed within neuronal cell lines have outlined the onset 
of ROS generation, associated with mitochondrial dysfunction, as occurring in response to 
dosing with the drugs (Schmuck et al., 2002). The potential for a link between artemisinin 
and onset of neurotoxicity within man has remained controversial (Efferth et al., 2010). 
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Isolated reports of ataxia and ototoxicity in response to malaria treatment have not been 
credited as providing definitive evidence of the ability of the drugs to impair neurological 
function, since cerebral malaria may form a confounding factor in the establishment of such 
a relationship (Newton et al., 2000). Mild, reversible impairment of auditory function 
following employment in combination with lumefantrine is identified across several clinical 
studies, albeit inconsistently (Hutagalung et al., 2006; Toovey, 2006), 
 
1.4.1.2. Artemisinin and Developmental Toxicity 
 
Persistent reports of embryotoxicity in animal studies have prompted the World Health 
Organisation (WHO) to recommend that the use of artemisinin derivatives be forbidden in 
mothers during the opening trimester of pregnancy (WHO, 2006). Artemisinin treatment 
has been found to be associated with the emergence of teratogenicity, embryo death and 
resorption in rats, rabbits and monkeys (Clark et al., 2008; Clark et al., 2004). Observation 
of anatomical defects within these impaired embryos revealed abnormalities in skeletal and 
cardiovascular development, with such effects being noted alongside an absence of toxicity 
in the mothers. Further in vitro studies performed in cultured rat embryos have allowed for 
a closer assessment of the routes through which the drugs affect development. The 
administration of DHA was found to impact significantly upon the process of 
haematopoiesis within the yolk sac, leading to depletion of embryonic erythrocytes (Longo 
et al., 2006; White et al., 2006). It is hypothesised that defects such as the malformation of 
the skeletal and the cardiovascular systems might arise as a consequence of the anaemia 
and hypoxia occurring subsequent to the lowering of red blood cell population 
(D'Alessandro et al., 2007). These embryonic erythrocytes are cells rich in both haem and in 
free Fe(II), identifying them as potential sites for artemisinin activation.  
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The toxicity witnessed in these systems has yet to be found to translate to humans within a 
clinical setting. Studies, albeit limited in scope, have indicated that the artemisinin 
derivatives retain a highly favourable safety profile, both in the mother and in the baby, 
throughout each stage of pregnancy (McGready et al., 1998; McGready et al., 2001). Larger 
patient samples, however, shall be required to verify absolutely that such effects are 
genuine prior to any relaxation of restrictions. 
 
1.4.2. Cytotoxic Effects of Artemisinin against Cancer Cell Lines 
 
Prompted by the initial investigations outlining the ability of artemisinin derivatives to 
induce death in selected cancer cells, a large-scale screening programme organised by the 
American National Cancer Institute (NCI) aimed to provide a wider assessment of their 
properties across a complete range of lines. Activity was demonstrated against leukaemia, 
lung, melanoma, colon, prostate, ovarian, and breast cancer cells, with the most sensitive 
again displaying IC50 values within the low micromolar range (Efferth et al., 2001). 
Since the emergence of these findings, artemisinin derivatives have been tested for their 
cytotoxic profiles against an array of immortalised lines. Mechanistic studies have outlined 
their abilities to promote apoptotic cell death, arrest proliferation and prevent metastasis, 
whilst further inducing the inhibition of angiogenesis (Singh et al., 2004). In the process of 
performing these acts, the drugs have been shown to be associated with a diverse range of 
deleterious effects upon cellular functions. These are known to include the initiation of cell 
cycle arrest through cyclin reduction, the suppression of neovascularisation through VEGF 
receptor downregulation,  the activation of pro-apoptotic mediators and the emergence of 
oxidative stress (Firestone et al., 2009). 
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1.5. Mechanistic Aspects of Artemisinin Activity in Mammalian 
Cells 
 
Attempts to elucidate the mechanistic route through which artemisinin induces toxicity 
across mammalian systems have highlighted both the aspects of cellular function impacted 
by their administration, and the factors responsible for mediating their progression. It is 
believed that, through means analogous to those within their antiparasitic mode of action, 
Fe(II) activation of the endoperoxide bridge produces reactive species accountable for 
promoting cellular dysfunction (Mercer, 2009). Research has identified that cell death, 
occurring through apoptotic and necrotic mechanisms, is stimulated through pathways 
dependent upon both the induction of mitochondrial damage and on the emergence of 
oxidative stress (Firestone et al., 2009; Mercer et al., 2011). A discussion of the current 
understanding which exists regarding the relationship between drug treatment and the 
onset factors contributing to each of these events shall now be presented. 
 
1.5.1. Artemisinin and Cell Death 
 
Studies within cancer cell lines have attested to the ability of artemisinin derivatives to 
induce termination through both apoptotic and necrotic routes. Prior to considering this 
evidence, a definition and overview of each of these two primary modes of death will be 
given.  
 
1.5.1.1. Necrotic Cell Death 
 
Necrotic death is characterised by its procession through a system of loosely-regulated 
signalling pathways stimulated as a consequence of sudden, external insult to cellular 
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integrity (Vanlangenakker et al., 2008). Its onset may be initiated courtesy of a variety of 
stressors, including common external instigators such as physical trauma, ischaemia and 
temperature extremes, and further internal sources typically related to activation of the 
immune system. Cells are observed to pass through an early phase of swelling, related to a 
dysfunction of the mechanisms of ionic regulation (Golstein et al., 2007). This culminates in 
irregular membrane blebbing and leakage of cell contents, typically resulting in the 
activation of an inflammatory response and the spread of death to neighbouring areas. 
 
1.5.1.2. Apoptotic Cell Death 
 
Apoptosis is a form of programmed death moderated under internal cellular regulation. Its 
activation may arise as a consequence of physiological or pathological stimuli, and it is 
implicated in the progression of a range of developmental processes and disease states 
(Taylor et al., 2008). In contrast to the disorder and lack of regulation which characterises 
the progression of necrosis, apoptosis occurs through a series of well-defined signalling 
pathways culminating in cellular degradation and clean phagocytic removal of debris. The 
internal and external alterations in cellular morphology which occur over the course of 
apoptosis have been identified and characterised (Krysko et al., 2008). A series of complex 
signalling cascades, themselves under the regulation of an array of hormones, growth 
factors and pro-apoptotic sensors, are accountable for mediating the activity of the caspase 
effector proteins responsible for the commencement of cell breakdown.  
The pathways which culminate in the activation of apoptosis may be broadly catergorised 
as proceeding along either “intrinsic” or “extrinsic” routes. A summary of key stages 
present within each course is provided in Figure 1.5. The regulatory role of the 
mitochondrion is central to the intrinsic pathway of apoptosis (Wang et al., 2009). Initiation 
of this process typically occurs in response to stresses such as oxidative and chemical 
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damage, DNA insult and the effects of radiation. Increases in mitochondrial permeability 
prompt the release of a variety of pro-apoptotic factors from the inner membrane into the 
cytosol, including cytochrome c, which moves to form, alongside apoptotic protease 
activating factor 1 (APAF-1), the body know as the apoptosome responsible for caspase 
activation (Tait et al., 2010). Alternatively, apoptosis can proceed through the extrinsic 
pathway (Elmore, 2007). In this pathway, activation of caspases is initiated through the 
binding of unique pro-apoptotic extracellular death ligands to respective surface death 
receptors. 
 
Figure 1.5. Scheme outlining primary stages within the pathways mediating apoptotic cell 
death. 
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1.5.1.3. Mechanistic Aspects of Artemisinin-Induced Cell Death 
 
Research has indicated that artemisinin is capable of inducing cell death along both 
apoptotic and necrotic pathways. It is stimulation of the mitochondrially-regulated intrinsic 
apoptotic pathway which is identified as being the dominant mechanism across the great 
majority of systems examined (Firestone et al., 2009). Evidence for its primacy is derived 
from the outcomes of studies which have established the induction of pro-apoptotic events 
occurring in response to drug treatment in cancer lines. Cell cycle arrest, inferred through 
increased populations within the G2/M and sub-G0/G1 phases, has been demonstrated 
(Morrissey et al., 2010; Steinbrueck et al., 2010). This is shown to occur alongside 
stimulation of pro-apoptotic Bax expression, release of cytochrome c and the activation of 
caspases (Anyasor et al., 2009; Hou et al., 2008). Support for involvement of the extrinsic 
pathway is less substantial. Limited upregulation in death receptor expression has been 
observed within prostate cancer lines, although the direct relevance of this remains at this 
time uncertain (He et al., 2010). Necrosis is reported under selected conditions. Within the 
HeLa ρ0 line, notable for its lack of functioning electron transport chain, cell death in 
response to artesunate treatment proceeds via a predominantly necrotic mechanism 
(Mercer et al., 2011). It is believed that this is a function of the inability of these cells to 
efficiently undergo apoptosis, a factor which itself derives from deficiencies in their 
capacity to generate the quantities of ATP required for initiation of such processes. 
 
1.5.2. Iron and Artemisinin Cytotoxicity  
 
Theories into the mode of action of artemisinin derivatives in human cells are centred, as 
they are in parasitic systems, upon an iron activation hypothesis. Through methods 
analogous to those employed in assessing its necessity for antimalarial action, studies have 
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demonstrated that the presence of the endoperoxide bridge is a key requirement for the 
emergence of cell death (Efferth et al., 2001). It is believed that the enhanced sensitivity of 
cancer cells towards artemisinin treatment occurs as a function of their reliance upon the 
maintenance of elevated intracellular iron concentrations (Mercer et al., 2011). 
Correlations between levels of cytotoxicity and the modulation of iron content within these 
systems have been witnessed, providing further evidence for the existence of such a 
connection. It shall be necessary to present an overview of some of the more relevant 
actions of iron within cells, including the routes through which it is handled and 
metabolised, in order that context for future discussions regarding its relevance towards 
artemisinin activity might be provided.  
 
1.5.2.1. The Cellular Functions of Iron 
 
Iron possesses numerous functions which are central to the performance of many essential 
cellular processes (Cairo et al., 2006). Its ability to exist in a variety of oxidation states lends 
it great utility as a mediator of redox pathways. For these roles, it is generally found either 
assembled into haem proteins, or bound up within Fe-S clusters. Haem is a key constituent 
of a myriad of enzymes and other proteins which are involved within an array of vital 
processes, and as such is present within electron transport molecules, metabolic catalysts 
of the cytochrome P-450 family, catalase antioxidant enzymes and in the haemoglobin 
oxygen transport mechanism (Warren, 2009). As a constituent of Fe-S clusters, iron is 
central to the regulation of additional redox routes, most notably within complexes I and II 
of the electron transport chain (Lill et al., 2000). 
Despite the necessity of iron for the maintenance of cell function, its reactivity can render it 
responsible for deleterious effects should it be present in excessive quantities. These are 
known to arise primarily as a product of an ability to generate highly reactive species, 
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including the OH• hydroxyl radical, upon interaction with hydrogen peroxide (Thomas et al., 
2009). Termed the Fenton reaction, its mechanism proceeds according to the following 
equation:  
Fe2+ + H2O2  Fe3+ + OH• + OH- 
 
As a consequence, it is necessary that cellular iron concentrations be regulated tightly in 
order to prevent the accumulation of excess. Free iron possesses the greatest potential for 
the stimulation of indiscriminate ROS formation, and as such metal ions are contained 
predominantly within bound states alongside transport or storage proteins (Galaris et al., 
2008). Within serum, iron remains conjoined to the glycoprotein transferrin, in which it is 
taken up into cells at transferrin receptors through a mechanism of endocytosis. Having 
entered, it becomes a constituent of the aggregate of free or weakly-bound iron termed the 
“labile iron pool” or “chelatable iron pool”, in which it usually remains until it is either 
assembled into haemoproteins or taken up into storage in combination with ferritin 
(Hentze et al., 2004). 
It is this chelatable iron pool which is implicated as having major involvement in the 
formation of ROS (Kakhlon et al., 2002). Iron in its unbound form is found in various 
compartments across the cell, with notable concentrations present within the cytosol, the 
mitochondrion, the nucleus and the lysosome. It is the latter, a body rich in hydrolytic 
enzymes and responsible for the breakdown of a broad range of biomolecules, which is 
distinguished by its particularly high content of the metal (Kurz et al., 2008). This arises 
particularly as a consequence of its action as the site for haemoprotein degradation, and as 
such implicates it in the emergence of iron-related oxidative stress. 
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1.5.2.2. Iron Content and Cellular Artemisinin Susceptibility 
 
Owing to its necessity for the construction of enzymes central to the processes of cell 
growth, metabolism and DNA synthesis, the tendency of cancer cells to undergo continuous 
active proliferation lends them a requirement for an enhanced internal concentration of 
iron (Kwok et al., 2002). Cellular uptake of the metal is controlled through membrane 
transferrin receptors, which are responsible for internalising transferrin-bound iron 
courtesy of an endocytotic route. Elevated manifestation of the transferrin receptor is 
typically found to occur upon the surface of cells involved in multiplication (Steegmann-
Olmedillas, 2011). In a direct comparison between the activities of artemisinin derivatives 
across immortalised lymphocytic  and non-proliferating peripheral blood mononuclear cells 
(PBMC), it was revealed that the former display a much heightened degree of sensitivity 
towards drug effects (Mercer et al., 2011). The cancer line studied, the HL-60, is particularly 
notable for both its susceptibility towards artemisinin-induced death and its elevated levels 
of transferrin receptor expression.  
The modulation of iron content through exogenous routes has been shown to impact upon 
cell sensitivity towards artemisinin administration. Increasing the presence of iron through 
co-treatment with holotransferrin was observed to produce a heightened susceptibility 
towards DHA across both molt-4 leukaemic cells and the HB27 breast cancer-derived line 
(Lai et al., 1995; Singh et al., 2001). Mirroring the findings from both HL-60 and Jurkat 
studies, this effect was absent in their non-proliferating counterparts.  
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1.5.2.3. Haem-Iron and Artemisinin Activity  
 
With evidence strongly suggesting a relationship between cellular iron and sensitivity 
towards artemisinin toxicity, research has sought to ascertain the identity of the metal 
source responsible for the mediation of bioactivation and related effects. The role of haem-
Fe(II) as the key mediator of cytotoxic effects has been identified through studies assessing 
the impact of modulators of haem biosynthesis upon drug response in cancer cells (Mercer 
et al., 2011; Mercer et al., 2010). It was demonstrated that the addition of the haem 
precursors aminolevulinic acid (ALA), protoporphyrin-IX and transferrin-bound iron 
produced enhanced susceptibility towards artemisinin derivatives in sensitive cell lines 
whilst simultaneously stimulating haem formation.  Co-treatment with the ALA synthase 
inhibitor succinyl acetone conversely reduced both cellular haem content and propensity 
towards cytotoxicity, whilst concurrently negating the formation of degradation products 
associated with bioactivation.  
In the model of artemisinin antiparasitic activity, it is suggested that the ability to form 
adducts with haem is a determinant of pharmacological activity. Accordingly, defective 
haemoprotein functioning resulting from alkylation has been forwarded as a factor 
responsible in the induction of cytotoxic effects (Mercer, 2009; Mercer et al., 2011). Owing 
to the role of haem units within enzymes responsible for the maintenance of redox 
processes, such as those found within the constituent complexes of the electron transport 
chain, it is posited that links might exist between reactivity with haem and the emergence 
of ROS formation. 
1.5.2.4. Artemisinin and Iron-Mediated Free Radical Species Formation   
 
It is hypothesised that the importance of iron towards the progression of artemisinin-
induced cancer cell death stems from its ability to spur the formation of reactive carbon-
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centred radical species through reduction of the endoperoxide bridge. Evidence derived 
from LC-MS studies has identified chemical species formed through the degradation of the 
artemisinin derivative 10β-(p-fluorophenoxy)dihydroartemisinin (PFDHA) (7) following 
incubation in HL-60 cells, indicating time-dependent drug activation occurring courtesy of a 
route which bears similarities to that observed within parasitic systems (Mercer, 2009; 
Mercer et al., 2007). It is hence rational to suggest that the chemical mechanism behind 
bioactivation remains conserved across these settings. The observation that succinyl 
acetone protects against cytotoxicity whilst simultaneously reducing bioactivation suggests 
the presence of a link between activation, radical formation and the induction of cell death 
(Mercer et al., 2011). As discussed previously, haem alkylation is proposed as being one 
route through which the cytotoxic mechanism might potentially be mediated.   
 
1.5.3. Artemisinin and the Mitochondrion 
 
It is interaction between artemisinin derivatives and the mitochondrion which is ultimately 
identified as being key to determining the response of cells towards treatment with the 
drugs. Evidence exists outlining the potential of the organelle to function as both a primary 
source for drug activation, and as the principal target for subsequent toxic impact. The 
emergence of reactive oxygen species formation and the induction of apoptotic cell death – 
processes both associated intimately with impact upon mitochondrial functions – have 
been demonstrated consistently across cell studies. 
1.5.3.1. Drug-Induced Mitochondrial Dysfunction 
 
Dysfunction of the mitochondrion is implicated as being of mechanistic relevance to the 
toxicity of a variety of drug classes. An overview of the key structural features possessed by 
the body is presented in Figure 1.6. The outer phospholipid bilayer membrane encases an 
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inner equivalent, which in turn surrounds the protein-dense matrix. It is this internal 
membrane which holds the substituent complexes of the electron transport chain. Situated 
between inner and outer membranes stands the intermembrane space, a region which 
folds into the matrix to form structures referred to as cristae. Mitochondrial liability has 
become associated with the deleterious impact of xenobiotics upon the functioning of 
targets ranging from the cardiovascular, hepatic, renal and central nervous systems, to 
skeletal muscle and the maintenance of lipid distribution (Dykens, 2008). Mechanisms 
through which drugs might impart damage to the operation of mitochondrial activities are 
numerous and varied. Many important cellular processes lie under the control of the 
organelle, with two of the most prominent being ATP generation through oxidative 
phosphorylation and the aforementioned regulation of intrinsic apoptosis (Newmeyer et 
al., 2003). Deleterious impact upon the operation of the former has the potential to bear a 
significant general effect upon general cellular function. 
 
Figure 1.6. Overview of the key topographical features of the mitochondrion. 
 
Acting as the dominant route towards ATP production, the process of oxidative 
phosphorylation is dependent upon the release of energy occurring through the series of 
consecutive redox reactions which collectively form the electron transport chain 
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(Huttemann et al., 2007). Structurally, the electron transport system is composed of four 
redox-active complexes situated within the inner membrane of the mitochondrion. Passage 
of electrons occurs from donor to acceptor molecules, culminating in releases of energy 
which are in turn utilised for the extrusion of protons from inside the matrix and out into 
the intermembrane space (Fig. 1.7.) (Huttemann et al., 2008). This imbalance in proton 
distribution creates an electrochemical gradient, referred to as the mitochondrial 
membrane potential, which hence drives the creation of ATP at ATP synthase. 
The initial phase in the electron transport procedure is the oxidation by complex I (NADH 
dehydrogenase) of NADH. This process results in the transferral of two electrons to the 
carrier molecule ubiquinone (CoQ10) and the movement of four protons into the 
intermembrane space. Ubiquinone is simultaneously fed by complex II (succinate 
dehydrogenase), which donates a pair of electrons accrued from succinate oxidation. The 
reduction of ubiquinone, fed through both sources, furnishes ubiquinol, which hence 
proceeds to function as a donor to complex III (cytochrome bc1 complex). Participation in 
the Q-cycle at this complex leads to the transferral of electrons to two units of the 
haemoprotein cytochrome c, alongside the net translocation of four protons from out of 
the matrix. At complex IV (cytochrome c oxidase), one electron is removed from each of 
four reduced molecules of cytochrome c. They are transferred, accompanied by four 
protons, to one molecule of oxygen – which functions as a terminal electron acceptor – 
culminating in the formation of water. Four further protons are simultaneously relocated 
into the intermembrane area. ATP synthase utilises the proton gradient to catalyse the 
phosphorylation of ADP, acting as the primary source for cellular ATP generation 
(Huttemann et al., 2007). 
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Figure 1.7. Diagram outlining the physiological functioning of the electron transport 
chain. Sites of ROS generation are highlighted in red. 
 
The inequitable distribution of protons about the membrane culminates in the 
establishment of an electrochemical gradient. The associated potential difference of this, 
termed ΔΨm, stands between 180-200 mV (Dykens, 2008). The maintenance of such 
dispersal is essential in order that the production of ATP might proceed freely through the 
oxidative route. The requirement for oxygen to act as the final acceptor for electrons 
ensures that its continued consumption by cells is a necessity. Accordingly, it is owing to 
this process that the mitochondrion itself is accountable for approximately 90% of total 
cellular oxygen demand (Nathan et al., 1999). Under physiological conditions, consumption 
of oxygen remains “coupled” to the establishment of ΔΨm and hence to the generation of 
ATP.  
Defective functioning of this system results in the generation of ATP becoming “uncoupled” 
from cellular oxygen uptake, resulting in a greatly reduced efficiency of energy production. 
This might arise either from the modification of any of the complexes which constitute the 
electron transport mechanism, from agents which act to compromise the integrity of the 
inner membrane or from a depletion of the substrates required to feed the redox chain 
(Dykens, 2008; Fosslien, 2001). Causes behind these effects include the specific inhibition of 
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enzymes, the sequestering of redox cofactors and also generalised damage occurring as a 
consequence of ROS production (Kirkinezos et al., 2001; Neustadt et al., 2008). Heightened 
oxidative stress generally finds its source in damage to the functioning of the electron 
transport chain, ensuring the common existence of a close link between mitochondrial 
injury and the elevation of ROS formation.  
As has been discussed previously, mitochondrial damage stimulates apoptosis through the 
intrinsic pathway (Firestone et al., 2009). Events which are known to occur alongside the 
onset of this process include the collapse of the mitochondrial membrane potential, the 
cessation of ATP production, and the permeabilisation of the outer membrane. The latter 
ultimately culminates in pore formation and the release of cytochrome c, initiating caspase 
activation and subsequent cell death. This pathway can be stimulated through events 
occurring outside of the mitochondrion, such as external ROS generation and the 
emergence of lysosomal dysfunction (Boya et al., 2008). 
 
 
 1.5.3.2. Mechanistic Aspects of Artemisinin-Induced Mitochondrial 
Dysfunction 
 
Evidence strongly suggests that dysfunction of the mitochondrion is a key stage in the 
mechanism through which artemisinin derivatives exert their cytotoxic effects. The 
production of ROS is observed within cancer cells upon drug treatment, with the protective 
effects afforded by the upregulation of cellular oxidative stress defence mechanisms and 
the co-administration of exogenous antioxidant agents indicating that damage arising from 
this is a major contributing factor towards the progression of cell death. Their emergence is 
witnessed to occur prior to the onset of toxic effects, identifying them as early mediators of 
response (Mercer et al., 2011). Owing the position of the mitochondrion as the primary site 
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for pathological ROS generation, it is posited that artemisinin administration impacts upon 
the redox processes within. Studies performed in HeLa ρ0 cells indicate that the absence of 
a functioning electron transport chain leads to a reduction ROS levels, conferring relative 
resistance to cytotoxic effects. Accordingly, damage to this system is implicated as being a 
route through which deleterious impact might be mediated (Firestone et al., 2009). Events 
occurring alongside the defective oxidative phosphorylation functioning, including the 
collapse of the mitochondrial membrane potential and the cessation of ATP production 
have further been reported.  
Attempts to rationalise these findings on a chemical level have been modelled primarily 
upon the iron activation hypothesis. Haem is believed to function as a source for 
endoperoxide bridge reduction, inducing decomposition of the artemisinin molecule and 
the formation of reactive carbon-centred radicals (Mercer et al., 2007; Zhang et al., 2009). 
Modification of proteins occurring as a consequence of alkylation by these species is 
posited as leading to their defective functioning, although definitive evidence for the 
significance of this has yet to be presented. It is additionally highly likely that the role of 
iron in the propagation of ROS through Fenton chemistry is additionally of great 
mechanistic relevance (O'Neill et al., 2010b). 
 
1.5.4. Reactive Oxygen Species in Artemisinin Cytotoxicity  
 
The term reactive oxygen species is given to any chemically reactive molecule formed as a 
consequence of oxygen metabolism. Despite possessing physiological roles relating to cell 
signalling and pathogen defence, their tendency towards indiscriminate reaction with 
proteins and lipids ensures that their presence in elevated quantities is detrimental towards 
the functioning of the cell. The formation of ROS is strongly implicated as playing a central 
role within the mechanism of artemisinin-induced cell death (Firestone et al., 2009). Studies 
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have shown that cell treatment with artemisinin derivatives results in increases in ROS 
levels, the abrogation of which can lend cytoprotective effects (Mercer et al., 2011). The 
relationship between enhanced oxidative stress and the toxicity of DHA was first 
demonstrated in a study assessing impact of treatment upon immortalised cervical cancer 
cells (Efferth et al., 2007). It was soon discovered that such an effect was general to many 
lines, and occurred alongside the onset of both necrotic and apoptotic cell death. 
The effects of antioxidants have indicated that oxidative stress is an important causative 
factor in artemisinin cytotoxicity. ROS scavengers including tiron have been shown to 
greatly reduce drug impact upon cell viability, whilst an inverse correlation between 
susceptibility to toxicity and the expression levels of enzymes involved in endogenous 
defence mechanisms such as catalase, superoxide dismutase and glutathione-S-transferase 
has been shown to exist (Efferth, 2006; Mercer et al., 2011). Despite such evidence strongly 
suggesting causality between ROS induction and the emergence of toxicity, a definitive 
route through which their formation is initiated has yet to be established (O'Neill et al., 
2010b). Owing to the importance of ROS towards the mechanism of action of artemisinin 
and its derivatives, it shall be necessary to explore the pathways through which they might 
be generated. An overview processes implicated in their production shall be given, so that 
consideration of the possible routes through which the drugs exert toxicity might be made.   
 
1.5.4.1. Routes towards the Formation of Reactive Oxygen Species 
 
ROS may be formed at many points within the cell, with their generation occurring as by-
product across an array of systems.  Under physiological circumstances, production is offset 
by the actions of cellular antioxidants, which act to convert oxygen radicals into more inert 
species and hence minimise potential for deleterious interactions (Vertuani et al., 2004). 
These compounds, including glutathione, melatonin and ubiquinol, are essential towards 
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the maintenance of cellular health (Rizzo et al., 2010). Should formation of ROS exceed the 
capability of the cell to neutralise them, then the system is said to exist under a condition of 
“oxidative stress”(Halliwell, 2007). The superoxide anion, O2-, generated through the one-
electron reduction of molecular oxygen, is of particular importance owing to the tendency 
towards its formation within the mitochondrion. Its generation may occur in cells through a 
process of indirect electron leakage, or through the actions of selected oxidase and 
reductase enzymes. The equation for its formation is: 
O2 + e-  O2- 
1.5.4.2. Reactive Oxygen Species and the Electron Transport Chain 
 
It is established that the great majority of ROS generated within cells have their origin 
within the mitochondrion – a factor generally attributed to the role which the organelle 
possesses as the site of oxidative phosphorylation (Murphy, 2009). It is accepted, therefore, 
that injuries to mitochondrial processes are heavily associated with elevated oxidative 
stress. The electron transport chain, which holds the central role within the generation of 
ATP through the aforementioned pathway, is identified as the leading foundation for the 
generation of ROS occurring under both general physiological and pathological conditions. 
The physiology of the electron transport system is outlined in Section 1.5.3.1. Despite the 
general efficiency of the pathway, electron leakage at various points within the chain is 
associated with ROS formation. Complex I and complex III are acknowledged as the primary 
sources of superoxide generation under physiological conditions (Le Bras et al., 2005). As 
such, defective functioning within these systems occurring through pathological means is 
linked closely to the elevated expression of ROS (Turrens, 2003). Compounds such as the 
complex I inhibitor rotenone and the complex III inhibitor antimycin are known to induce 
oxidative stress and resultant cell death through specific action at sites within these bodies.  
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1.5.4.3. Reactive Oxygen Species Independent of the Electron Transport 
Chain 
 
Although the electron transport chain is identified as being the dominant point of ROS 
generation within cells, numerous alternative sources unconnected with the machinery of 
oxidative phosphorylation are known to exist. It is understood that enzymes within the 
mitochondrion have the potential to produce significant quantities of ROS, either as a 
function of the physiological roles or as a consequence of defective operation (Dykens, 
2008; Tahara et al., 2009). Amongst these are the matrix oxidoreductase α-ketoglutarate 
dehydrogenase, the inner membrane-bound sn-glycerophosphate dehydrogenase and the 
outer-membrane-located cytochrome b5 reductase and monoamine oxidase (Andreyev et 
al., 2005). 
Sources external to the mitochondrion include NADPH oxidase, located within the plasma 
membrane, xanthine oxidase, and nitric oxide synthase (Bedard et al., 2007; Papi et al., 
2008). ROS in significant quantities are generated within the endoplasmic reticulum, and 
might also arise within the lysosomal compartment as a consequence of its elevated free 
iron content (Galaris et al., 2008). Furthermore, oxidative stress occurring peripheral to the 
mitochondrion is capable of inducing damage to the functioning of the organelle, spurring 
the additional production of ROS through a mechanism termed “ROS-induced ROS release” 
(Zorov et al., 2006). 
1.5.4.4. Mechanistic Aspects of Artemisinin-Induced Reactive Oxygen 
Species Formation 
 
As previously alluded to, the production of ROS is intimately connected with the induction 
of cytotoxic effects arising as a consequence of artemisinin treatment. The mechanistic 
routes through which the emergence of oxidative stress is mediated following drug 
administration remain largely unknown. Owing to the established relationship between 
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mitochondrial dysfunction and the onset of ROS formation, it is plausible to suggest the 
existence of a close association between the oxidative stress stimulated by artemisinin 
derivatives, and impact imparted by the compounds upon the processes mediated within 
the organelle. The ρ0 HeLa line, which respires solely through glycolysis on account of the 
defective functioning of its electron transport chain, exhibits significant resistance towards 
the effects of the drugs (Chevallet et al., 2006; Mercer et al., 2011). Such an outcome is 
postulated as being linked with reduced incidence of ROS formation arising secondary to 
the bypassing of oxidative respiration, thus suggesting that artemisinin-induced 
interference with the operation of the electron transport system forms a dominant route 
through which oxidative stress is stimulated. The theorised contribution of reactive carbon-
centred radicals towards drug-induced deficiencies in the operation of cellular systems 
provides a feasible mechanism towards the mediation of such impact. 
It is further possible that cellular ROS might arise as a consequence of an oxidant function 
derived from the chemistry of the endoperoxide moiety (Haynes et al., 2010). Several 
mechanisms through which this might be mediated within parasitic systems have been 
postulated, with the most prominent being discussed within Section 1.3.4.7. Should such 
pathways, dependent upon interference with the redox status of flavin cofactors, possess 
significance towards the pharmacological activity of the compounds, conservation of 
relevant processes within mammalian cells may influence the progression of cytotoxic 
effects.  
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1.6. Rationale for Study 
 
1.6.1. Artemisinin Derivatives Assessed 
 
Over the course of the studies constituting this thesis, a variety of endoperoxide 
compounds originating from several drug classes shall be examined for their activity 
profiles within cell systems. Assessment into the mechanistic aspects of artemisinin 
function within cancer cells will be performed using the first-generation, semi-synthetic 
derivative artesunate. This compound finds widespread employment across clinical 
settings, and has further been utilised in an assortment of examinations into the general 
cytotoxic effects of the drug class in vitro. Additional investigations shall make use of DHA, 
and the related derivative PFDHA. The latter is noted for its enhanced metabolic stability, 
and has been developed for use in assessment of drug bioactivation through LC-MS 
methods (Mercer et al., 2011; Mercer et al., 2007). 
Research into the development of novel endoperoxide forms has been prompted owing to 
concerns regarding the toxicity and cost-effectiveness of the artemisinin derivatives in 
current general use (Ridley, 2002). An array of wholly synthetic compounds have been 
tested and developed over the preceding decades, with investigations into their 
antiparasitic profiles suggesting that many possess activities comparable to or greater than 
those of the traditional artemisinin-based agents (Jefford, 2007). The 1,2,4-trioxolane and 
1,2,4,5-tetraoxane classes, illustrated respectively by OZ277 (8) and its derivative (9), have 
exhibited notable promise as regards to their progression towards clinical utility (Uhlemann 
et al., 2007). As such, the cytotoxic potentials of novel antimalarial candidates belonging to 
these series, synthesised by the group of Prof. Paul O’Neill, shall each be examined in order 
that the mechanistic aspects of their actions within mammalian systems might be 
elucidated. Further investigations have sought to explore the feasibility for exploiting 
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artemisinin activity against cancer cell lines as the basis for the development of a range of 
new compounds intended for employment as anticancer treatment (Chaturvedi et al., 
2010; O'Neill et al., 2010a). Common design strategy has centred upon construction of 
hybrid classes, such as those exemplified by the artemisinin-acridine assembly (10), in order 
that cell killing potential relative to the lone endoperoxide be enhanced (Jones et al., 2009).  
Several compounds belonging to a series of novel DHA-polypyrrole conjugates are hence 
examined for their impact upon cellular function. 
 
 
1.6.2. Cell Lines Examined 
 
The activities of the aforementioned endoperoxides shall be determined across a variety of 
immortalised cell lines. The HeLa cell, derived from a cervical cancer tumour, is employed 
widely as a model in the in vitro assessment of xenobiotic function. It has accordingly found 
use in previous studies examining the cytotoxic profiles of artemisinin compounds, across 
which it is noted to display sensitivity towards effects of the drugs (Chen et al., 2003; 
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Mercer et al., 2011). As has been alluded to previously, the sustained culturing of HeLa cells 
in the presence of ethidium bromide has the effect of depleting the mitochondria of their 
DNA, preventing the assembly of a functioning electron transport chain and forcing reliance 
for ATP generation upon the glycolytic pathway (Chevallet et al., 2006; Mercer et al., 2011). 
Utilisation of this ρ0 line can allow for direct assessment of the importance of the electron 
transport mechanism towards the progression of cytotoxic impact arising from drug 
treatment. 
Owing to their great sensitivity towards an array of artemisinin-derived and synthetic 
endoperoxide classes, further assessments of cytotoxic potential shall be performed within 
promyelocytic leukaemic HL-60 cells (Efferth et al., 2001; Mercer et al., 2007). In addition, 
the Hep G2 hepatocellular carcinoma line, which constitutes an established vehicle for the 
assessment of toxic activity, shall be employed in selected assessments. Culturing 
techniques intended to heighten the sensitivity of cancer cells towards the impact of 
mitochondrial toxins shall further utilised for the same purposes. 
1.7. Aims of Thesis 
 
The discussion presented within this chapter has served to provide account of the 
historical, clinical and mechanistic perspectives related to the activity profiles of artemisinin 
and its derivatives across both pharmacological and toxicological settings. Concerns over 
the potential of the compounds in current use to impart developmental and neurological 
toxicity in clinical settings remain persistent, prompting examination into the routes 
through which such effects are mediated. Research has indicated the ability to induce 
significant, selective cytotoxic effects against sensitive, proliferating mammalian cells. It is 
widely believed that this impact is mediated through a mechanism reliant upon activation 
of the endoperoxide bridge, occurring as a direct consequence of interaction with sources 
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of Fe(II). ROS production has been identified as a key stage in the progression of cell death, 
a phenomenon which is held to occur alongside the onset of mitochondrial dysfunction and 
the activation of intrinsic apoptosis. 
The impact of artemisinin upon the metabolic functioning of the mitochondrion has yet to 
be fully assessed, and neither have the sources of oxidative damage been conclusively 
elucidated. It shall be the intention of the research performed within this thesis to provide 
a deeper insight into the effects held by drugs upon the health of the organelle, further 
examining the roles of iron and oxidative damage in the determination of such a response. 
It is acknowledged that the long-term future of endoperoxide compounds as frontline 
antimalarial treatment lies in the successful development of novel synthetic classes. 
Accordingly, assessment into of the cytotoxic profiles of newly developed synthetic and 
semi-synthetic experimental derivatives shall be made. In order to achieve these aims, a 
variety of in vitro techniques employing immortal cancer cell lines shall be employed. The 
ultimate aim of these studies shall be to develop current our understanding of the 
mechanism through which cytotoxicity proceeds, so that this might in turn contribute 
towards the future safer use of the drugs and to a clearer view of how their chemistry 
relates to their cellular activity. 
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Chapter Two 
 
 
Investigation into the Function of 
Mitochondrial Liability within the 
Development of Artemisinin Cytotoxicity 
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2.1. Introduction 
 
It is established that the mitochondrion holds involvement in the mechanism through which 
endoperoxide compounds exert cytotoxicity in cancer cell lines (Mercer et al., 2011). 
Although the effects of drug treatment have been documented across several studies, 
comparatively little is known regarding the nature of the interactions which underpin their 
activity within this body. This chapter shall be focused upon testing the hypothesis that cell 
death induced through the artemisinin derivative artesunate occurs through a mechanism 
reliant upon direct targeting of the organelle. In order to achieve this, response to 
treatment shall be examined across Hep G2 and HeLa cells sensitised towards 
mitochondrial toxins through culturing in the absence of glucose. These studies shall be 
complemented by an assessment of mitochondrial bioenergetic function performed using 
techniques developed for the Seahorse extracellular flux (XFe) analyser, in order that a 
more complete view regarding their bearing upon respiration might be attained. 
Deleterious impact upon the physiological function of the mitochondrion is a defining 
feature of the mechanism of action through which artemisinin-derived compounds impart 
their cytotoxic influence within mammalian cells. The collapse of the mitochondrial 
membrane potential, the generation of ROS and the onset of intrinsic apoptosis are events 
which are noted to occur uniformly across a variety of cancer lines upon treatment with 
this class (Firestone et al., 2009). Studies have further  indicated that ρ0 HeLa cells, which do 
not possess a functioning electron transport chain and hence lack an ability to produce ATP 
through oxidative phosphorylation, exhibit reduced sensitivity towards drug effects (Mercer 
et al., 2011). The primary chemical and molecular basis behind these observations, 
combined with their relevance towards any toxicity which may be observed in a clinical 
setting, remain largely undefined.  
48 
 
Studies into this area have typically been performed in vitro within immortalised, cancer-
derived cell lines. A key area in which these cells differ with respect to both those found in 
living systems and those maintained in primary culture is that of their bioenergetic profiles. 
Whilst it is typical of cells under general physiological conditions to generate ATP primarily 
and preferentially through oxidative phosphorylation within the mitochondrion, it is 
characteristic of cancer cells that they derive their energy almost exclusively through 
glycolytic routes (Moreno-Sanchez et al., 2007; Pedersen, 1978). This observation may be 
explained through the phenomenon referred to as the Crabtree Effect, whereby cells 
undergoing rapid proliferation are capable, dependent upon conditions and substrate 
availability, of switching their primary source of metabolism between oxidative and 
glycolytic routes (Dakubo, 2010). It is theorised that the prevalence of glycolytic respiration 
within cancer cells arises through their adaptation towards growth within the hypoxic 
environments common across many tumour types.   
A consequence of this preference for glycolysis and concurrent reduced reliance upon 
oxidative phosphorylation is that the sensitivity of many commonly employed lines towards 
the effects of compounds exerting toxicity through activity within the mitochondrion is 
often greatly reduced (Xu et al., 2005). In order that these cells might be modified towards 
the provision of a more physiologically relevant model for assessment of mitochondrial 
toxins in otherwise resistant systems, effective methods allowing for the circumvention of 
the Crabtree Effect have been developed (Marroquin et al., 2007). The culturing of the 
hepatic carcinoma-derived Hep G2 cell in the presence of galactose, with the simultaneous 
exclusion of glucose, has been shown to inhibit the glycolytic generation of ATP, and hence 
force  derivation of energy through solely mitochondrial means (Rossignol et al., 2004). The 
increased dependence upon the organelle in order to ensure cell survival ensures that 
susceptibility towards mitochondrially toxic compounds is enhanced. This state stands in 
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direct contrast to that witnessed within ρ0 HeLa cells, which are capable of respiring 
exclusively through the route of glycolysis. 
This technique has been increasingly employed as a means of screening for mitochondrial 
activity in drugs which display cytotoxic effects (Dykens et al., 2008a; Dykens et al., 2008b). 
It is methods adapted from it that shall be utilised within the forthcoming studies in order 
to investigate the profile of artesunate with regards to action upon the organelle. Both 
cytotoxicity, investigated using the MTT assay, and ATP content, examined using the 
CellTiter-Glo kit, shall be compared across cells cultured under each set of conditions. Full 
time courses shall be run for the assessment of these parameters, so that onset the 
progression of drug action may be observed. Furthermore, cellular oxygen consumption 
shall be measured using the Seahorse XFe analyser so that any variations in bioenergetic 
function might be monitored. These studies shall be performed in the Hep G2 cells, which 
have classically been employed in determining response to potential mitochondrial toxins 
through the methods described, before being expanded to the more sensitive HeLa line.  
The generation of ATP through oxidative phosphorylation is one of the primary functions of 
the mitochondrion, and interference with this process is heavily indicative of impairment to 
the integrity of the body. Since it is established that maintaining the performance of this 
process is accountable for approximately 90% of total cellular oxygen consumption, 
methods for determining the variation in atmospheric oxygen levels in the environment of 
cells have found extensive use in the assessment of mitochondrial health (Nathan et al., 
1999). Classically, apparatus such as the Clark oxygen electrode has been utilised in order to 
monitor respiratory capability (Diepart et al., 2010). The development of XFe technology 
has allowed for the simultaneous measurement of oxygen consumption (OCR) and 
extracellular acidification rates (ECAR), facilitating the assessment of oxidative and 
glycolytic performance with greatly improved levels of sensitivity (Dranka et al., 2011). 
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In this chapter, the Seahorse XFe unit shall be employed so that respiratory function in HeLa 
cells may be examined in response to artesunate administration. Using mitochondrial and 
glycolytic stress test techniques, the bioenergetic performance of the mitochondrion is 
determined with reference to several parameters indicative of physiological activity. These 
are quantified through monitoring variations in OCR and ECAR associated with the addition 
of compounds known to impact upon the progress of respiration. Through this, it is possible 
to ascertain the efficiency at which oxidative phosphorylation is coupled to oxygen 
consumption in drug-treated cells, whilst simultaneously measuring the total respiratory 
capacity and basal respiratory levels (Hill et al., 2009). Assessment of the impact of drug 
treatment upon these indicators allows for insight into the identity of the defects in 
mitochondrial performance induced, thus allowing for greater elucidation of their role 
towards the greater mechanism of cytotoxicity. Experiments are performed over full drug 
concentration and time courses, so that the relationship between the onset of 
mitochondrial dysfunction and the emergence of accompanying cell death might be studied 
in full. It is intended that, through these assessments, the hypothesis that artemisinin 
derivatives hold function as direct mitochondrial toxins can be granted thorough 
examination. 
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2.2. Materials and Methods 
 
2.2.1. Materials 
 
Dulbecco's Modified Eagle's Medium (DMEM), L-glutamine, penicillin/streptomycin 
solution, galactose, trypsin-EDTA solution (0.25%), (4-(2-Hydroxyethyl)-1-
piperazineethanesulphonic acid (HEPES), sodium pyruvate, Hanks’ balanced salt solution 
(HBSS), glucose, MTT, N,N-dimethylformamide (DMF), sodium dodecyl sulphate (SDS), MTT, 
oligomycin, rotenone, FCCP, artesunate and all additional solvents were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). Foetal bovine serum (FBS) was purchased from Life 
Technologies (Paisley, UK). Nunc cell culture plates and flasks were purchased from Thermo 
Scientific (Loughborough, UK). Seahorse XFe96 Analyser, XF Cell Mito Stress Test Kits, XF 
Glycolysis Stress Test Kits, XFe96 FluxPaks, XF96 V3 PET Cell Culture Microplates, XFAssay 
Medium, and XFe Calibrant were purchased from Seahorse Bioscience (Boston, USA). 
CellTiter-Glo Luminescent Cell Viability Assay Kit was purchased from Promega 
(Southampton, UK). HeLa and Hep G2 cells were acquired from the European Collection of 
Cell Cultures (Salisbury, UK). 
 
2.2.2. Cell Culture and Experimental Preparation 
 
HeLa cells were cultured in high-glucose DMEM, with supplemental FBS (10% v/v), L-
glutamine (1% v/v), sodium pyruvate (1% v/v) and penicillin/streptomycin solution (1% v/v). 
Hep G2 cells were cultured in high-glucose DMEM, with supplemental FBS (10% v/v), 
sodium pyruvate (1% v/v), HEPES (0.5% v/v) and penicillin/streptomycin solution (1% v/v). 
All cells were incubated at 37°C, in humidified air containing 5% CO2. Cell counting was 
performed using a haemocytometer under a light microscope (Leica DME, Leica 
Microsystems, Milton Keynes, UK). 
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2.2.3. Preparation and Treatment of Cells in Galactose-containing 
Media 
 
The tendency of cells within cancer-derived lines to preferentially derive ATP through 
glycolysis ahead of oxidative phosphorylation has been attributed to the Crabtree effect 
(Moreno-Sanchez et al., 2007). Studies have shown that the culturing of cells in galactose-
containing media, to the exclusion of glucose, can induce the cessation of glycolytic ATP 
production, and hence increase greatly reliance upon oxidative phosphorylation and the 
mitochondrion (Marroquin et al., 2007). Cells respiring under these conditions display 
greater sensitivity towards mitochondrial toxins than those which continue dependence 
upon glycolysis, allowing for their use in the screening of compounds potentially exerting 
cytotoxicity through mitochondrion-dependent means. 
HeLa cells were reconstituted in glucose-free DMEM supplemented with dialysed FBS (10% 
v/v), L-glutamine (2% v/v), sodium pyruvate (1% v/v), penicillin/streptomycin solution (1% 
v/v) and galactose (1 mM). Cells were washed in media three times in order to remove 
traces of glucose, before being added to relevant culture plates and left to adhere for a 
minimum period of 4 h prior to drug treatment. Hep G2 cells were reconstituted in glucose-
free DMEM supplemented with dialysed FBS (10% v/v), L-glutamine (2% v/v) HEPES (2% 
v/v), sodium pyruvate (1% v/v), penicillin/streptomycin solution (1% v/v) and galactose (1 
mM). Cells were washed in media three times in order to remove traces of glucose, before 
being added to relevant culture plates and left to adhere for a minimum period of 4 h prior 
to drug treatment. 
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2.2.4. Assessment of Cell Viability using the MTT Assay 
 
The MTT assay is employed as a means of determining the viability of cells. It utilises the 
ability of mitochondrial reductase enzymes, which function only in living cells, to induce the 
reduction of the yellow tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to an insoluble purple formazan salt. There is a direct 
proportionality between amount of formazan formed and quantity of living cells present, 
with the colour change accompanying this transformation used as a basis for the 
spectrophotometric determination of cell viability (Mosmann, 1983). 
 
HeLa or Hep G2 cells (5 x 103/well) were plated, in triplicate, into flat-bottomed, 96-well 
plates, and left to adhere overnight. Cells were subsequently exposed to concentrations of 
drug ranging from 0.1 µM to 1000 µM, dependent upon the nature of the assay, and 
incubated for time periods of up to 72 h. Upon the completion of incubation, 20 µL of MTT 
solution (5 mg/ml in HBSS) was added to each well. Following a further 2 h incubation at 
37°C, 200 µL of a lysis buffer (20 % w/v SDS, 50 % w/v DMF) was added to each well, and a 
further 4 h incubation at 37°C performed. Absorbance of each well was read on a plate 
reader (Dynex MRX, Magellan Bioscience, Worthing, UK), using a test wavelength of 570 nm 
and a reference wavelength of 590 nm. Results are expressed as a percentage of 
absorbance relative to untreated vehicle control, with IC50 derived from curves plotted 
using the GraFit Software (Erithacus Software, Surrey, UK). 
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2.2.5. Luminescent Analysis of Cellular ATP Content 
 
Cellular ATP content was determined through use of the commercial CellTiter-Glo 
Luminescent Cell Viability Assay kit. The function of the assay is reliant upon the luciferase-
dependent oxidation of a beetle luciferin substrate, resulting in the formation of 
oxyluciferin with the accompanying emission of light. The activity of the luciferase enzyme 
is proportional to the quantity of ATP present, allowing for ATP content to be inferred from 
detected luminescence 
 
The kit was used according to the protocol provided by the manufacturers. HeLa or Hep G2 
cells (5 x 103/well) were plated, in triplicate, into flat-bottomed, 96-well plates, before 
being left to adhere overnight. Cells were subsequently exposed to concentrations of drug 
ranging from 0.1 µM to 1000 µM, dependent upon the nature of the assay, and incubated 
at 37°C for time periods of up to 72 h. Following incubation, cells were treated with 20 µL of 
reconstituted Cell-TiterGlo reagent, before 100 µL of the reagent/media mixture was 
transferred to white-walled 96-well plates. After having been shaken for a period of 5 
minutes, plates were read on a luminescence spectrophotometer (Varioskan Flash, Thermo 
Scientific, Loughborough, UK) at an absorbance wavelength of 560 nm. Results are 
expressed as a percentage of absorbance relative to untreated vehicle control, with IC50 
derived from curves plotted using GraFit Software. 
55 
 
2.2.6. Seahorse XF Analysis of Oxygen Consumption and 
Extracellular Acidification Rates 
 
OCR and ECAR were measured using the Seahorse XFe96 Analyser. The unit quantifies these 
parameters simultaneously through determining the variations in fluorescence intensity in 
two probes, one of which displays sensitivity towards oxygen concentration, and the other 
towards proton content. Measurements are made in assay medium located above a cell 
monolayer positioned on the surface of each well, and are typically repeated over seven-
minute intervals for the duration of the experiment. The use of unbuffered DMEM allows 
for fluctuations in pH associated with variation in the rate of glycolysis, represented 
through ECAR, to be measured (Dranka et al., 2011). 
Typically, HeLa or Hep G2 cells (2.5 x 104/well) were plated in 96-well XF Cell Culture 
Microplates, and left to adhere overnight. HeLa cells and Hep G2 cells grown in high-
glucose DMEM and adhered on 96-well XF Cell Culture Microplates had their media 
replaced with unbuffered minimal DMEM supplemented with L-glutamine (1% v/v), sodium 
pyruvate (1% v/v) and glucose (4.5 g/L). HeLa and Hep G2 cells grown in galactose-
containing DMEM and adhered on 96-well XF Cell Culture Microplates had their media 
replaced with unbuffered minimal DMEM supplemented with L-glutamine (2% v/v), sodium 
pyruvate (1% v/v) and galactose (1 mM). Cells were then incubated at 37°C in a 0% CO2 
environment for a period of 1 h. XFe96 FluxPaks were prepared separately: 200 µL XF 
Calibrant Solution was added to each well on the day prior to the performance of the assay, 
ahead of overnight incubation at 37°C in 0% CO2.  
2.2.7. Direct Infusion 
 
Artesunate was added to the injection port of a hydrated XFe96 FluxPak. Following 
injection, measurement of OCR and ECAR was performed over a 2 h period. 
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2.2.8. Mitochondrial Stress Test 
 
The mitochondrial stress test allows for the assessment and quantification of mitochondrial 
bioenergetic function through determining cellular OCR and ECAR responses to the 
sequential addition of compounds impacting upon the function of oxidative 
phosphorylation (Hill et al., 2012). Cells are initially treated with the ATP synthase inhibitor 
oligomycin, in order to bring about a cessation of oxidative energy generation and hence 
abolish oxygen consumption unrelated to proton leak. The addition of the ionophoric inner 
mitochondrial membrane permeabiliser carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone  (FCCP) dissipates the membrane potential and produces 
a theoretical maximal OCR, before rotenone inhibits oxygen consumption related to the 
activity of complex I. 
 
HeLa cells plated on an XF Cell Culture Microplate (2.5 x 104/well) and dosed with 
artesunate (1 – 100 µM) were incubated at 37°C for periods between 0 and 24 h. Culture 
media was replaced with unbuffered DMEM, as described in Section 2.2.6. Oligomycin (1.5 
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µM), FCCP (0.4 µM) and rotenone (1 µM) were placed respectively in injection ports A, B 
and C on a hydrated XFe96 FluxPak, ahead of calibration. Cellular OCR and ECAR were 
recorded at seven minute intervals over twelve cycles, with the injection of oligomycin, 
FCCP and rotenone occurring following the third, sixth and ninth intervals. Normalisation 
was performed with respect to cell number, which was determined using a 
haemocytometer following conclusion of recording. 
 
2.2.9. Glycolytic Stress Test 
 
Determining ECAR response to the addition of compounds stimulating and inhibiting rates 
of glycolysis allows for cellular glycolytic function to be assessed. Cells in glucose-free media 
are treated first with a saturating concentration of glucose, in order to stimulate glycolysis. 
Subsequent addition of oligomycin prevents oxidative ATP generation, hence increasing 
glycolytic rate to a maximal level. The introduction of the final compound, 2-deoxyglucose 
(2-DG), induces the cessation of glycolysis and limits ECAR to that associated with non-
glycolytic mechanisms. 
 
 
HeLa cells plated on an XF Cell Culture Microplate (2.5 x 104/well) and dosed with 
artesunate (5 – 50 µM) were incubated at 37°C for 24 h. Culture media was replaced with 
unbuffered, glucose-free DMEM, as described in Section 2.2.6. Glucose (10 mM), 
oligomycin (1.5 µM) and 2-DG (100 mM) were placed respectively in injection ports A, B 
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and C on a hydrated XFe96 FluxPak, ahead of calibration. Cellular OCR and ECAR were 
recorded at seven minute intervals over twelve cycles, with the injection of glucose, 
oligomycin and 2-DG occurring following the third, sixth and ninth intervals. Normalisation 
was performed with respect to cell number, which was determined using a 
haemocytometer following conclusion of recording. 
 
2.2.10. Statistical Analysis 
 
All values are expressed as a mean, ± standard deviation (SD) as represented through error 
bars on graphs. Following the assessment of data normality using the Shapiro-Wilk test, the 
Student’s paired-t-test was employed in order to determine significance. In the event of 
non-normality, the Mann-Whitney U test was instead used for this purpose. Results were 
deemed significant when p-value was smaller than 0.05. Significance is represented as: * 
equivalent to P < 0.05, ** equivalent to P < 0.01 and *** equivalent to P < 0.001. 
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2.3. Results 
 
2.3.1. Artesunate Toxicity and Mitochondrial Liability 
 
2.3.1.1. Hep G2 Cells 
 
2.3.1.1.1. Sensitivity of Galactose-Cultured and Glucose-Cultured Cells towards 
Rotenone Treatment 
 
In order to verify that Hep G2 cells cultured in galactose exhibited heightened sensitivity 
towards mitochondrial toxins relative to those grown in glucose, the response to the 
complex I inhibitor rotenone was examined across both variants. Cells grown under either 
set of conditions were treated with rotenone for 24 h, before levels of cell viability were 
ascertained using the MTT assay. It was demonstrated that galactose-cultured cells 
exhibited greatly enhanced susceptibility towards rotenone-induced cytotoxicity (Table 
2.1.), with relevant IC50 values calculated from the dose-response curves outlined in Figure. 
2.1. This augmented response towards compounds impacting upon the functioning of the 
organelle indicates an increased reliance upon mitochondrial ATP production. 
T (h) IC50 (µM) 
  Glucose Galactose 
          
24 > 10 0.027 ± 0.009 
 
Table 2.1. IC50 values of glucose-cultured and galactose-cultured Hep G2 cells dosed with 
rotenone. Cytotoxicity was determined using the MTT assay. Results are shown as the 
mean of three independent experiments, ± SD. 
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Figure 2.1. Representative traces outlining dose-response relationships in glucose-
cultured and galactose-cultured Hep G2 cells  upon artesunate treatment. Cells were 
exposed to 0 – 10 µM artesunate for a period of 24 h, before viability was ascertained using 
the MTT assay. Values are expressed as percentage of live cells relative to vehicle control, 
and are presented as the mean of three independent experiments, ± SD. * represents p < 
0.05, ** represents p < 0.01 and *** p < 0.001, as determined through the paired t-test. 
2.3.1.1.2. Response of Galactose-Cultured and Glucose-Cultured Cells towards 
Artesunate Treatment 
 
Glucose-cultured and galactose-cultured Hep G2 cells were examined for their response to 
treatment with artesunate. Investigation into dose-response was performed following 24, 
48 and 72 h incubation, with the MTT assay employed in order to determine the viability. 
Small differences, none statistically significant, were witnessed between IC50 values 
obtained after 24 and 48 h drug treatment (Table 2.2.). 
T (h) IC50 (µM) p 
  Glucose Galactose   
            
24 94.7 ± 10.6 79.7 ± 26.2 > 0.05 
48 48.0 ± 4.80 40.6 ± 1.97 > 0.05 
72 28.8 ± 5.80 28.7 ± 2.70 > 0.05 
 
Table 2.2. IC50 values of glucose-cultured and galactose-cultured Hep G2 cells dosed with 
artesunate. Cytotoxicity was determined using the MTT assay. Results are shown as the 
mean of three independent experiments, ± SD. p < 0.05 denotes statistical significance, as 
determined through the paired t-test. 
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2.3.1.1.3. Effect of Artesunate upon Oxygen Consumption Rate in Galactose-
Cultured and Glucose-Cultured Cells 
 
The Seahorse XFe96 analyser was used in order to assess the impact of artesunate upon 
mitochondrial respiratory function in Hep G2 cells. Glucose-cultured or galactose-cultured 
cells were dosed in situ with 500 µM artesunate, before OCR and ECAR responses were 
recorded over a period of 2 h. Drugged cells exhibited a gradual and significant decrease in 
levels of OCR, which had fallen to 78% and 74% of control values in glucose-cultured and 
galactose-cultured lines respectively following 120 minutes of exposure (Fig. 2.2. A). There 
was no significant variation in response between the two cell types. ECAR was observed to 
spike immediately upon drug administration over both cell varieties, before entering into 
decline (Fig. 2.2. B). The magnitude of this initial increase was substantially greater in the 
galactose-grown line, reaching 800% of control quantity at its maximum extent. After 2 h of 
measurement, ECAR had fallen to 73% and 79% of control respectively in the glucose-
cultured and galactose-cultured varieties. Variation in response between types did not 
achieve significance. 
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Figure 2.2. Cellular oxygen consumption and extracellular acidification rates in glucose-
cultured and galactose-cultured Hep G2 cells responding to artesunate treatment. Cells 
were treated with 500 µM artesunate before variations in OCR (A) and ECAR (B) were 
measured over a 2 h period. Values are expressed as percentage of OCR relative to vehicle 
control, and are presented as the mean of three independent experiments, ± SD. * 
represents p < 0.05, ** represents p < 0.01 and *** p < 0.001, as determined through the 
paired t-test. 
 
2.3.1.2. HeLa Cells 
 
2.3.1.2.1. Sensitivity of Galactose-Cultured and Glucose-Cultured Cells towards 
Rotenone Treatment 
 
HeLa cells cultured in either glucose-containing or galactose-containing media were treated 
with rotenone for 24 h, before their viability was examined using the MTT assay. Similar to 
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the pattern observed in the Hep G2 line, galactose-cultured cells exhibited a far greater 
sensitivity towards the cytotoxic effects of the compound (Table 2.3.). 
 
T (h) IC50 (µM) p 
  Glucose Galactose   
            
24 0.24 ± 0.054 0.0038 ± 0.0023 0.0072 
 
Table 2.3. IC50 values of glucose-cultured and galactose-cultured HeLa cells dosed with 
rotenone. Cytotoxicity was measured using the MTT assay. Results are shown as the mean 
of three independent experiments, ± SD. p < 0.05 denotes statistical significance, as 
determined through the paired t-test. 
 
2.3.1.2.2. Response of Galactose-Cultured and Glucose-Cultured Cells towards 
Artesunate Treatment 
 
Glucose-cultured and galactose-cultured HeLa cells were treated with artesunate, with 
dose-response relationships examined using the MTT assay following 6, 16, 24, 48 and 72 h 
incubation. Significant deviation between the sensitivity of the cell types to the drug is 
apparent at 16, 24 and 48 h (Table 2.4.).  
T (h) IC50 (µM) p 
  Glucose Galactose   
        
 
  
6 > 1000 > 1000 - 
16 193  ± 15.6  129 ± 2.60 0.0082 
24 77.3 ± 5.92 24.8 ± 8.41 0.0095 
48 27.1 ± 3.18 9.70 ± 0.98 0.0048 
72 15.0 ± 2.31 10.0 ± 4.45 > 0.05 
 
Table 2.4. IC50 values of glucose-cultured and galactose-cultured HeLa cells dosed with 
artesunate, obtained using MTT assay. Results are shown as the mean of three 
independent experiments, ± SD. p < 0.05 denotes statistical significance, as determined 
through the paired t-test. 
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2.3.1.2.3. ATP Content in Galactose-Cultured and Glucose-Cultured Cells following 
Artesunate Treatment 
 
The impact of artesunate administration upon ATP levels in glucose-cultured and galactose-
cultured HeLa cells was determined using the CellTiter-Glo luminescent ATP content assay. 
Variation in ATP abundance between cells was found to be significant following 16 and 24 h 
treatment (Table 2.5.).  
T (h) IC50 (µM) p 
  Glucose Galactose   
  
 
  
 
    
6 > 1000 > 1000 - 
16 210 ± 27.1 14.7 ± 10 0.0014 
24 47.6 ± 9.3 5.37 ± 1.2 0.0092 
48 13.5 ± 2.60 12.6 ± 0.20 > 0.05 
72 16.3 ± 2.40 12.1 ± 1.50 > 0.05 
 
Table 2.5. IC50 values of glucose-cultured and galactose-cultured HeLa cells dosed with 
artesunate, obtained using ATP content assay. Results are shown as the mean of three 
independent experiments, ± SD. p < 0.05 denotes statistical significance, as determined 
through the paired t-test.  
 
The time-dependence of the IC50 values assayed through MTT and ATP content assays, as 
outlined in Table 2.4. and Table 2.5., is displayed graphically in Figure 2.3. A fall in ATP 
levels is shown to precede cytotoxicity in glucose-cultured (Fig. 2.3 A) and galactose-
cultured (Fig. 2.2. B) HeLa cells. The extent of this effect is greater within the latter variety. 
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Figure 2.3. Time-dependence of IC50 values obtained through MTT and ATP content 
assays. HeLa cells cultured in glucose (A) and galactose (B) were exposed to artesunate for 
over time periods ranging from 6 – 72 h.  Results are shown as the mean of three 
independent experiments, ± SD.  
 
2.3.1.2.4. Effect of Artesunate upon Oxygen Consumption Rate in Galactose-
cultured and Glucose-cultured Cells 
 
The Seahorse XFe96 analyser was used in order to assess the impact of artesunate upon 
mitochondrial respiratory function in HeLa cells. Glucose-cultured or galactose-cultured 
cells were dosed in situ with 50 µM artesunate, before OCR response was recorded across a 
period of 2 h. OCR had fallen to 78% and 77% of control values in glucose-cultured and 
galactose-cultured cells respectively following 120 minutes of exposure (Fig. 2.4. A). ECAR 
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increased initially upon drug exposure within each cell type, growing to 250-300% of 
control levels at its greatest extent (Fig. 2.4. B). Levels subsequently fluctuated, before 
reaching 66% and 67% of control in the glucose-cultured and galactose-cultured cells 
respectively upon 2 h treatment. 
 
Figure 2.4. Cellular oxygen consumption and extracellular acidification rates in glucose-
cultured and galactose-cultured HeLa cells responding to artesunate treatment. Cells 
were treated with 50 µM artesunate before variations in OCR (A) and ECAR (B) were 
measured over a 2 h period. Values are expressed as percentage of OCR or ECAR relative to 
vehicle control, and are presented as the mean of three independent experiments, ± SD. * 
represents p < 0.05, as determined through the paired t-test. 
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2.3.2. Impact of Artesunate upon Mitochondrial Bioenergetic 
Function 
 
2.3.2.1. The Mitochondrial Stress Test 
 
The mitochondrial function of HeLa cells in response to artesunate treatment was 
examined using the Seahorse XFe analyser. Through determining variation in OCR and ECAR 
associated with the addition of compounds known to impact upon structures associated 
with oxidative phosphorylation, it is possible to examine several parameters indicative of 
mitochondrial health. A model trace, outlining the typical OCR response of cells to the 
addition of compounds over the course of a stress test, is displayed in Figure 2.5. It is typical 
for a set of twelve OCR or ECAR measurements to be made over a period of 80 minutes, 
with a seven minute equilibration and mixing cycle occurring between each.  
 
Figure 2.5. Idealised OCR trace displaying parameters discernible during the course of the 
mitochondrial stress test. OCR response to the sequential addition of oligomycin, FCCP and 
rotenone is outlined. 
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Three measurements are made corresponding to levels of basal cellular respiratory oxygen 
consumption, prior to the injection of the first compound. The addition of the ATP synthase 
inhibitor oligomycin has the effect of blocking oxidative phosphorylation, thus removing all 
oxygen consumption associated with the generation of ATP. A fall in OCR is witnessed to 
occur, the magnitude of which is dependent upon the extent of remaining consumption 
unrelated to oxidative ATP synthesis. Typically, this OCR can be attributed both to the 
passive leakage of protons across the inner mitochondrial membrane, and also to non-
mitochondrial respiration. 
FCCP is an ionophoric compound, which permeabilises the inner membrane of the 
mitochondrion to the passage of protons, and thus induces a collapse in membrane 
potential. The removal of the proton gradient uncouples oxygen consumption from ATP 
production, leading to an increase in OCR to levels approaching their theoretical maximum.  
The complex I inhibitor rotenone, which suspends predominant oxygen consumption 
through the electron transport chain, reduces OCR to that occurring primarily through non-
mitochondrial routes. Experimental OCR traces displayed Figure 2.6. outline the variations 
in response to oligomycin and FCCP administration in control cells (Fig. 2.6. A), and in those 
treated with 50 µM artesunate (Fig. 2.6. B), for a period of 24 h. Increased proton leak and 
decreased maximal respiration are clearly evident in the latter. Figure 2.7. displays the 
corresponding variations in ECAR, with growth in basal glycolytic rate readily apparent. 
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Figure 2.6. Representative experimental OCR traces derived from mitochondrial stress 
tests. OCR response to the sequential addition of oligomycin, FCCP and rotenone is outlined 
in control (A) and 50 µM artesunate-treated (B) HeLa cells following 24 h incubation. 
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Figure 2.7. Representative experimental ECAR traces derived from mitochondrial stress 
tests. ECAR response to the sequential addition of oligomycin, FCCP and rotenone is 
outlined in control (A) and 50 µM artesunate-treated (B) HeLa cells following 24 h 
incubation. 
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2.3.2.1.1. Effects of Artesunate upon Basal Oxygen Consumption Rate 
 
Basal OCR was measured in HeLa cells following 24 h treatment with artesunate over 
concentrations ranging from 1 to 100 µM (Fig. 2.8. A), and with 20 µM artesunate across 
times ranging from 0 to 24 h (Fig. 2.8. B). No significant variations in OCR levels were seen 
with respect to either concentration or to time. 
 
Figure 2.8. Effects of artesunate upon basal oxygen consumption rate. HeLa cells were 
treated for 24 h with artesunate in concentrations ranging from 1 – 100 µM (A) and with 20 
µM artesunate over time courses ranging from 0 – 24 h (B). Values are expressed as 
percentage of normalised OCR relative to vehicle control, and are presented as the mean of 
three independent experiments, ± SD. 
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2.3.2.1.2. Impact of Artesunate upon Mitochondrial Coupling Efficiency 
 
The efficiency of oxidative coupling and ATP production may be inferred through 
determining the proportion of OCR linked to the generation of ATP, relative to that 
attributable to proton leak. As outlined in Figure 2.5., the addition of oligomycin induces 
reduction in OCR from basal levels, with that which remains assignable to both the leak of 
protons and to non-mitochondrial respiration.  
If u is OCR following oligomycin addition, b is basal OCR and n is non-mitochondrial OCR, 
the coupling efficiency CE can be determined through the equation: 
𝐶𝐸 = 1 −
(𝑢 − 𝑛)
(𝑏 − 𝑛)
 
So that as incidence of proton leak increases, coupling efficiency falls. Treatment of HeLa 
cells with artesunate for 24 h over concentrations from 1 to 100 µM (Fig. 2.9. A) induced a 
significant decrease in the efficiency of coupling, with levels falling to 60% of those in 
vehicle control. Dosing with 20 µM artesunate (Fig. 2.9. B) resulted in significant reductions 
following 16 and 24 h incubation. 
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Figure 2.9. Impact of artesunate upon mitochondrial coupling efficiency. HeLa cells were 
treated for 24 h with artesunate in concentrations ranging from 1 – 100 µM (A) and with 20 
µM artesunate over time courses ranging from 0 – 24 h (B). Values are expressed as 
percentage of normalised OCR relative to vehicle control, and are presented as the mean of 
three independent experiments, ± SD. * represents p < 0.05 and ** p < 0.01, as determined 
through the paired t-test. 
 
2.3.2.1.3. Effect of Artesunate upon Mitochondrial Reserve Capacity 
 
It is typical that cells respire and consume oxygen under resting conditions at rates far 
smaller than those of which they are capable under instances of increased bioenergetic 
demand. The maximal respiratory capacity of a cell can be determined through examining 
the magnitude of the OCR increase induced through addition of the ionophore FCCP, a 
compound which collapses proton gradient and uncouples ATP production. If m is OCR 
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following FCCP addition, b is basal OCR and n is non-mitochondrial OCR, reserve capacity RC 
can be determined through the equation: 
𝑅𝐶 =
(𝑚 − 𝑛)
(𝑏 − 𝑛)
 
A significant, steady and dose-dependent decrease in HeLa cell reserve capacity occurred 
upon 24 h artesunate treatment (Fig. 2.10. A), with values falling to 40% of control at the 
maximal 100 µM concentration. Time-dependence was additionally evident, with significant 
falls in response to 20 µM artesunate apparent following 16 and 24 h (Fig. 2.10. B). 
 
Figure 2.10. Effect of artesunate upon mitochondrial reserve capacity. HeLa cells were 
treated for 24 h with artesunate in concentrations ranging from 1 – 100 µM (A) and with 20 
µM artesunate over time courses ranging from 0 – 24 h (B). Values are presented as the 
mean of three independent experiments, ± SD. * represents p < 0.05 and ** p < 0.01, as 
determined through the paired t-test. 
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2.3.2.1.4. Effect of Artesunate upon Basal Extracellular Acidification Rate 
 
Rates of cellular glycolysis are determined through measuring media acidification (ECAR) 
stimulated though increased proton production. Basal ECAR is recorded prior to addition of 
oligomycin. HeLa cells treated with 1 – 100 µM artesunate for a period of 24 h exhibit 
significant, dose-dependent increases in levels of basal acidification up to 50 µM, before 
falling to those of control (Fig. 2.11. A). Cells dosed with 20 µM artesunate display a time-
dependent growth in ECAR, which becomes significant following 16 and 24 h (Fig. 2.11. B). 
 
Figure 2.11. Effect of artesunate upon basal extracellular acidification rate. HeLa cells 
were treated for 24 h with artesunate in concentrations ranging from 1 – 100 µM (A) and 
with 20 µM artesunate over time courses ranging from 0 – 24 h (B). Values are presented as 
the mean of three independent experiments, ± SD. * represents p < 0.05, as determined 
through the paired t-test. 
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2.3.2.2. Glycolytic Stress Test 
 
The Seahorse XFe analyser was used in order to determine the glycolytic capacity of HeLa 
cells in response to artesunate treatment. ECAR variation resulting from the sequential 
addition of compounds impacting upon the progression of glycolysis enables such functions 
to be quantified. An idealised ECAR trace taken over the course of a typical glycolytic stress 
test is outlined in Figure 2.12. Twelve ECAR measurements are generally made over a 
period of 80 minutes, with a seven minute equilibration and mixing period occurring 
between each. 
 
 
Figure 2.12. Idealised ECAR trace displaying parameters discernible during the course of 
the glycolytic stress test. ECAR response to the sequential addition of glucose, oligomycin 
and 2-DG is outlined. 
 
77 
 
Culture media is replaced with glucose-free DMEM, before the introduction of glucose 
stimulates basal glycolysis. Maximal levels are attained through addition of oligomycin – a 
compound inhibiting ATP synthase and hence shifting energy production from oxidative 
phosphorylation. The final compound added, 2-DG, blocks glycolysis, reducing remaining 
ECAR to that arising from non-glycolytic sources. Experimental OCR traces displayed Figure 
2.13. outline the response to administration of these compounds both in control cells (Fig. 
2.13. A) and in those treated with 50 µM artesunate (Fig. 2.13. B) for a period of 24 h. 
Increased proton leak and decreased maximal respiration are clearly evident in the latter. 
 
Figure 2.13. Representative experimental ECAR traces derived from glycolytic stress tests. 
ECAR response to the sequential addition of glucose, oligomycin and 2-DG is outlined in 
control (A) and 50 µM artesunate-treated (B) HeLa cells incubated for a period of 24 h. 
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2.3.2.2.1. Impact of Artesunate upon Glycolytic Reserve Capacity 
 
The glycolytic reserve capacity of a cell may be inferred from the relative magnitude of the 
ECAR response following addition of oligomycin.  
If o is ECAR level following oligomycin addition, g is glucose-stimulated ECAR and n is non-
glycolytic ECAR, glycolytic reserve GR is given by the equation: 
𝐺𝑅 =
(𝑜 − 𝑛)
(𝑔 − 𝑛)
 
Following 24 h treatment with 50 µM artesunate, a significant, dose-dependent decrease in 
the glycolytic reserve capacity of HeLa cells is noted (Fig. 2.14.). 
 
 
Figure 2.14. Impact of artesunate upon glycolytic reserve capacity. HeLa cells were treated 
for 24 h with artesunate in concentrations ranging from 5 – 50. Values are expressed as 
percentage of normalised ECAR relative to vehicle control, and are presented as the mean 
of three independent experiments, ± SD. * represents p < 0.05, as determined through the 
paired t-test. 
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2.4. Discussion 
 
The activity of artesunate has been examined with respect to its functions as a 
mitochondrial toxin. Studies into its effects across cells sensitised towards mitochondrial 
liability through galactose culturing have indicated a tendency towards enhanced 
cytotoxicity, albeit with variability dependent upon cell line and length of treatment. It was 
generally observed that the sensitivity of cervical carcinoma-derived HeLa cells towards 
artesunate was greater than that of the hepatocellular Hep G2 line – an effect which was 
found to occur uniformly irrespective of culture conditions. This may be understood with 
reference to the bioenergetic profile of the Hep G2 cells, which possess elevated glycolytic 
capacity and hence a relative general resistance to the effects of mitochondrially toxic 
compounds (Marroquin et al., 2007). Their choice as the initial cell line in which to 
investigate artesunate toxicity through galactose culture was made owing to their 
prevalence across studies performed within the literature.  
No significant variation was noted between the artesunate IC50 values obtained through the 
MTT assay in glucose-cultured and galactose-cultured Hep G2 cells over all incubation time 
points examined (Table 2.2.). Although this response would appear inconsistent when 
viewed alongside the existing evidence testifying to the role of endoperoxides as 
mitochondrial toxins, it has been noted that compounds such as tamoxifen, doxorubicin 
and imipramine, which are further known disrupters of mitochondrial function, possess 
near-identical cytotoxicity profiles within both glucose-cultured and galactose-grown Hep 
G2 cells (Dykens et al., 2008b; Marroquin et al., 2007). In these instances, it is theorised 
that their action in the mitochondria forms only a single facet of the mechanism through 
which they induce cell death, with effects upon other areas of cellular function being of 
considerable additional importance (Will et al., 2014).  
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Repetition of this experiment within the more sensitive HeLa line produced a greater 
general variance in the response between glucose-cultured and galactose cultured cells, 
with significant differences in MTT-defined IC50 value noted following 16, 24 and 48 h 
artesunate treatment (Table 2.4.). The magnitude of this variation was greatest at the 24 
and 48 h points, at which galactose-cultured cells were observed to possess a three-fold 
greater sensitivity to the effects of the drug relative to those grown in glucose. The 
relevance of the extent of such disparities in susceptibility has been subject to discussion, 
with consensus across the literature generally holding a difference of at least two-fold to 
three-fold in the Hep G2 line to be indicative of a compound possessing mitochondrial 
liability (Swiss et al., 2013; Will et al., 2014). Variations observed at the 24 and 48 h 
treatment would place artesunate within this range, although a lack of corresponding data 
within the literature from HeLa cells makes comparison imperfect. Contrast is noted with 
respect to the effects witnessed in response to the direct mitochondrial toxin rotenone, 
which exhibits sixty-fold greater activity within the galactose-cultured cells (Table 2.3.).  
Examination into artesunate effects upon ATP content in HeLa cells was performed using 
the luciferase-based CellTiter-Glo assay. Galactose-cultured cells displayed greatly 
enhanced sensitivity following 16 h and 24 h incubation, with fourteen-fold and nine-fold 
decreases in IC50 witnessed respectively relative to those grown in glucose (Table 2.5.). 
These differences had abated after 48 and 72 h, at which points there was almost no 
variability between types. It was generally observed that diminished ATP levels preceded a 
fall in MTT-detected cell viability, although such an effect was most prominent in galactose-
cultured cells up to 24 h and in glucose-cultured cells between 24 and 48 h. A fall in ATP 
content occurring prior to cell death suggests that drug-induced disruption to ATP synthesis 
is causative in cytotoxicity, whilst the more pronounced nature of this within galactose-
grown cells indicates that action upon mitochondrial energy generation serves additional 
importance (Fig. 2.3.). 
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Cellular bioenergetic function was impacted through artesunate treatment. Use of the 
Seahorse XFe analyser allowed for a broad investigation of the respiratory profile of HeLa 
cells to be performed, outlining the consequence of drug effects upon the activity of the 
mitochondrion. Full concentration and time-courses for stress test experiments were 
obtained for 0 – 24 h drug incubation, so that the onset of mitochondrial dysfunction could 
be related to the emergence of cytotoxicity. Evidence obtained suggests that artesunate 
imparts deleterious effects upon the performance of oxidative phosphorylation. Whilst no 
significant impact upon basal OCR level was noted with respect either to concentration of 
drug or to length of treatment (Fig. 2.8.), clear dose-dependent and time-dependent 
increases in basal ECAR were apparent until the dropping-off at heightened concentration 
(Fig. 2.11.). Elevation in ECAR is indicative of a growth in glycolytic respiration rate – an 
effect which is apparent as a compensatory mechanism in cells possessing compromised 
capacity to generate ATP through oxidative means. Nevertheless, the maximal glycolytic 
capacity of the cell, ascertained through the glycolytic stress test, fell steadily with 
artesunate dose (Fig. 2.14.). This signifies that supplementation of ATP through increased 
shift towards glycolysis grows increasingly unsustainable at higher drug concentration, 
enabling swifter depletion of energy and enhanced resultant levels of cell death. 
Coupling efficiency of ATP production is inferred through determining the extent of proton 
leak across the inner mitochondrial membrane. The pumping of protons from the matrix 
into the intermembrane space is mediated through the four complexes constituting the 
electron transport chain, with the resultant gradient utilised for the purpose of ATP 
generation through ATP synthase. Whilst the non-productive diffusion of protons back 
across the inner membrane is found to occur at a basal rate under physiological conditions, 
significant increases are associated with dysfunctions in oxidative phosphorylation 
(Divakaruni et al., 2011; Jastroch et al., 2010). It is observed from stress test data that 
coupling efficiency decreases in a manner which is dependent upon artesunate dose and 
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length of incubation, falling to approximately 60% of control value in response to 5 µM 
treatment following 24 h, and 20 µM following 16 h (Fig. 2.9.). No further fall beyond the 
60% minimum is witnessed, despite the continued decline in cell viability with respect to 
dose and time beyond those points.  
A factor commonly associated with diminished coupling and enhanced proton leak is 
damage to the electron transport chain complexes or to the inner mitochondrial membrane 
(Hill et al., 2012). There are an array of mechanisms through which this might occur in 
response to drug treatment, ranging from generalised oxidative stress to specific, targeted 
inhibition and modification of individual enzymes and proteins. The existing evidence 
regarding the activity of endoperoxide compounds within cells suggests several routes 
through which they might potentially induce functional modifications impacting adversely 
upon the progression of oxidative phosphorylation. It is hypothesised that the Fe(II)-
mediated formation of carbon-centred radicals is key to both cytotoxic and 
pharmacological mechanisms of action, with the reactivity of these species affording them 
potent ability as alkylating agents (Mercer, 2009; Mercer et al., 2010). Modification of 
haem in the presence of artemisinin has been demonstrated through biomimetic and in 
vitro studies, with structural changes noted within a variety of enzymes (Selmeczi et al., 
2004; Yang et al., 1994). It is known that haemoproteins are a common feature within 
electron transport chain complexes, leading to a proposed route whereby defective 
complex function resulting from alkylation might contribute towards ROS formation 
(Mercer et al., 2011). It has not been established, however, whether these structural 
alterations have the ability to impact significantly upon the activity of the proteins, 
prompting certain authors to doubt their relevance towards drug cytotoxic and antiparasitic 
action (Haynes et al., 2013; Haynes et al., 2011; Haynes et al., 2004).  
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The mitochondrial reserve capacity relates to the spare respiratory potential possessed by a 
cell. Under instances of increased bioenergetic demand, the ability of the mitochondrion to 
increase rate of energy generation in order to match heightened requirements can act as a 
key determinant of its facility to overcome stress (Dranka et al., 2011). Reduction in reserve 
capacity is associated with a diminished capacity to respond in such conditions – postulated 
as holding relationship with decreases in mitochondrial mass – with a total depletion 
culminating in death (Hill et al., 2012). Experimentally, it is OCR response to the addition of 
the ionophoric uncoupler FCCP which is employed in order to determine the magnitude of 
maximal respiration, with reserve capacity inferred through relating this value to the basal 
and non-mitochondrial constituents of OCR. It was found that steady decreases in this 
parameter were witnessed with respect to both artesunate dose and incubation time, 
declining to a minimum value of 40% following 100 µM treatment over a 24 h period (Fig. 
2.10.). It is understood that the extent of the reserve capacity is determined through the 
general efficiency of oxidative phosphorylation, a factor which is dependent upon the 
degree of respiratory coupling. Combined with the corresponding data outlining the 
reduction in coupling efficiency, its fall provides further evidence suggesting the presence 
of damage to the electron transport system. Whilst dysfunction might result from specified 
complex inhibition, as discussed earlier, it can arise additionally as a consequence of 
general oxidative stress. The effects of elevated ROS levels are well known to be deleterious 
towards an array of processes within cells, and it has been established that structural 
changes resulting from lipid peroxidation and protein modification may be causative of 
these (Fiers et al., 1999; Imlay, 2003; Kowaltowski et al., 1999). Studies have associated the 
induction of ROS with reduced reserve capacity across several cell systems, suggesting that 
damage resulting from oxidative stress can impact upon the ability of the cell to respond to 
further insult (Dranka et al., 2010; Hill et al., 2009; Perron et al., 2013). The resulting cycle 
of ever-increasing oxidative damage would lead to a further diminished ability to restore 
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cell functions, resulting ultimately in its death. The source of this stress with respect to 
artesunate cytotoxicity remains to be elucidated, although this shall be granted further 
investigation in due course. 
The relationship between the onset of artesunate cytotoxicity and the progression of 
mitochondrial dysfunction can be examined up to 24 h. No indication of bearing upon cell 
viability, reserve capacity or coupling efficiency is evident following 6 h treatment. Impact 
upon each of these parameters emerges only following 16 h incubation, before progressing 
further at 24 h. It can be observed that decline in mitochondrial function occurs alongside 
decrease in cell viability – strongly suggesting that drug impact upon the performance of 
the mitochondrion is a key determinant of cytotoxicity. This correlation is also witnessed to 
occur with respect to dose across the 1 – 100 µM range at a single, 24 h incubation period. 
The in situ dosing of glucose-cultured and galactose-cultured cells with a single, elevated 
drug dose produced only modest declines in OCR following 2 h exposure, which appears 
commensurate with the lack of substantial toxicity noted at this point (Fig. 2.4.). Contrasts 
must be made with the outcomes obtained from the studies performed by Dykens et al., in 
which profound, sustained decreases in OCR – accompanied with commensurate increases 
in ECAR – were noted to occur over identical time-spans upon the administration of the 
mitochondrially-active compounds rotenone and nefazodone (Dykens et al., 2008b). 
When combined, the data presented within this chapter indicates that impact upon the 
bioenergetic profile of the mitochondrion is a key feature of the route through which 
artesunate is able to impart cytotoxic effects. Defective mitochondrial functioning, 
witnessed in terms of a diminished efficiency of oxidative phosphorylation and an 
accompanying increased reliance upon glycolytic respiration, is found to occur alongside 
cell death. Variations in sensitivity to the drug across galactose-cultured and glucose-
cultured cell lines imply that increased dependence upon mitochondrial ATP production is 
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associated with heightened susceptibility towards toxicity. However, the relatively modest 
magnitude of these differences relative to direct mitochondrial toxins such as rotenone 
would suggest that non-mitochondrial activity is also a contributing factor towards their 
mechanism of action. In order to define the route through which defects arise, detailed 
investigation into the factors affecting their emergence shall follow. 
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3.1. Introduction 
 
In establishing the mechanistic routes through which artesunate induces the emergence of 
mitochondrial dysfunction, consideration must be given both to the initial interactions 
which underpin susceptibility towards the effects of the drug, and to the consequences 
which these later possess regarding physiological activity within the cell. Evidence strongly 
suggests that the cytotoxic impact of artemisinin is related intimately to its ability to 
stimulate the onset of ROS formation (Firestone et al., 2009). Whilst knowledge of the 
pathways underpinning such an occurrence remains incomplete, it is widely accepted that 
cellular iron possesses roles within both the early bioactivation of the compound, and 
within the propagation of oxidative stress (Mercer et al., 2010). The intention of this 
chapter is to examine the hypothesis that the iron-mediated generation of ROS forms an 
essential stage in the emergence of defective mitochondrial bioenergetic functioning.  
Particular focus shall be given to examination of the impact that the modulation of 
oxidative stress and iron levels has upon the respiratory activity of the organelle. This work 
shall be accompanied by further investigations centred upon elucidation of the cellular 
origins of such events.  
It is acknowledged that there exists a variety of mechanisms through which aberrant 
functioning of the mitochondrion might arise as a consequence of drug treatment (Dykens, 
2008). Studies have demonstrated that the administration of artemisinin derivatives in 
cancer cells is accompanied by substantial impact upon the operation of several 
physiological processes mediated at the organelle, associated with impairment of 
bioenergetic activity, efficiency of oxidative phosphorylation and energy generation linked 
to reduction in ATP production capacity, collapse of the mitochondrial membrane potential, 
and the eventual initiation of cell death through the intrinsic apoptotic pathway (Mercer et 
al., 2011). The outcomes of examinations performed within the previous chapter suggest 
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that the origin of these defects might arise from the effects of drug action at both 
mitochondrial and non-mitochondrial sites.  
A theme common across many studies performed assessing the activities of artemisinin 
derivatives within mammalian systems is an observed ability to impart the induction of 
oxidative stress. It has been noted that the time-dependent and dose-dependent 
generation of ROS occurs upon administration of the compounds across an array of cancer 
cell lines (Firestone et al., 2009). ROS prevalence is heavily associated with the progression 
of cytotoxicity, with the capacity for antioxidant compounds to abrogate oxidative stress 
linked closely to cytoprotective effect (Mercer et al., 2011). The impact of oxidative damage 
upon the functioning of cellular systems may be widespread and substantial. Such effects 
typically arise as a product of the structural modifications occurring subsequent to 
interaction between reactive oxyl radicals and biomolecules including phospholipids, DNA, 
Fe-S clusters and haemoproteins (Apel et al., 2004). As a consequence of central role which 
many of these elements play within physiological processes occurring in the organelle, it is 
hypothesised that the effects of ROS impart substantial impact upon mitochondrial function 
and morphology.  
Oxidative stress is characterised by the elevated production of ROS ahead of levels which 
can be safely detoxified through the actions of endogenous antioxidant pathways(Apel et 
al., 2004). Such an occurrence may arise owing to the defective operation of a variety of 
systems across the cell predisposed which are towards their formation. Many appropriate 
sites are situated within the mitochondrion – a body identified as the primary cumulative 
source for ROS generation (Murphy, 2009). It is accepted that the great majority of these 
ROS have their origin in the initial conversion of molecular oxygen to the superoxide radical, 
which occurs as a consequence of electron leakage from the electron transport chain 
(Dykens, 2008). Accordingly, damage to the machinery associated with the maintenance of 
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oxidative phosphorylation is linked closely with emergence of oxidative stress (Turrens, 
2003). In addition, a variety of alternative ROS-producing systems are known to exist within 
the organelle. Amongst these stand enzymes such as monoamine oxidase, aconitase and 
cytochrome b5 reductase (Andreyev et al., 2005). 
Sources of ROS external to the mitochondrion are further acknowledged as possessing roles 
significant towards both physiological and pathological processes (Orient et al., 2007). 
Enzymes such as xanthine oxidase and NADPH oxidase are capable of generating quantities 
of superoxide as part of immune response to pathogens (Papi et al., 2008; Segal et al., 
2012). Its production may further be associated with the activities of cytochrome P450, 
cyclooxygenase and nitric oxide synthase enzymes. ROS emerging from these sources have 
potential to impact across all areas of the cell, including within the mitochondrion (Li et al., 
2013). It is feasible, therefore, that defective operation within these systems might have 
potential to function as an indirect route towards the initiation of mitochondrial damage 
and dysfunction. 
Irrespective of source, interactions occurring between ROS and cellular iron, such as those 
outlined in Section 1.5.2.1., Chapter 1,  are noted as being of central importance towards 
both the progression of oxidative stress and to the deleterious effects imparted by the 
reactive molecules upon the structural and functional integrity of cell systems (Galaris et 
al., 2008). ROS possess an ability to instil substantial damage to iron-containing elements, 
such as haem units and Fe-S clusters, present across many proteins possessing essential 
roles within both mitochondrial and non-mitochondrial processes (Davies, 1990). It is 
hypothesised that enzymatic inactivation arising through this route might be accountable 
for the dysfunction of, amongst other systems, the complexes involved within the electron 
transport chain (Cortes-Rojo et al., 2011). Alongside direct damage to protein structure, it is 
further acknowledged that ROS-iron interaction serves to stimulate propagation of 
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oxidative stress (Thomas et al., 2009). Free, unbound Fe(II) is relevant within this pathway, 
owing to its ability to participate alongside hydrogen peroxide in the generation of the 
hydroxyl radical through Fenton chemistry (Kakhlon et al., 2002). The concentration of free 
iron is found to be significant at points within the mitochondrial matrix and the lysosomal 
bodies. Owing to their position as sites at which the degradation of iron-containing proteins 
largely occurs, the latter are particularly notable for their elevated content (Kurz et al., 
2011). Modulation of levels within through use of loaders or chelators is accordingly 
associated with alleviation of oxidative stress and a diminished likelihood of progression 
towards cell death in response to drug treatment (Hamacher-Brady et al., 2011). 
 
The studies presented in this chapter are intended to provide a greater mechanistic insight 
into the relationship between ROS formation and onset of mitochondrial damage in the 
context of artesunate treatment, and hence examine the hypothesis that defective 
bioenergetic function arises as a consequence of iron-associated oxidative damage towards 
the organelle. The impacts of the antioxidant ROS scavengers tiron and 4-hydroxy-2,2,6,6-
tetramethylpiperidin-1-oxyl (TEMPOL) upon the response of HeLa cells towards drug 
administration are examined, with particular focus being given to their influence on cell 
survival and mitochondrial function. Bioenergetic performance shall be monitored once 
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again using the Seahorse XFe unit. In order that the contribution of unbound iron might be 
examined, the lysosomal chelator DFO shall be dosed alongside the artesunate derivative, 
and its ability to modulate drug effects upon ROS production, cell viability and 
mitochondrial activity assayed. Further investigation shall seek to elucidate the importance 
of the electron transport chain towards the generation of superoxide, whilst additionally 
determining the potential relevance of extra-mitochondrial ROS sources in the emergence 
of oxidative stress.  
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3.2. Materials and Methods 
 
3.2.1. Materials  
 
Uridine, bovine serum albumin (BSA), sucrose, mannitol, ethylene glycol tetraacetic acid 
(EGTA),magnesium chloride, magnesium sulphate, potassium phosphate monobasic, 
potassium phosphate dibasic, ammonium acetate, sodium succinate, tiron, TEMPOL, DFO, 
diphenyleneiodonium (DPI), metyrapone, allopurinol, indomethacin, DHE, NADH, CoQ1, 
DDM, potassium cyanide, potassium ferricyanide, cytochrome c, iodonitrotetrazolium 
chloride (INT) and all additional solvents were purchased from Sigma-Aldrich (Poole, 
Dorset, UK). 3-(N-morpholino)propansulphonic acid (MOPS) was purchased from Fisher 
Scientific (Loughborough, UK). MitoSOX was purchased from Life Technologies (Paisley, UK). 
Bradford assay reagent was purchased from Bio-Rad (Hertfordshire, UK). PFDHA was 
synthesised by the group of Prof. Paul O’Neill (University of Liverpool, Liverpool, UK). HeLa 
ρ0 cells were donated by Dr Edward Bampton (Medical Research Council Toxicology Unit, 
Leicester, UK). 
3.2.2. Cell Culture and Experimental Preparation  
 
HeLa cells were cultured and maintained according to the protocol outlined in Section 
2.2.2., Chapter 2. HeLa ρ0 cells were cultured in DMEM, with supplemental FBS (10% v/v,) 
sodium pyruvate (1% v/v), uridine (1% v/v) and penicillin/streptomycin solution (1% v/v). All 
cells were incubated at 37°C, in humidified air containing 5% CO2. 
3.2.3. Isolation of Mitochondria 
 
Mitochondria were isolated from rat liver using a protocol adapted from that of Will et al. 
(Will et al., 2006). Wistar rats were sacrificed, before their liver was removed, diced and 
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suspended in a buffer containing 210 mM mannitol, 70 mM sucrose, 5 mM HEPES, 1 mM 
EGTA and 0.5% w/w BSA. The resulting mixture was homogenised prior to centrifugation 
(10 minutes, 700g), after which the supernatant was filtered and centrifuged once more (10 
minutes, 14000g) to yield a mitochondria-rich pellet. This was resuspended in buffer, 
before being centrifuged (10 minutes, 10000g) and suspended in an alternative buffer 
composed of 210 mM mannitol, 70 mM sucrose, 10 mM magnesium chloride, 5mM 
potassium phosphate dibasic, 10 mM MOPS and 1 mM EGTA. Protein content of this 
mitochondrial suspension was assayed using the method of Bradford (Bradford, 1976). 
 
3.2.4. Analysis through Flow Cytometry 
 
Cells were analysed using the BD FACSCanto II flow cytometer ( BD, Oxford, UK), upon 
which was running the FACSDiva software. Forward scatter (FSC) and side scatter (SSC) 
parameters, alongside voltage threshold, were adjusted so that a population of viable cells 
could be obtained to the exclusion of debris (Fig. 3.1.). A minimum of 1x104 cells were 
analysed for each sample, with fluorescence output measured in the appropriate channels. 
 
Figure 3.1. Representative dotplot displaying population of untreated HeLa cells. The 
exclusion of debris through gating is outlined. Viable cells appear within area “P1”. 
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3.2.5. Detection of Cellular Reactive Oxygen Species through use of 
Dihydroethidium 
 
 
 
Dihydroethidium (DHE) is a fluorescent compound which may be employed in flow 
cytometric protocols for the detection of ROS (Peshavariya et al., 2007). Interaction with 
products such as hydrogen peroxide, superoxide, peroxynitrite and the hydroxyl radical 
leads to the formation of oxidised ethidium and hydroxyethidium derivatives, the presence 
of which may be monitored in combination following excitation at a wavelength of 488 nm. 
HeLa cells (2 x 105) were drug-treated for a period of 24 h before undergoing preparation 
for analysis through flow cytometry. Having been washed with HBSS and centrifuged 
(1000g), the remaining cell pellet was resuspended in 0.5 ml DHE solution (final 
concentration 500 µM), before incubation was carried out at 37°C for a period of 10 
minutes. Performance of assay upon the flow cytometer followed immediately.  
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3.2.6. Measurement of Total Mitochondrial Reactive Oxygen Species 
using MitoSOX 
 
 
MitoSOX is a fluorescent dye which functions as a mitochondrially-targeted derivative of 
DHE. As with its parent compound, the formation of oxidised ethidium and 
hydroxyethidium derivatives, the combined prevalence of which may be detected following 
excitation at a wavelength of 488 nm, occurs upon interaction with reactive species such as 
hydrogen peroxide, superoxide, peroxynitrite and the hydroxyl radical (Zielonka et al., 
2010). HeLa cells (2 x 105) were treated with drug for a period of 24 h prior to being readied 
for employment upon the flow cytometer. Following addition of MitoSOX (final 
concentration 1 µM), incubation was performed at 37°C for 10 minutes before cells were 
washed with HBSS and centrifuged (1000g) to produce a pellet. This was subsequently 
resuspended in 0.5 ml HBSS, with samples then being analysed immediately through flow 
cytometry. 
 
3.2.7. Measurement of Mitochondrial Superoxide using MitoSOX 
 
The generation of a characteristic hydroxyethidium derivative arises as a function of 
superoxide-mediated oxidation at the functionalised DHE moiety (Zhao et al., 2003). As 
such, detection of this species allows for the specific quantification of superoxide presence. 
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Experimentally, this is achieved through monitoring fluorescence at the distinctive 
excitation and emission wavelengths of 396 nm and 579 nm (Robinson et al., 2006). HeLa 
and HeLa ρ0 cells (1 x 105), were plated, in duplicate, into 24-well plates. Following 
artesunate dosing, incubation was performed for a period of 24 h. Upon completion, 5 µL 
MitoSOX solution (final concentration 1 µM) was added to each well, before a further 
incubation for 10 minutes at 37°C. Cells were subsequently washed wish HBSS and 
centrifuged (1000g), producing a pellet which was resuspended in 300 µL HBSS. 100 µL 
aliquots of this solution were plated, in duplicate, into a white 96-well plate, before 
MitoSOX fluorescence was read (excitation 396 nm, emission 579 nm) on the Varioskan 
Flash reader (Thermo Scientific, Loughborough, UK). The remaining solution was sonicated 
to produce cell lysates, the protein content of which was determined using the method of 
Bradford. (Bradford, 1976). Fluorescence was ultimately normalised towards protein 
abundance. 
 
3.2.8. Assessment of Cell Viability using the MTT Assay 
 
Cell viability within the HeLa line was ascertained through use of the MTT assay, as detailed 
in Section 2.2.4., Chapter 2.  
 
3.2.9. Determination of Mitochondrial Bioenergetic Function 
through the Seahorse XF Stress Test 
 
The impact of artesunate, and assorted modulators of its activity, upon the mitochondrial 
functioning of HeLa cells was examined on the Seahorse XFe 96 unit through means of the 
mitochondrial stress test, according to the protocols described in Section 2.2.8., Chapter 2. 
 
99 
 
3.2.10. Analysis of Drug Bioactivation using an LC-MS Method 
 
 
 
Bioactivation of the DHA derivative PFDHA was quantified using an existing LC-MS method 
(Mercer et al., 2011; Mercer et al., 2007).  The degradation of PFDHA and the formation of 
its THF acetate isomer occur as a consequence of Fe(II)-mediated reduction of the 
endoperoxide bridge. The quantity of each compound present may be determined through 
monitoring transitions corresponding to characteristic fragmentation patterns. In order to 
prepare samples for analysis, cells (1 x 106) were incubated in the presence of 25 µM 
PFDHA and 10 µM DFO. Following incubation, 4 nmol artesunate was added as an internal 
standard, and cells were extracted using chloroform (3 x 3 ml), before combined extracts 
were dried over anhydrous magnesium sulphate. Debris was removed through filtration, 
and solvent in vacuo, to yield final samples which were dissolved in 100 µL methanol prior 
to analysis. Standards were produced to enable the quantification of materials recovered 
(0.025 – 50 nmol), and these were ran before and following samples.  
LC-MS was performed using the 4000 QTRAP (AB Sciex, Warrington, UK). Separation was 
attained using the Agilent ZORBAX Eclipse XDB-C8 column (150 mm x 3.9 mm, Agilent 
Technologies, Santa Clara, USA), with an eluent of methanol and 10 mM ammonium 
acetate (70:30, v/v) delivered at a flow rate of (rate). The machine was operated in positive 
ion mode, with an ion spray voltage of + 5.0 kV. Back pressure for collision gas was 2 p.s.i., 
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curtain gas 20 p.s.i., nebuliser gas 30 p.s.i. and turbo gas 65 p.s.i.. Nitrogen was used for all 
purposes. 
Parameter PFDHA THF acetate Artesunate 
 
      
Fragmentation transition 
396.0 to 
163.0 
396.0 to 
266.7 
402.1 to 
163.1 
Declustering potential (V) 6 21 21 
Focusing potential (V) 370 370 370 
Entrance potential (V) 8 5 12 
Collision energy (V) 17 30 30 
Collision cell entrance potential (V) 14 19 18.6 
Collision cell exit potential (V) 10 14 26 
Dwell time (s) 200 100 200 
 
Table 4.1. Parameters for the LC-MS quantification of PFDHA and THF-acetate. 
 
 
3.2.11. Assessment of Electron Transport Chain Complex Activity 
 
The functioning of the constituent complexes composing the respiratory chain was 
measured using a series of spectrophotometric methods (Frazier et al., 2012). Isolated 
mitochondria, obtained using the protocol described in Section 3.2.3., were suspended in 
relevant assay buffers before alterations in the absorbance related to characteristic 
reaction substrates was monitored through use of a spectrophotometer (Cary 4000, Varian 
Inc., USA). 
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3.2.11.1. Complex I 
 
Decreases in NADH oxidation, a process which proceeds through the pathway outlined in 
the equation below, are diagnostic of defective operation at complex I. 
 
NADH + H+ + CoQ1  NAD+ + CoQ1-H2 
 
Monitoring the extent of NADH prevalence, achieved through determining characteristic 
absorbance at 340 nm, facilitates assessment of activity. Isolated mitochondria, treated in 
situ with 1 mM artesunate, were suspended in assay buffer containing 50 mM potassium 
phosphate monobasic, 50 mM NADH, 1 mM KCN, 10 mM antimycin A, 0.1% (w/v) BSA and 
50 mM CoQ1. NADH depletion was measured over a 5 minute period, with rate in the 
presence of artesunate normalised towards that of vehicle control. 
 
3.2.11.2. Complex II 
 
Activity of complex II is assayed through measuring decreases in absorbance at 280 nm 
associated with the reduction of CoQ1. 
 
Succinate + CoQ1  Fumarate + CoQ1-H2 
 
 
Isolated mitochondria, treated in situ with 1 mM artesunate, were suspended in assay 
buffer containing 50 mM potassium phosphate monobasic, 10 mM sodium succinate, 1 mM 
potassium cyanide, 10 mM antimycin A and 2.5 mM rotenone. Addition of CoQ1 at a final 
concentration of 50 mM initiated reaction, which was subsequently monitored for 5 
minutes. Normalisation of detected rate was performed towards vehicle control. 
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3.2.11.3. Complex III 
 
Complex III activity may be determined through detecting increased absorbance 
characteristic of the formation of reduced cytochrome c, as measured at 550 nm, upon 
stimulation with reduced CoQ1. 
DB-H2 + Cytochrome c (ox)  DB + Cytochrome c (red) 
 
 
To an assay buffer composed of 50 mM potassium phosphate monobasic, 1 mM n-
dodecylmaltoside (DDM), 1 mM KCN, 2.5 mM rotenone, and 0.1% (w/v) BSA was added 0.1 
mM reduced DB and 1 mM artesunate. Cytochrome c at a final concentration of 15 µM was 
introduced to initiate reaction, which was recorded for 5 minutes. Detected rate was 
subsequently normalised towards vehicle control. 
 
3.2.11.4. Complex IV 
 
Complex IV performance is assayed through monitoring decrease in the prevalence of 
reduced cytochrome c. This is again measured at 550 nm.  
Cytochrome c (red) + O2  Cytochrome c (ox) + H2O 
 
To a 50 mM solution of potassium phosphate monobasic was added mitochondrial 
suspension dosed in situ with 1 mM artesunate. Reduced cytochrome c to a final 
concentration of 15 µM was introduced to commence reaction, which was read for 3 
minutes prior to its termination with potassium ferricyanide. Normalisation of detected 
rate was performed towards vehicle control. 
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3.2.12. Measurement of Complex II Activity 
 
 
 
 
The activity of Complex II was measured in isolated mitochondria using a 
spectrophotometric method derived from that of Green and Narahara (Armstrong et al., 
2010; Green et al., 1980). Complex II, alternatively known as succinate dehydrogenase 
(SDH) reduces INT to a formazan compound, the absorbance of which may be monitored at 
458 nm following alcohol extraction. 0.1 ml of mitochondrial suspension obtained through 
the route described in Section 3.2.3. (0.5 mg protein) was added to 0.4 ml of reaction 
mixture containing 50 mM sucrose, 50 mM sodium succinate, 10 mM potassium phosphate 
monobasic and 0.8 mM INT. Having been dosed with 0 – 1000 µM artesunate, samples 
were incubated at 37°C for 30 minutes. Following this period, 1.5 ml ethanol was added to 
each tube, and samples were left on ice for a further 15 minutes. Centrifugation was 
subsequently performed (5 minutes, 1000g), before the absorbance was 1 ml of resultant 
supernatant was determined at 458 nm (Varioskan Flash, Thermo Scientific, Loughborough, 
UK). 
3.2.13. Statistical Analysis 
 
Data is presented and analysed in line with the protocols described in Section 2.2.10., 
Chapter 2.  
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3.3. Results 
 
3.3.1. Impact of Antioxidants upon Cellular Response to Artesunate 
Treatment 
 
3.3.1.1. Mitochondrial Reactive Oxygen Species 
 
3.1.1.1.1. Effects of Tiron upon Artesunate-Induced Mitochondrial Reactive 
Oxygen Species  
 
Mitochondrial ROS prevalence was examined through use of flow cytometry and the 
MitoSOX dye. MitoSOX is a derivative of DHE localised towards the mitochondrion through 
the affixing of a charged triphenylphosphonium functionality. The polycyclic compound 
becomes oxidised upon contact with cellular ROS, producing cationic ethidium and 
hydroxyethidium derivatives which emit red fluorescence upon intercalation within DNA.  
Their presence might be quantified through monitoring emission stimulated as a 
consequence of excitation at 488 nm. Owing to spatial containment inside the organelle, 
the scope of ROS detection remains confined within. Representative histograms displaying 
fluorescence distribution in vehicle control (Fig. 3.2. A) and 100 µM artesunate-dosed HeLa 
cells (Fig. 3.2. B) outline the increases in fluorescence associated with heightened ROS 
abundance. 
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Figure 3.2. Representative histograms outlining variation in MitoSOX fluorescence 
between control and drug-treated HeLa cells. The distribution of MitoSOX fluorescence is 
displayed in untreated control (A) and 100 µM artesunate-dosed HeLa cells (B) following 24 
h incubation. 
 
HeLa cells were co-treated with 50 and 100 µM artesunate and 2 mM tiron for a period of 
24 h. The antioxidant was able to impart significant reductions in levels of ROS, with 
detected quantities falling from 200 – 250% of control values in solely drug-treated cells to 
~ 150% on co-dosing (Fig. 3.3.). 
 
Figure 3.3. Effects of tiron upon artesunate-induced mitochondrial reactive oxygen 
species. HeLa cells were co-treated with 50 – 100 µM artesunate and 2 mM tiron for a 
period of 24 h. Mitochondrial ROS levels were determined through monitoring variation in 
MitoSOX fluorescence using flow cytometry. Values are expressed as percentage fold-
increase relative to vehicle control, and are presented as the mean of three independent 
experiments, ± SD. * represents p < 0.05 and ** p < 0.01, as determined through paired t-
test. 
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3.3.1.1.2. Impact of TEMPOL upon Artesunate-Stimulated Mitochondrial Reactive 
Oxygen Species  
 
HeLa cells were dosed with 50 and 100 µM artesunate alongside 2 mM TEMPOL for a 
period of 24 h, prior to assessment of mitochondrial oxidative stress using flow cytometry 
and the MitoSOX dye. The antioxidant was able to impart significant reductions in the 
quantities of drug-stimulated ROS detected within the organelle (Fig. 3.4.). 
 
Figure 3.4. Impact of TEMPOL upon artesunate-induced mitochondrial reactive oxygen 
species. HeLa cells were co-treated with 50 – 100 µM artesunate and 2 mM TEMPOL for a 
period of 24 h. Mitochondrial ROS levels were determined through monitoring variation in 
MitoSOX fluorescence using flow cytometry. Values are expressed as percentage fold-
increase relative to vehicle control, and are presented as the mean of three independent 
experiments, ± SD. * represents p < 0.05, as determined through paired t-test. 
 
3.3.1.2. Cytotoxicity  
 
3.3.1.2.1. Protective Impact of Tiron against Artesunate Cytotoxicity  
 
The ability of tiron to impact upon the susceptibility of HeLa cells towards artesunate 
treatment was investigated using the MTT assay. Significant increases in viability following 
24 h were noted on the co-administration of 2 mM tiron alongside 50 and 100 µM 
artesunate, with the presence of the  antioxidant preserving the survival of ~ 90% of cells 
(Fig. 3.5.). 
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Figure 3.5. Protective impact of tiron against artesunate cytotoxicity. HeLa cells were co-
treated with 50 – 100 µM artesunate and 2 mM tiron for a period of 24 h. Cytotoxicity was 
measured using the MTT assay. Values are expressed as percentage fold-change relative to 
vehicle control, and are presented as the mean of three independent experiments, ± SD. 
*** represents p < 0.001, as determined through paired t-test. 
 
 
3.3.1.2.2. Protective Effects of TEMPOL against Artesunate Cytotoxicity   
 
TEMPOL was additionally tested for its cytoprotective capability against artesunate toxicity 
within HeLa cells. Cells were co-treated with 50 or 100 µM artesunate alongside 2 mM 
TEMPOL for a period of 24 h, before viability was ascertained using the MTT assay. Whilst 
the antioxidant was able to significantly abrogate drug-induced impact upon cell survival, 
effects were not as profound as those witnessed upon the co-administration of tiron (Fig. 
3.6.). 
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Figure 3.6. Protective effects of TEMPOL against artesunate cytotoxicity. HeLa cells were 
co-treated with 50 – 100 µM artesunate and 2 mM TEMPOL for a period of 24 h. 
Cytotoxicity was measured using the MTT assay. Values are expressed as percentage fold-
change relative to vehicle control, and are presented as the mean of three independent 
experiments, ± SD. * represents p < 0.05, as determined through paired t-test. 
 
3.3.1.3. Cellular Reactive Oxygen Species  
 
3.3.1.3.1. Impact of Tiron upon Artesunate-Induced Cellular Reactive Oxygen 
Species  
 
Levels of oxidative stress within the whole cell were determined through flow cytometry 
using the DHE dye. DHE is the parent compound of MitoSOX, and owing to its lack of 
specific localisation, possesses the capacity to quantify ROS abundance across the cell body. 
Activity arises as a consequence of the formation of cationic ethidium and hydroxyethidium 
derivatives upon contact with ROS – the fluorescence of which may be monitored following 
excitation at 488 nm. Representative traces outline patterns of fluorescence observed 
within vehicle control (Fig. 3.7. A) and 100 µM artesunate-treated HeLa cells (Fig. 3.7. B). 
Increased emission associated with greater prevalence of ROS is clearly evident within the 
latter. 
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Figure 3.7. Representative histograms outlining variation in DHE fluorescence between 
control and drug-treated HeLa cells. The distribution of DHE fluorescence is displayed in 
untreated control (A) and 100 µM artesunate-dosed HeLa cells (B) following 24 h 
incubation. 
 
50 and 100 µM artesunate and 2 mM tiron were administered together for 24 h in HeLa 
cells, prior to the flow cytometric determination of mitochondrial ROS levels. Addition of 
the ROS scavenger led to a significant attenuation of oxidative stress within the organelle, 
mirroring effects observed within the mitochondrion (Fig. 3.8). 
 
Figure 3.8. Impact of tiron upon artesunate-induced cellular reactive oxygen species. HeLa 
cells were co-treated with 50 – 100 µM artesunate and 2 mM tiron for a period of 24 h. 
Cellular ROS levels were determined through monitoring variation in DHE fluorescence 
using flow cytometry. Values are expressed as percentage fold-increase relative to vehicle 
control, and are presented as the mean of three independent experiments, ± SD. ** 
represents p < 0.01, as determined through paired t-test. 
110 
 
3.3.1.4. Mitochondrial Bioenergetic and Respiratory Function  
 
3.3.1.4.1. Impact of Tiron upon Artesunate-Induced Mitochondrial Dysfunction 
 
The capacity for tiron to modulate the impact of artesunate upon the bioenergetic 
functioning of the mitochondrion was ascertained through use of the Seahorse XF 
mitochondrial stress test. Employment of the methods described in Section 2.2.8., Chapter 
2 has allowed for determination of both the reserve capacity and coupling efficiency in 
HeLa cells responding to treatment with drug and antioxidant.  
Cells were again dosed with 2 mM tiron alongside either 50 or 100 µM artesunate. 
Following 24 h incubation, the stress test was performed and the relevant parameters were 
quantified. Co-administration of the antioxidant imparted significant protective effect 
against artesunate-induced reductions in mitochondrial coupling efficiency (Fig. 3.9. A) and 
reserve capacity (Fig. 3.9. B). In each instance, normalised values approached those found 
in untreated controls. 
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Figure 3.9. Impact of tiron upon artesunate-induced mitochondrial dysfunction. HeLa cells 
were treated for 24 h with 50 – 100 µM artesunate and 2 mM tiron, before coupling 
efficiency (A) and reserve capacity (B) were determined using the XF mitochondrial stress 
test. Values are expressed as percentage of normalised OCR relative to vehicle control, and 
are presented as the mean of three independent experiments, ± SD. * represents p < 0.05 
and ** p < 0.01, as determined through paired t-test. 
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3.3.2. The Mitochondrial Origin of Reactive Oxygen Species 
Formation 
 
3.3.2.1. Influence of the Electron Transport Chain upon Superoxide 
Formation 
 
The contribution of the electron transport mechanism towards the artesunate-stimulated 
formation of mitochondrial superoxide was examined through monitoring variation in 
MitoSOX fluorescence arising in response to drug treatment across HeLa and HeLa ρ0 cells. 
Specific detection of the prevalence of superoxide was achieved through detecting solely 
formation of the hydroxyethidium oxidation product at excitation wavelength 396 nm and 
emission wavelength 579 nm. Cells of each line were treated with 50 and 100 µM 
artesunate for a period of 24 h, before levels of the species were ascertained. It was 
revealed that, although results between lines did not achieve significance, higher 
prevalence was found within the HeLa cells (Fig. 3.10.). Such an outcome suggests that the 
electron transport chain is linked with maximal ROS expression. Significant quantities of 
superoxide were nevertheless detected relative to control upon drug treatment within the 
ρ0 line, indicating that artesunate retains capacity to induce elevated formation of 
superoxide within these bodies even in the absence a functioning respiratory pathway. 
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Figure 3.10. Influence of the electron transport chain upon superoxide formation. HeLa 
and HeLa ρ0 cells were treated with 50 and 100 µM artesunate for a period of 24 h. 
Mitochondrial ROS levels were determined through monitoring variation in MitoSOX 
fluorescence. Values are expressed as percentage fold-increase relative to vehicle control, 
and are presented as the mean of three independent experiments, ± SD. * represents p < 
0.05, as determined through paired t-test. 
 
 
3.3.2.2. Effects of Artesunate upon the Activities of Complexes Constituting 
the Electron Transport Chain 
 
The impact of artesunate administration upon the activities of complexes within the 
electron transport chain was determined in isolated mitochondria through use of relevant 
spectrophotometric methods. Significant yet partial inhibition of complex II was noted to 
occur upon treatment with 1 mM artesunate, with function being reduced to approximately 
60% of that of vehicle control (Fig. 3.11.). Effects upon the operation of other constituents 
were observed to be minimal. 
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Figure 3.11. Effects of artesunate upon the activities of complexes constituting the 
electron transport chain. Isolated rat liver mitochondria were treated with 1 mM 
artesunate. Complex function was determined using relevant spectrophotometric methods. 
Values are expressed as percentage fold-change relative to vehicle control, and are 
presented as the mean of three independent experiments, ± SD. ** represents p < 0.01, as 
determined through paired t-test. 
 
3.3.2.3. Impact of Artesunate upon Complex II Function 
 
The ability of artesunate to induce defective functioning of complex II was further 
examined through monitoring drug-induced variation in absorbance attributed to the 
formazan product formed as a consequence of enzymatic reduction of INT in isolated 
mitochondria. Mitochondria prepared from rat liver were suspended in reaction mixture 
containing succinate and INT, before being dosed with 0 – 1000 µM artesunate. Following a 
30 minute period of incubation, conclusion of the assay revealed that the presence of drug 
was able to reduce activity to a minimum of 65% of vehicle control value (Fig. 3.12.). Such 
extent of inhibition correlates with that detailed in Section 3.3.2.2. 
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Figure 3.12. Impact of artesunate upon complex II function. Isolated rat liver mitochondria 
were treated with 0 – 1000 µM artesunate. Following 30 minutes incubation, SDH activity 
was determined using a spectrophotometric method. Values are expressed as percentage 
fold-change relative to vehicle control, and are presented as the mean of three 
independent experiments, ± SD. * represents p < 0.05, as determined through paired t-test. 
 
 
 
3.3.3. Non-Mitochondrial Reactive Oxygen Species and Artesunate 
Cytotoxicity 
 
In order to examine the potential relevance of extra-mitochondrial ROS upon the 
progression of artesunate-induced toxicity, the roles of several enzymes implicated in 
possessing significance as sites for superoxide generation were examined for their impact in 
determining cell response to drug treatment. HeLa cells were co-treated with artesunate 
alongside compounds known to function as inhibitors of these systems, in order that their 
contribution towards ROS production and the progression of cell death might be 
ascertained. The effects of inhibitors of NADPH oxidase, cytochrome P450, xanthine oxidase 
and cyclooxygenase – DPI, metyrapone, allopurinol and indomethacin respectively – were 
examined for their activities with respect to modulating artemisinin toxicity.   
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3.3.3.1. Impact of Enzyme Inhibitors upon Cell Viability 
 
Prior to their employment in assays alongside artesunate, the cytotoxicity of the inhibitors 
alone was examined. HeLa cells were treated for 24 h with 0 – 1000 µM of each compound, 
before cell viability was determined using the MTT assay. DPI exhibited significant impact 
upon survival at concentrations greater than 0.5 µM (Fig. 3.13. A), metyrapone at greater 
than 300 µM (Fig. 3.13. B), indomethacin in excess of 100 µM (Fig. 3.13. C) and allopurinol 
exceeding 300 µM (Fig. 3.13. D).  
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Figure 3.13. Impact of enzyme inhibitors upon cell viability. HeLa cells were treated for a 
period of 24 h with 0 – 1000 µM DPI (A), metyrapone (B), indomethacin (C) and allopurinol 
(D). Cytotoxicity was measured using the MTT assay. Values are expressed as percentage 
fold-change relative to vehicle control, and are presented as the mean of three 
independent experiments, ± SD.  * represents p < 0.05 , ** p < 0.01 and *** p < 0.001  as 
determined through paired t-test. 
 
3.3.3.2. Protective Effects of Enzyme Inhibitors upon Artesunate-
Stimulated Cytotoxicity 
 
The ability of each inhibitor to modulate the impact of artesunate-induced cytotoxicity in 
HeLa cells was determined through use of the MTT assay. Cells were treated for 24 h with 
50 or 100 µM artesunate and either 0.5 µM DPI (Fig. 3.14. A), 250 µM metyrapone (Fig. 
3.14. B), 100 µM indomethacin (Fig. 3.14. C) or 300 µM allopurinol (Fig. 3.14. D). DPI was 
able to induce a mild yet significant protective effect in response to 100 µM artesunate, 
whereas all other compounds exerted no notable alterations.  
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Figure 3.14. Protective effects of enzyme inhibitors upon artesunate-stimulated 
cytotoxicity. HeLa cells were co-treated for 24 h with 50 – 100 µM artesunate and 0.5 µM 
DPI (A), 250 µM metyrapone (B), 100 µM indomethacin (C) and 300 µM allopurinol (D). 
Cytotoxicity was measured using the MTT assay. Values are expressed as percentage fold-
change relative to vehicle control, and are presented as the mean of three independent 
experiments, ± SD.  * represents p < 0.05, as determined through paired t-test. 
 
3.3.3.3. Impact of Enzyme Inhibitors upon the Prevalence of Cellular 
Reactive Oxygen Species  
 
The effect of the inhibitors upon the formation of cellular ROS emerging through 
artesunate treatment was examined using DHE. Either 0.5 µM DPI (Fig. 3.15. A), 250 µM 
metyrapone (Fig. 3.15. B), 100 µM indomethacin (Fig. 3.15. C) or 300 µM allopurinol (Fig. 
3.15. D) was administered alongside 50 or 100 µM artesunate in HeLa cells prior to 24 h 
treatment. No significant impact upon level of drug-stimulated oxidative stress was evident 
across each compound. 
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Figure 3.15. Impact of enzyme inhibitors upon the prevalence of cellular ROS. HeLa cells 
were co-treated for 24 h with 50 – 100 µM artesunate and 0.5 µM DPI (A), 250 µM 
metyrapone (B), 100 µM indomethacin (C) and 300 µM allopurinol (D). Cellular ROS levels 
were determined through monitoring variation in DHE fluorescence using flow cytometry. 
Values are expressed as percentage fold-change relative to vehicle control, and are 
presented as the mean of three independent experiments, ± SD.   
 
3.3.4. Effects of Iron-Chelator DFO upon Cellular Response to 
Artesunate Treatment 
 
3.3.4.1. Cytotoxicity of DFO towards HeLa Cells 
 
Prior to its employment in assays alongside artesunate, the cytotoxicity of DFO within HeLa 
cells was examined using the MTT assay. Cells were treated for 24 h with DFO in 
concentrations ranging from 0 – 1000 µM. Viability did not decrease beneath 70% of 
control values, even at elevated dose (Fig. 3.16.). 
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Figure 3.16. Cytotoxicity of DFO towards HeLa cells. HeLa cells were treated with 0 – 1000 
µM DFO for a period of 24 h. Cytotoxicity was measured using the MTT assay. Values are 
expressed as percentage fold-change relative to vehicle control, and are presented as the 
mean of three independent experiments, ± SD. * represents p < 0.05 and ** p < 0.01, as 
determined through paired t-test. 
 
3.3.4.2. Capacity of DFO to Impact upon Artemisinin Bioactivation 
 
Fe(II) reduction of the endoperoxide bridge culminates in the structural rearrangement of 
parent artemisinin compounds to furnish stable isomeric products through mechanisms 
proceeding via the  formation of reactive radical intermediates.  The bioactivation of PFDHA 
can be monitored through means of an established LC-MS method quantifying the 
degradation of parent compound alongside the emergence of its THF acetate isomer (Fig. 
3.17.). 
Figure 3.17. Mechanism of THF acetate formation through Fe(II)-mediated PFDHA 
degradation. 
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Characterisation of the levels of PFDHA and THF acetate present in samples extracted from 
cells following co-incubation with DFO is achieved through monitoring respectively the 
fragmentation transitions 396.0 to 163.0 (Fig. 3.18. A) and 396.0 to 266.7 (Fig. 3.18. B). 
Extraction efficiency is determined through ascertaining the quantity of internal standard 
artesunate (Fig. 3.18. C, transition 402.1 to 163.1) recovered following isolation. In order to 
enable quantification of the materials present in absolute molar values, reference is made 
to standard curves constructed for each particular compound.  
 
Figure 3.18. Representative selected-ion chromatogram traces detailing retention 
patterns for monitored fragmentation transitions. Traces correspond to the transitions 
PFDHA 396.0 to 163.0 (A), PFDHA THF-acetate 396.0 to 266.7 (B) and artesunate 396.0 to 
166.7 (C). 
 
HeLa cells were co-incubated with 25 µM PFDHA and 10 µM DFO for a period of 24 hours, 
prior to organic extraction. Upon LC-MS analysis, it was observed that the presence of the 
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chelator imparted significant increase in the proportion of recovered starting material (Fig. 
3.19. A) and decrease in the fraction of detected THF acetate (Fig. 3.19. B). Such an 
outcome illustrates the facility to DFO to protect against Fe(II)-mediated endoperoxide 
bridge bioactivation. 
 
Figure 3.19. Capacity of DFO to impact upon artemisinin bioactivation. HeLa cells were co-
treated with 25 µM PFDHA and 10 µM DFO for a period of 24 h, before quantities of 
recovered parent compound (A) and THF acetate isomer (B) were determined. Values are 
expressed in terms of the quantity of PFDHA and THF acetate retrieved as a percentage of 
starting material, and are presented as the mean of three independent experiments, ± SD. * 
represents p < 0.05, as determined through paired t-test. 
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3.3.4.3. Impact of DFO upon Artesunate-Induced Mitochondrial Reactive 
Oxygen Species 
 
The ability of DFO to impact upon levels of artesunate-induced ROS within the 
mitochondrion was examined through flow cytometry using the MitoSOX dye. HeLa cells 
were co-treated for 24 h with 50 or 100 µM artesunate alongside 10 µM DFO, before 
quantification was performed. Significant reductions in ROS levels were evident owing to 
administration of the chelator, with fold-changes relative to vehicle control falling to 
approximately 140% from the 200 – 220% observed in solely artesunate-treated cells (Fig. 
3.20.).  
 
 
 
Figure 3.20. Impact of DFO upon artesunate-induced mitochondrial reactive oxygen 
species. HeLa cells were co-treated with 50 – 100 µM artesunate and 10 µM DFO for a 
period of 24 h. Mitochondrial ROS levels were determined through monitoring variation in 
MitoSOX fluorescence using flow cytometry. Values are expressed as percentage fold-
increase relative to vehicle control, and are presented as the mean of three independent 
experiments, ± SD. ** represents p < 0.01 and *** represents p < 0.001, as determined 
through paired t-test. 
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3.3.4.4. Effect of DFO upon Artesunate-Induced Cellular Reactive Oxygen 
Species 
 
The impact of DFO upon drug-stimulated cellular oxidative stress was examined using DHE. 
HeLa cells were dosed with 10 µM DFO alongside 50 and 100 µM artesunate, prior to 24 h 
incubation. The chelator was able to impart significant reductions in the prevalence of ROS 
(Fig 3.21.). 
 
Figure 3.21. Effect of DFO upon artesunate-induced cellular reactive oxygen species. HeLa 
cells were co-treated with 50 – 100 µM artesunate and 10 µM DFO for a period of 24 h. 
Cellular ROS levels were determined through monitoring variation in DHE fluorescence 
using flow cytometry. Values are expressed as percentage fold-increase relative to vehicle 
control, and are presented as the mean of three independent experiments, ± SD. * 
represents p < 0.05 and *** p < 0.001, as determined through paired t-test. 
 
3.3.4.5. Protective Effects of DFO against Artesunate Cytotoxicity 
 
The cytoprotective potential of DFO against artesunate toxicity was examined using the 
MTT assay. HeLa cells were co-treated for 24 h with 50 and 100 µM artesunate and 10 µM 
DFO. The presence of DFO imparted significant reductions in levels of cell death arising 
from drug administration, with viability maintained at greater than 80% of control value 
(Fig 3.22.). 
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Figure 3.22. Protective effects of DFO against artesunate cytotoxicity. HeLa cells were co-
treated with 50 – 100 µM artesunate and 10 µM DFO for a period of 24 h. Cytotoxicity was 
measured using the MTT assay. Values are expressed as percentage fold-change relative to 
vehicle control, and are presented as the mean of three independent experiments, ± SD. * 
represents p < 0.05 and *** p < 0.001, as determined through paired t-test. 
 
 
3.3.4.6. Impact of DFO upon Artesunate-Induced Mitochondrial 
Dysfunction 
 
Mitochondrial function was again assessed through use of the Seahorse XF stress test 
method. Co-treatment of HeLa cells with 10 µM DFO alongside 50 and 100 µM artesunate 
proceeded over 24 h. DFO demonstrated an ability to abrogate drug-induced impact upon 
coupling efficiency (Fig. 3.23. A) and reserve capacity (Fig. 3.23. B), restoring bioenergetic 
performance to levels commensurate with those apparent within vehicle controls.  
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Figure 3.23. Impact of DFO upon artesunate-induced mitochondrial dysfunction. HeLa 
cells were treated for 24 h with 50 – 100 µM artesunate and 10 µM DFO, before coupling 
efficiency (A) and reserve capacity (B) were determined using the XF mitochondrial stress 
test. Values are expressed as percentage of normalised OCR relative to vehicle control, and 
are presented as the mean of three independent experiments, ± SD. * represents p < 0.05, 
as determined through paired t-test. 
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3.4. Discussion 
 
The intention of the studies performed within this chapter has been to examine the 
hypothesis that iron-stimulated oxidative stress constitutes a central contributing factor 
towards the development of artemisinin-induced defects in mitochondrial bioenergetic 
functioning. Accordingly, the impact both of ROS scavenging antioxidants and the iron 
chelator DFO upon cellular response to artesunate treatment has been examined. Such 
investigations have been supplemented with assessment into the potential relevance of 
acknowledged superoxide-generating sources, including the substituent complexes of the 
electron transport chain, towards the emergence of oxidative stress. 
In order that the importance of the contribution of artesunate-stimulated oxidative stress 
towards dysfunction across the cell could be ascertained, the impact of the antioxidant ROS 
scavengers tiron and TEMPOL upon the response of HeLa cells to drug treatment was first 
investigated. Although both compounds were able to exert significant cytoprotective 
effects against the artemisinin derivative, the effect of the former in preserving cell viability 
was notably more pronounced. Approaching 90% of treated cells exhibited evidence of 
survival in the presence of 2 mM tiron (Fig. 3.5.), as opposed to approximately 60% in 
response to an identical concentration of TEMPOL (Fig. 3.6.). In explaining the apparent 
greater impact of tiron in abrogating the cytotoxic effects of artesunate, it is necessary to 
consider the wider properties possessed by each compound, and the consequences that 
these might hold in determining the extent of any protective influence. Evidence suggests 
that tiron, unlike TEMPOL, contains the ability to permeate the mitochondrial outer 
membrane, and hence localise itself within the organelle (McArdle et al., 2005; Supinski et 
al., 1999). Whilst it appears rational, in light of the capacity of artemisinin derivatives to 
function as disruptors of mitochondrial function, to attribute the reduced susceptibility of 
cells towards drug effects solely upon an improved capability of the antioxidant to 
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neutralise mitochondrial ROS, it is apparent that further factors additionally influence such 
outcomes. It is observed that the impact of each compound upon the levels of artesunate-
induced mitochondrial oxidative stress, as assayed through the flow cytometric MitoSOX 
protocol, is roughly equivalent, with fold changes in fluorescence detected relative to 
untreated controls decreasing to approximately 150% in both instances (Figs 3.3. and 3.4.). 
Studies have demonstrated that the protective impact of tiron against the deleterious 
effects of ROS is derived from actions imparted by the antioxidant across several aspects of 
cellular function (Ghosh et al., 2002). Its ability to diminish oxidative damage towards 
mitochondrial and nuclear DNA sustained as a consequence of UV irradiation and hydrogen 
peroxide loading in dermal fibroblastic cells is witnessed to stand in excess of that 
possessed by the mitochondrially-targeted ubiquinone derivative MitoQ (Oyewole et al., 
2014). It is strongly implied, therefore, that the scope of its actions exceed merely those 
mediated within the mitochondrion. The capacity to function as a chelator for cellular 
transition and heavy metals has been suggested owing to outcomes obtained across a 
number of reports (Domingo et al., 1997; Krishna et al., 1992). As a result of the role 
possessed by free iron both in the propagation of ROS and in the progression of 
artemisinin-induced cell death, it is feasible that this capability might contribute towards its 
potential in abrogating toxicity. 
Deficits in mitochondrial bioenergetic function stimulated through artesunate treatment 
were significantly minimised upon tiron co-administration. The presence of the antioxidant 
was observed to restore both the coupling efficiency and reserve capacity, as determined 
through the Seahorse XF stress test, to levels approaching those of control values (Fig. 3.9.). 
Such outcomes strongly suggest that oxidative damage is an essential causative factor in 
the emergence of impairment in the mitochondrion, serving furthermore to indicate that 
the formation of ROS constitutes an early event in the pathway towards cell death. A 
variety of systems within the organelle are susceptible to the disruptive impact of ROS. 
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Alongside their ability to cause insult to the structural integrity of DNA, their interactions 
culminating in the peroxidation of phospholipids and in the dismantling of Fe-S clusters are 
acknowledged as being central contributing factors towards interference with the 
machinery regulating energy production through oxidative phosphorylation (Cortes-Rojo et 
al., 2011; Davies, 1990).  
Investigation into formation of mitochondrial superoxide across HeLa and ρ0 HeLa cells 
revealed, in line with the trends observed across previous whole-cell studies performed 
using DCFH-DA, that the presence of a functioning electron transport system contributes 
towards the emergence of elevated levels of oxidative stress (Fig. 3.10.) (Mercer et al., 
2011). Under physiological conditions, shuttling of electrons between operational 
complexes occurs continuously, with intermittent leak stimulating ROS formation. Damage 
to the integrity of this mechanism is associated with enhanced generation of superoxide, as 
compromised transport facilitates electron escape (Turrens, 2003). The ρ0 line, owing to the 
characteristic depletion of mitochondrial DNA, expresses forms of the constituent units 
which exhibit incomplete assembly arising as a consequence of a variety of structural 
deficits imparted by the removal of relevant coding information (Chevallet et al., 2006). The 
resulting inability of these cells to perform oxidative phosphorylation ensures that such an 
avenue towards the emergence of ROS generation is closed. In spite of these abnormalities, 
increases in superoxide levels detected within the ρ0 line remain significant relative to 
control quantities upon artesunate dosing. The continued capacity for the drugs to 
stimulate substantial ROS production in the presence of a non-functioning respiratory chain 
serves to provide evidence that the primary mechanism through which the induction 
oxidative stress is imparted within these cell systems lies independent of the initiation of 
damage to the operation of the complexes constituting the electron transport 
arrangement. Accordingly, examination into the effects of artesunate upon the activity of 
these units within isolated mitochondria indicated that the presence of the compound 
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possesses no notable bearing upon the functioning of complexes I, III and IV. Significant but 
partial disruption to the operational capacity of complex II was observed, with the ability of 
the drug to reduce functioning of the enzyme to levels 60-65% of those in vehicle controls 
confirmed through two assay methods (Figs 3.11. and 3.12.). Investigations performed 
outlining the protective influence of tiron upon drug-stimulated mitochondrial respiratory 
dysfunction provide further evidence to support the assertion that the primary source of 
ROS-initiated damage to the organelle exists external to the system of electron transport. It 
can be hypothesised that the enhanced quantities of superoxide detected in the presence 
of an active respiratory chain arise as a function of defective operation imparted as a 
consequence of an initial oxidative injury. ROS-induced ROS release is identified as a 
phenomenon whereby ROS-stimulated mitochondrial damage proceeds to promote  
further, large-scale oxidative stress upsurge (Zorov et al., 2014). It is believed that such a 
process is associated closely with the collapse of membrane potential and subsequent 
opening of the mitochondrial permeability transition pore, with the formation of ROS 
mediated as a consequence of defective functioning at the electron transport pathway. As 
such, the propagation of ROS about the whole cell might be readily facilitated. 
In identifying an initial source for the formation of the ROS which ultimately stimulate 
mitochondrial damage, it was therefore necessary to consider the relevance of systems 
located outside of the organelle. Determination of the potential for the involvement of 
alternative ROS-generating enzymes in the emergence of artesunate-induced oxidative 
stress culminated in a series of investigations centred upon examining the contributions of 
NADPH oxidase, cytochrome P450, xanthine oxidase, and cyclooxygenase towards both 
cytotoxicity and levels whole-cell ROS. The rationale for the study was based upon the work 
performed by Lee et al. and Bobba et al., in which delineation of the enzymatic sources 
behind ROS generation in tamoxifen treatment and in granulocyte apoptosis was achieved 
through assessing the impact of inhibitory agents upon cell response to stimuli (Bobba et 
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al., 2008; Lee et al., 2000). A significant, albeit very limited cytoprotective effect towards 
artesunate was evident upon co-administration of the NADPH oxidase inhibitor DPI – an 
occurrence which was not mimicked across the other systems studied (Fig. 3.14.). Levels of 
drug-stimulated cellular ROS were similarly unaffected by inhibition of the examined 
enzymes (Fig. 3.15.). Such findings combined strongly indicate that the origin of oxidative 
stress in artemisinin treatment is not mediated through imparting changes to the 
functioning of these systems.  
Further examinations of the pathways responsible for the formation and proliferation of 
the ROS which contribute ultimately towards the onset of artemisinin-stimulated 
mitochondrial injury considered the potential roles held by cellular free iron in the 
development of such phenomena. Unbound iron is strongly associated both with the 
enhanced formation of ROS arising through chemical mechanisms such the Fenton reaction, 
and furthermore with the initiation of radical formation courtesy of artemisinin 
endoperoxide bridge reduction (Dixon et al., 2014; Mercer et al., 2007; Thomas et al., 
2009). Pools of potentially reactive chelatable iron are found distributed at selected points 
within the cell, the most prominent of which lie within the lysosomal bodies (Kurz et al., 
2011). The impact of the lysosomal iron chelator DFO was examined with respect to its 
influence upon cell response to artesunate treatment. It was revealed that its co-
administration alongside the artemisinin derivative had potential to elicit significant 
cytoprotective outcome, with cell viability restored to roughly 80% of control values 
following 24 h (Fig. 3.22.). This effect was accompanied by an ability to impart substantial 
decreases in quantities of drug-stimulated ROS detected both across the whole cell (Fig. 
3.21.) and within the mitochondrion (Fig. 3.20.). Such findings indicate that the abrogation 
of cytotoxicity which occurs as a consequence of iron chelation is associated with 
diminution in oxidative stress. In delineating the events underpinning these observations, it 
was necessary to perform assessment into the capacity of DFO to impact upon 
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endoperoxide bridge bioactivation. Accordingly, this was achieved through the monitoring 
of decomposition of the artemisinin derivative PFDHA via the established LC-MS method 
(Mercer et al., 2007). Outcomes indicated that the presence of the chelator imparted 
significant protective effect against the degradation of the parent compound following 24 h 
cell treatment, whilst simultaneously inhibiting the formation of its THF acetate isomer (Fig. 
3.19.). The quantity of PFDHA recovered in DFO-treated cells stood at approximately 80% of 
that initially administered, strongly indicating that the ability of the chelator to abrogate 
bioactivation is not total. Previous studies have demonstrated that the recovery of the 
artemisinin derivative approaches totality following short incubation spans, hence 
suggesting that the recovered fraction in this assay is indeed not indicative of complete 
chelator-mediated prevention of Fe(II)-stimulated endoperoxide bridge reduction (Mercer 
et al., 2011; Mercer et al., 2007). Unfortunately, attempts to quantify cellular iron content 
using a ferrozine-based method were unsuccessful. Additional evidence has suggested that 
further DFO antioxidant capacity might derive from an ability to stimulate the expression of 
endogenous ROS-neutralising agents through activation of the nuclear factor erythroid 2-
related factor (Nrf2) pathway (Chung et al., 2014). The greater relevance of such an 
occurrence in the context of the systems examined remains uncertain.  
In a manner similar to that of tiron, DFO was observed to exert significant protective effect 
against artesunate-induced mitochondrial dysfunction. At a concentration of 10 µM, the 
chelator raised coupling efficiency and reserve capacity to levels approximately 
commensurate with those in control cells (Fig. 3.23.). It can therefore be concluded that 
free iron plays an essential role in the progression of mitochondrial damage. Owing to the 
contribution of the unbound metal in propagating ROS, and to the efficacy of tiron in 
abrogating injury towards the processes of the organelle, it is rational to suggest that at 
least part of this association is attributable to antioxidant properties (Dixon et al., 2014). It 
is, however, further plausible that protection might arise courtesy of the regulatory impact 
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of iron chelation upon alternative pathways, including drug bioactivation, in which the 
metal has involvement. Evidence exists to suggest that mobilisation of the unbound metal 
towards the mitochondrion occurs as a consequence of lysosomal dysfunction (Uchiyama et 
al., 2008; Zhang et al., 2013). It has been demonstrated that the employment of DFO has 
the potential to halt mitochondrial uptake of iron induced through bafilomycin-stimulated 
collapse of the lysosome membrane potential (Hung et al., 2013). The outcomes of a 
further study, in which the relevance of lysosomal iron content towards the toxicity of 
artemisinin in breast cancer cells was investigated, have served to provide further 
indication of the importance of the chelatable pool towards the progression of cytotoxic 
effects (Hamacher-Brady et al., 2011). These findings have prompted the authors to 
hypothesise that lysosomally-mediated programmed cell death occurs as an early stage 
during artemisinin-induced toxicity.  
It can be concluded from the outcomes of the studies performed as part of this assessment 
that the emergence of artemisinin-induced mitochondrial dysfunction might be attributed 
primarily to the impact of oxidative damage upon the organelle. Abrogation of cellular and 
mitochondrial ROS levels has the effect of ameliorating drug-stimulated deficiency in 
bioenergetic activity, whilst simultaneously protecting against cytotoxic effects. Further 
evidence would appear to indicate that cellular free iron possesses roles both in the 
bioactivation of the drug and in the propagation of oxidative stress, with chelation 
associated with reduced prevalence of ROS and cessation in defective mitochondrial 
operation. The outcomes of examinations performed within ρ0 HeLa cells attest that an 
operational electron transport chain, although contributing to the enhanced generation of 
ROS, does not function as an absolute requirement for their initiation. In combination with 
the apparently limited impact of the compound upon the activity of the substituent 
complexes within this system, such findings provide evidence that the initial source for ROS 
lies independent of the machinery of oxidative phosphorylation. The potential role of non-
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mitochondrial ROS sources in the initiation of such effects is given examination, although 
with results proving ultimately inconclusive. The efficacy of the lysosomal iron chelator DFO 
in protecting against artesunate-induced cell termination provides tentative evidence that 
death pathways mediated through that body might influence treatment outcomes. 
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Chapter Four 
 
 
Elucidation of the Role of Cardiolipin in the 
Progression of Artemisinin-Induced 
Cytotoxicity 
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4.1. Introduction 
 
The ability of artemisinin derivatives to induce cell death through apoptosis forms an 
established feature of their mechanism of cytotoxicity (Firestone et al., 2009; Mercer et al., 
2011). As understanding of the physiological processes underpinning mitochondrial 
function and the progression of programmed cell death continues to advance, the potential 
relevance of novel pathways and effectors grows more apparent. Recent research has 
revealed that the phospholipid cardiolipin performs numerous roles which are significant to 
both the respiratory functioning of the mitochondrion and to the regulation of apoptosis, 
transforming it into a growing focus of interest (Orrenius et al., 2005). Despite great strides 
having been made in ascertaining its functions on a physiological level, its potential for a 
role in drug toxicity has yet to be explored. 
It has been demonstrated that artemisinin derivatives can induce the peroxidation of 
phospholipids in both parasitic and mammalian systems (Berman et al., 1997). Whilst this 
event may occur solely as a consequence of generalised damage associated with the 
presence of elevated levels of ROS within cells, it is alternatively hypothesised that the 
drugs might exert direct oxidising effects as a function of their chemical reactivity. Evidence 
from biomimetic studies attests to the capacity of  artemisinin to stimulate substantial 
oxidative degradation of phospholipid structures (Kumura et al., 2009). A proposed 
mechanism through which such effects might proceed, outlined in Section 1.3.4.6., Chapter 
1, centres upon the postulated abstraction of protons from unsaturated fatty acid chains by 
reactive carbon radical species formed courtesy of the Fe(II)-mediated degradation of the 
parent compound (Mercer et al., 2007; O'Neill et al., 2004). This chapter shall seek to 
examine the potential relevance of this model with respect to the interaction between 
artesunate and cardiolipin, with studies focused upon investigating the impact of a 
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recently-developed small molecular inhibitor of physiological cardiolipin oxidation upon 
cellular response to the drug. 
Cardiolipin is a unique phospholipid located almost exclusively within the mitochondrion 
(Houtkooper et al., 2008). It possesses a characteristic diphosphatidylglycerol structure, 
consisting of a total of four fatty acyl chains bonded to a central glycerol-containing 
backbone. Although this assembly has the potential to lead to a great diversity of variant 
isoforms, it is arrangements containing the 18-carbon, doubly-unsaturated linoleic acid 
chain which are found to predominate overwhelmingly across mammalian tissues (Fig. 4.1.) 
(Schlame et al., 2000). Tetralinoleoyl cardiolipin possesses heightened susceptibility 
towards lipid peroxidation mediated by free radical species, and it is hypothesised that it is 
this sensitivity which lends cardiolipin its key role in apoptotic progression.  
The inner mitochondrial membrane accounts for the location of over 95% of cardiolipin, 
where it comprises roughly 25% of phospholipids present (Paradies et al., 2009). Cardiolipin 
possesses numerous roles critical to the maintenance of optimal mitochondrial 
bioenergetic function, derived primarily from interactions with the substituent proteins of 
complexes which form the electron transport chain (Pfeiffer et al., 2003). The presence of 
cardiolipin is required for maximal activity in complexes I, III, and V, but it is its relationship 
with cytochrome c which has attracted most interest on account of its relevance during the 
early phases of apoptotic cell death (Crimi et al., 2011). 
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Figure 4.1. Generic structure of cardiolipin (left), and the structure of tetralinoleoyl 
cardiolipin, the most abundant form present in mammalian cells (right). 
 
Cytochrome c, a haem-containing protein associated predominantly with the inner 
mitochondrial membrane, forms an essential constituent of complex III. During apoptosis, it 
migrates from its resting position, undergoing release into the cytosol, where it is found to 
activate caspase cleavage through binding of APAF-1 (Elmore, 2007). Recent research has 
uncovered that the regulation of cytochrome c motility during the early phases of apoptosis 
is heavily dependent upon its interaction with cardiolipin, with each protein possessing a 
significant influence over the positioning and the function of the other (Belikova et al., 
2006). In the absence of apoptotic stimuli, the primary function of cytochrome c as an 
electron transfer protein is maintained through its anchoring to the inner mitochondrial 
membrane, a process dependent upon cardiolipin association.  
Evidence suggests that cytochrome c and cardiolipin are able to form specific complexes 
with one another, with two primary variant binding modes facilitated through the presence 
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electrostatic and hydrophobic interactions (Ott et al., 2007). Loose binding is primarily 
hydrophobic in nature, and is observed between the lengthy acyl chains of cardiolipin, and 
the hydrophobic cleft present within cytochrome c (Belikova et al., 2006). An alternative 
tight binding mode is the result of electrostatic attraction existing between the positively-
charged cytochrome c, and the anionic head of cardiolipin. Loosely-bound complexes are 
associated with the electron-shuttling role of cytochrome c, whereas tightly-bound 
complexes have been shown to possess potent peroxidase activity. It is these which are 
heavily implicated during the process of cytochrome c release in early apoptosis (Kagan et 
al., 2005). 
 
Figure 4.2.  Cardiolipin is situated predominantly at the inner mitochondrial membrane, 
where it acts to anchor cytochrome c at its position within the electron transport chain. An 
elevated level of H2O2, which occurs as a by-product of ROS generation, triggers the 
peroxidation of cardiolipin. Cytochrome c is released from its resting position, diffusing into 
the intermembrane space. Transmembrane relocation of oxidised cardiolipin facilitates the 
binding of pro-apoptotic factors such as bax and t-bid, enabling pore formation and passage 
of cytochrome c into the cytosol. 
The mechanism through which these peroxidase complexes mediate their effects has been 
ascertained primarily through molecular modelling studies, with the presence of tightly-
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bound cardiolipin being found to exert a series of conformational changes upon 
cytochrome c which  culminate in the exposure of its peroxidase active site (Kagan et al., 
2009b). Elevated levels of hydrogen peroxide, found accompanying a surge in ROS 
production during the early phases of apoptosis, spur these complexes to induce the direct, 
selective oxidation of cardiolipin. The phospholipid, in its oxidised state, develops a 
significantly reduced binding affinity for cytochrome c, facilitating its release from an 
anchored position at the inner mitochondrial membrane, and enabling its diffusion into the 
intermembrane space (Belikova et al., 2006). It is additionally hypothesised that cardiolipin 
possesses a role in assisting the permeabilisation of the outer mitochondrial membrane, 
enabling the ultimate release of cytochrome c into the cytoplasm (Crimi et al., 2011). 
Transmembrane relocation is believed to be initiated through the activity of scramblase 
enzymes, with the increased presence of oxidised cardiolipin in the outer membrane 
associated with a greater binding affinity for the apoptosis-promoting proteins bax and t-
bid (Schlattner et al., 2009). Through their action, pore formation across the membrane 
facilitates the passage of cytochrome c from the mitochondrion (Fig. 4.2.). 
The studies presented within this chapter shall be centred upon examining the hypothesis 
that artemisinin-derived compounds possess a capacity to stimulate the direct oxidation of 
cardiolipin. Recently, the development of a series of compounds for the inhibition of 
peroxidase function in the cardiolipin-cytochrome c complexes has been reported (Atkinson 
et al., 2011; Kagan et al., 2009a). The employment of in silico modelling techniques has 
facilitated the rational design of a series of inhibitors which are intended to occupy the 
haem active-site of cytochrome c, thus preventing protein unfolding and impairing ability to 
induce cardiolipin peroxidation. These compounds, derived from unsaturated long-chained 
molecules such as ricinoleic and stearic acids, exert their activity primarily through their 
imidazole functionalities, which are able to act as ligands about the Fe(II) centre. 
Employment in an in vitro study performed across mouse embryonic cells has 
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demonstrated their ability to actively suppress peroxidase activity, resulting in the 
inhibition of cardiolipin oxidation and of accompanying apoptosis as part of a general 
cytoprotective effect. These outcomes have translated into in vitro models, with 
administration of the inhibitors being associated with greatly improved survival rates 
amongst mice subjected to radiation exposure. 
 
 
 
The impact of the ricinoleic acid-derived peroxidase inhibitor TPP-IOA (12) upon cellular 
response to artesunate treatment shall be examined.  Its effects are ascertained through a 
range of assays, focusing upon two primary areas of investigation. Firstly, the capacity of 
the compound to induce reduction in drug-induced cardiolipin oxidation, and the 
consequences that this possesses regarding the progression of cytotoxic activity, shall be 
investigated. A second, parallel strand of study – spurred by evidence suggesting a potential 
role for microperoxidase-11 (MP-11) in the stimulation of endoperoxide bridge 
bioactivation – shall examine the effects of the peroxidase complex inhibition upon the 
structural integrity of the artemisinin derivative PFDHA (Rodriguez et al., 2002). The 
development of an alternative route towards the chemical synthesis of the inhibitor is also 
given detailed description. Assessment of activity shall be performed across three cell types 
– the human promyelocytic leukaemia-derived HL-60 line, the HeLa and the HeLa ρ0 variety. 
The latter of these forms has been depleted of mitochondrial DNA through prolonged 
culturing in the presence of ethidium bromide, and thus possesses no functional electron 
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transport chain. It is intended that this work shall allow for an initial examination into the 
potential for endoperoxides to directly alter the structure and activity of cardiolipin, ahead 
of any expansive future studies. 
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4.2. Materials and Methods 
 
4.2.1. Materials 
 
Roswell Park Memorial Institute (RPMI) medium, alongside all further chemicals and 
solvents, were purchased Sigma-Aldrich (Poole, Dorset, UK). HL-60 cells were acquired from 
the European Collection of Cell Cultures (Salisbury, UK). 
 
4.2.2. Cell Culture and Experimental Preparation 
 
HeLa and ρ0 HeLa cells were cultured and maintained according to the protocols outlined 
respectively in Sections 2.2.2., Chapter 2 and 3.2.2., Chapter 3. HL-60 cells were maintained 
in RPMI 1640 medium, with the addition of supplemental FBS (10% v/v), L-glutamine (1% 
w/v) and penicillin/streptomycin solution (1% v/v). Cell density was maintained below 
1x106 cells/ml, in order to ensure exponential growth and to prevent differentiation.  
 
4.2.3. Analysis through Flow Cytometry 
 
Flow cytometric analysis was performed in accordance with the parameters described in 
Section 3.2.4., Chapter 3.  
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4.2.4. Determination of Cardiolipin Oxidation using Nonyl Acridine 
Orange 
 
 
Nonyl acridine orange (NAO) is a fluorescent dye possessing high affinity for cardiolipin. 
Decreases in fluorescence are associated with reduced cardiolipin presence within the 
mitochondrion (Kaewsuya et al., 2007). Drug-treated HL-60, HeLa and HeLa ρ0 cells (2 x 105) 
were washed with HBSS and centrifuged (1000g) to produce a pellet which was 
resuspended in 0.5 ml of 10 µM NAO solution. Following 15 minutes incubation at 37°C, 
cells were again centrifuged (1000g), before NAO solution was replaced by 0.5 ml HBSS. 
Cells (1x104 per sample) were analysed immediately through flow cytometry, with 
fluorescence monitored following excitation at a wavelength of 488 nm. 
 
 
 
 
 
 
 
 
 
 
146 
 
4.2.5. Analysis of Apoptotic Cell Population using Propidium Iodide 
 
 
Propidium iodide (PI) acts as a DNA intercalator, having great affinity for binding within 
major grooves (Krishan, 1975). Following drug treatment, cells (2 x 105) were centrifuged (5 
minutes, 1000g), and the resultant supernatant removed. Cells were washed with HBSS, 
before being fixed in 1 ml ice-cold 70% ethanol, and frozen at -20°C for a period of at least 2 
h. The 70% ethanol was removed, and the cells washed again with HBSS, before they were 
re-suspended in 0.5 ml PI solution (40 µM, 1% RNAse, 1 % sodium citrate) and incubated at 
37°C for 10 minutes. A minimum of 1x104 cells were analysed immediately upon the flow 
cytometer, with fluorescence monitored following 488 nm excitation. 
 
4.2.6. Assessment of Cell Viability using the MTT Assay 
 
Cell viability within the HeLa line was ascertained through use of the MTT assay, as detailed 
in Section 2.2.4., Chapter 2.  
HL-60 cells (5 x 104/well) were plated, in triplicate, into flat-bottomed 96-well plates. They 
were subsequently exposed to concentrations of drug ranging from 0.1 µM to 100 µM, 
dependent upon the nature of the assay, and incubated for time periods of up to 24 h. 
Upon the completion of incubation, 20 µL of MTT solution (5 mg/ml in HBSS) was added to 
each well. Following a further 2 h incubation, 200 µL of a lysis buffer (20 % w/v SDS, 50 % 
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w/v DMF) was added to each well, and a further 4 h incubation at 37°C performed. 
Absorbance of each well was read on a plate reader (Dynex MRX, Magellan Bioscience, 
Worthing, UK), using a test wavelength of 570 nm and a reference wavelength of 590 nm. 
Results are expressed as a percentage of absorbance relative to untreated vehicle control, 
with IC50 derived from curves plotted using the GraFit Software. 
4.2.7. Measurement of Mitochondrial Reactive Oxygen Species using 
MitoSOX 
 
The specific formation of superoxide within the mitochondrion was quantified through use 
of the MitoSOX fluorescent dye, following the procedures described in Section 3.2.7., 
Chapter 3. 
 
4.2.8. Analysis of Drug Bioactivation using an LC-MS Method 
 
Bioactivation of the artemisinin derivative PFDHA was monitored according to the LC-MS 
method detailed in Section 3.2.10., Chapter 3. 
 
4.2.9. Statistical Analysis 
 
Data is presented and analysed in line with the protocols described in Section 2.2.10., 
Chapter 2.  
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4.2.10. Chemical Synthesis of TPP-IOA 
 
 
 
Figure 4.3. Scheme outlining the route towards synthesis of TPP-IOA. 
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Synthesis of the chemical cardiolipin/cytochrome c complex inhibitor TPP-IOA was achieved 
following a scheme derived from that employed by Atkinson et al. (Fig. 4.3.) (Atkinson et 
al., 2011). Castor oil consists of a complex mixture of fatty acids, with approximately 90% of 
this content attributed to ricinoleic acid (11a) (Yang et al., 2002). Formation of the methyl 
ester of ricinoleic acid, (Z)-methyl 12-hydroxyoctadec-9-enoate (11b), was effected through 
treatment of unpurified castor oil with the methylating agent boron trifluoride-methanol, 
with silica column chromatography facilitating the isolation of a pure product in 67% yield. 
Introduction of the methanesulphonyl (mesyl) leaving group produced (Z)-methyl 12-
((methylsulphonyl)oxy)octadec-9-enoate (11c) at a yield of 85%. Substitution of this mesyl 
group with the imidazole functionality, in order to form (Z)-methyl 12-(1H-imidazol-1-
yl)octadec-9-enoate (11d), was facilitated through heating in the presence of the weak base 
potassium carbonate. Yields were held between 25-30%, owing to the preponderance of 
elimination side-products.  Deprotection of the methyl ester was achieved through 
hydrolysis under basic conditions, with the presence of aqueous sodium hydroxide 
sufficient to produce (Z)-12-(1H-imidazol-1-yl)octadec-9-enoic acid (11e) at a yield of 90%. 
This compound was coupled with (3 hydroxypropyl)triphenylphosphonium bromide (11f) in 
the presence of N,N-dicyclohexylcarbodiimide (DCC) to furnish TPP-IOA (12) in 75% yield. 
Overall process yield, from starting material to the final product, stood at 9.6%. (3 
hydroxypropyl)triphenylphosphonium bromide itself was formed through the heating of 3-
bromopropanol alongside triphenylphosphine, with a yield 80% achieved. 
 
4.2.10.1. (Z)-methyl 12-hydroxyoctadec-9-enoate (11b) 
 
Castor oil (6.00 g), methanol (50 ml) and boron trifluoride-methanol (12 ml) were 
combined, with the resulting mixture stirred at 65°C for 1 h. Following extraction with ether 
(3 x 50 ml), the pooled organic layers were concentrated and purified through silica column 
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chromatography (3:7 ethyl acetate/petroleum ether) to yield (Z)-methyl 12-
hydroxyoctadec-9-enoate as a light-yellow oil (4.2 g, 67%).     
1H NMR (400 MHz, CDCl3); 0.9 (m, 3H), 1.2-1.7 (m, 22H), 2.0 (m, 2H), 2.2 (m, 2H), 2.4 (m, 
2H), 3.6 (s, 1H) 3.7 (s, 1H), 4.6 (m, 1H), 5.4 (m, 1H), 5.6 (m, 1H); 13C NMR (400 MHz, CDCl3); 
δ 174.7, 133.8, 125.6, 71.9, 53.8, 51.9, 37.3, 35.8, 34.5, 32.2, 30.0, 29.8, 29.5, 29.4, 27.8, 
26.1, 25.3, 23.0, 14.5; MS; m/z 335.3 (M+Na)  
 
4.2.10.2. (Z)-methyl 12-((methylsulphonyl)oxy)octadec-9-enoate (11c) 
 
A stirred solution of (Z)-methyl 12-hydroxyoctadec-9-enoate (4.00 g, 1.3 x 10-2 mol), 
dimethylaminopyridine (0.313 g, 1.30 x 10-3 mol) and triethylamine (2.60 g, 2.6 x 10-2 mol) 
in anhydrous dichloromethane was cooled to 0°C, with methanesulphonyl chloride (2.93 g, 
2.6 x 10-2 mol) introduced drop-wise over 5 minutes. The resulting mixture was allowed to 
warm to room temperature and stirred overnight, after which it was quenched with brine 
(50 ml) and 10% sulphuric acid (30 ml). Following extraction with dichloromethane (3 x 40 
ml), organic phases were combined and concentrated to afford crude product. Purification 
through column chromatography was performed quickly, in order to minimise effects of 
product degradation upon silica. (Z)-methyl 12-((methylsulphonyl)oxy)octadec-9-enoate 
eluted at 3:7 ethyl acetate/petroleum ether  (4.23 g, 85%), appearing as a yellow oil. 
1H NMR (400 MHz, CDCl3); δ 0.9 (m, 3H), 1.2-1.5 (m, 16H), 1.7 (m, 4H), 2.0 (m, 2H), 2.2 (m, 
2H), 2.4 (m, 2H), 3.0 (s, 3H), 3.7 (s, 3H), 4.6 (1H), 5.4 (m, 1H), 5.6 (m, 1H); 13C NMR (400 
MHz, CDCl3); δ 174.7, 134.8, 123.4, 84.0, 77.1, 51.8, 39.1, 34.6, 34.5, 32.9, 32.0, 29.8, 29.5, 
29.5, 29.4, 27.8, 25.4, 25.3, 22.9, 14.4; MS; m/z 413.2 (M+Na) 
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4.2.10.3. (Z)-methyl 12-(1H-imidazol-1-yl)octadec-9-enoate (11d) 
 
Imidazole (0.348 g, 5.10 x 10-3 mol) and potassium carbonate (0.707 g, 5.10 x 10-3 mol) were 
introduced to a stirred solution of (Z)-methyl 12-((methylsulphonyl)oxy)octadec-9-enoate 
(1.00 g, 2.60 x 10-3 mol) in acetonitrile. This mixture was heated overnight at a temperature 
of 80°C, before the addition of sodium bicarbonate (15 ml), brine (40 ml), and extraction 
with ethyl acetate (3 x 50 ml). The combined organic phases were concentrated to produce 
a crude product, which was purified through silica column chromatography (4:6 ethyl 
acetate/petroleum ether) to yield (Z)-methyl 12-(1H-imidazol-1-yl)octadec-9-enoate (0.227 
g, 25%) as a pale yellow oil.  
1H NMR (400 MHz, CDCl3); δ 0.9 (m, 3H), 1.2 (m, 16H), 1.5-1.8 (m, 6H), 2.2 (m, 2H), 2.4 (m, 
2H), 3.7 (s, 3H), 3.8 (m, 1H) 5.1 (m, 1H), 5.3 (m, 1H), 6.8 (m, 1H), 7.0 (m, 1H), 7.4 (1H); 13C 
NMR (400 MHz, CDCl3); δ 174.6, 136.5, 134.3, 129.5, 124.6, 117.0, 59.5, 51.8, 36.3, 35.8, 
34.5, 33.7, 32.7, 32.0, 29.7, 29.4, 27.6, 26.8, 26.3, 25.6, 25.3, 14.5; MS; m/z 363.3 (M+) 
 
4.2.10.4. (Z)-12-(1H-imidazol-1-yl)octadec-9-enoic acid (11e) 
 
A solution containing (Z)-methyl 12-(1H-imidazol-1-yl)octadec-9-enoate (0.227 g, 6.50 x 10 -
4 mol) and aqueous sodium hydroxide (2N, 5 ml) in methanol was stirred for 1 h at 70°C. 
Upon completion, the reaction mixture was acidified with 2% aq. hydrochloric acid until a 
neutral PH had been acquired. Water was added, prior to extraction with ethyl acetate (3 x 
30 ml). Combined organic phases were concentrated to yield (Z)-12-(1H-imidazol-1-
yl)octadec-9-enoic acid (0.210 g, 80%) as a sticky, yellow oil. 
1H NMR (400 MHz, CDCl3); δ 0.9 (m, 3H), 1.1-1.4 (m, 18H), 1.6 (m, 2H), 1.8 (m, 2H), 2.4 (m, 
2H), 2.6 (m, 2H), 4.1 (m, 1H), 5.2 (m, 1H), 5.4 (m, 1H), 7.0 (m, 1H), 7.3 (m, 1H), 8.5 (1H), 11.0 
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(s, 1H); 13C NMR (400 MHz, CDCl3); δ 178.0, 135.5, 135.1, 123.4, 123.1, 118.4, 61.2, 35.4, 
34.8, 34.1, 31.9, 29.4, 29.2, 28.9, 27.5, 26.3, 25.3, 24.8, 24.1, 22.9, 14.4; MS; m/z 349.3 
(M+) 
4.2.10.5. TPP-IOA (12) 
 
(Z)-12-(1H-imidazol-1-yl)octadec-9-enoic acid (0.210 g, 6.03 x 10-4 mol), (3-
hydroxypropyl)triphenylphosphonium bromide (0.315 g, 7.84 x 10-4 mol) and DCC (0.162 g, 
7.84 x 10-4 mol) were combined in dichloromethane. The resulting mixture was left to stir 
overnight, following which it was filtered through celite and concentrated to yield a crude 
product. Purification through silica chromatography (1:9 methanol/dichloromethane) 
furnished TPP-IOA (0.332 g, 75 %) as a thick, yellow-brown oil. 
1H NMR (400 MHz, CDCl3); δ 0.9 (m, 3H), 1.2 (m, 16H), 1.4 (m, 2H), 1.6-2.0 (m, 6H), 2.2 (m, 
2H), 2.4 (m, 2H), 3.7-4.0 (m, 2H), 4.3 (m, 1H), 5.1 (m, 1H), 5.3 (m, 1H), 6.8 (m, 1H), 7.0 (m, 
1H), 7.4 (1H), 7.6-7.9 (m, 15H); 13C NMR (400 MHz, CDCl3); δ 177.6, 135.9, 135.6, 134.9, 
133.8, 132.7, 131.4, 123.6, 122.8, 118.0, 60.7, 35.9, 34.8, 32.2, 31.1, 29.6, 29.0, 28.1, 27.0, 
25.3, 25.1, 24.9, 24.3, 22.6, 14.7; MS; m/z 651.4 (M+) 
 
4.2.10.6. (3-hydroxypropyl)triphenylphosphonium bromide (11f) 
 
Triphenylphosphine (4.35 x 10-3 mol, 1.13 g) was heated to 120°C, after which 1-bromo-3-
propanol (3.60 x 10-3 mol, 0.5 g) was added. After being stirred for 15 minutes, a white 
precipitate appeared and ethanol (10 ml) was introduced. Heating was maintained for a 
further 10 minutes, during which the precipitate dissolved. The mixture was placed on ice, 
and ether added to induce the formation of (3-hydroxypropyl)triphenylphosphonium 
bromide as white crystals, with filtration yielding (0.985 g, 68%) of product.  
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1H NMR (400 MHz, CDCl3); δ 1.3 (m, 2H), 1.8-2.0 (m, 2H), 3.8-4.0 (m, 2H), 3.9 (s, 1H), 7.6-8.0 
(m, 15H); 13C NMR (400 MHz, CDCl3); δ 135.5, 133.9, 131.0, 118.7, 60.7, 26.3, 20.6; MS; m/z 
321.2 (M+); Elemental analysis; Anal. calcd. C21H22BrOP: C, 62.86%, H, 5.53%; Found: C 
62.75%, H, 5.55%. 
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4.3. Results 
 
4.3.1. Effects of TPP-IOA upon Cell Viability 
 
The impact of TPP-IOA upon viability was examined across each of the three cell types. IC50 
values were obtained through use of the MTT assay, following 24 h incubation in HL-60 cells 
and following 48 h incubation in the HeLa and ρ0 HeLa lines. Cytotoxic effects in the low 
micromolar range were evident in each instance, with greatest sensitivity exhibited within 
the HL-60 cells (Table 4.1.). As a consequence, the upper concentration limit at which the 
compound could be administered within each line corresponded to 1 µM within the HL-60 
and 10 µM within HeLa and HeLa ρ0 lines. 
Cell Line IC50 (µM) 
    
HL-60 1.55 ± 0.71 
HeLa 16.1 ± 3.69 
HeLa ρ0 20.0 ± 4.73 
  
Table 4.1. IC50 values of HL-60, HeLa and ρ0 HeLa cells dosed with TPP-IOA. Cytotoxicity 
was measured using the MTT assay. Results are shown as the mean of three independent 
experiments, ± SD. 
 
4.3.2. Impact of TPP-IOA upon Artesunate-Induced Cardiolipin 
Oxidation 
  
Levels of oxidised cardiolipin within cells were determined through flow cytometry using 
NAO. NAO is a fluorescent dye which possesses affinity for cardiolipin, binding it in 
preference to other structurally related phospholipids. Intensity of fluorescence is generally 
proportional to the content of unoxidised cardiolipin present within the mitochondrion, 
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despite the existence of evidence suggesting that uptake of the compound within the 
organelle is influenced through membrane potential (Kaewsuya et al., 2007). 
Quantification of intact and oxidised cardiolipin was achieved through monitoring 
fluorescence following excitation at a wavelength of 488 nm. In Figure 4.4. A, a 
representative histogram in a sample of HeLa cells treated with vehicle control is outlined. 
An increase in the proportion of cells possessing the diminished fluorescence associated 
with cardiolipin oxidation is apparent following 24 h treatment with 25 µM artesunate (Fig. 
4.4. B), as population within the gated area rises from 8.9% of total to 38.1%. 
 
Figure 4.4. Representative histograms outlining variation in NAO fluorescence between 
control and drug-treated HL-60 cells. The distribution of NAO fluorescence is displayed in 
untreated control (A) and 25 µM artesunate-dosed HeLa cells (B) following 24 h incubation. 
 
HL-60 cells were co-incubated with 0 – 10 µM artesunate and 0.5 µM TPP-IOA for a period 
of 24 h. The addition of the inhibitor was found to induce significant reductions in levels of 
cardiolipin oxidation with respect to those in cells administered solely with drug (Fig. 4.5. 
A). In HeLa (Fig. 4.5. B) and HeLa ρ0 cells (Fig. 4.5. C) treated for 48 h with 0 – 50 µM 
artesunate, the presence of 10 µM TPP-IOA imparted no significant impact upon extent of 
cardiolipin oxidation relative to control. 
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Figure 4.5. Impact of TPP-IOA upon artesunate-induced cardiolipin oxidation. HL-60 cells 
(A) were co-treated with 0 – 10 µM artesunate and 0.5 µM TPP-IOA for a period of 24 h. 
HeLa (B) and HeLa ρ0  cells (C) were co-incubated with 0 – 50 µM artesunate and 10 µM 
TPP-IOA over 48 h. Cardiolipin oxidation was determined through measuring variation in 
NAO fluorescence using flow cytometry. Values are presented as the mean of three 
independent experiments, ± SD. * represents p < 0.05 as determined through paired t-test. 
 
 
4.3.3. Cytoprotective Potential of TPP-IOA against Artesunate 
Treatment  
 
The potential of TPP-IOA to ameliorate the toxicity of artesunate was investigated using the 
MTT assay. In HL-60 cells treated with 5 µM artesunate for 24 h, the co-administration of 1 
µM TPP-IOA elicited a significant increase in cell viability (Fig. 4.6. A). Conversely, no 
significant cytoprotection was evident upon the co-incubation of 10 µM TPP-IOA alongside 
25 µM artesunate in HeLa (Fig. 4.6. B) and HeLa ρ0 cells (Fig. 4.6. C) following 48 h. 
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Figure 4.6. Cytoprotective potential of TPP-IOA against artesunate treatment. HL-60 cells 
(A) were co-treated with 5 µM artesunate and 1 µM TPP-IOA for a period of 24 h. HeLa (B) 
and HeLa ρ0 cells (C) were co-incubated with 25 µM artesunate and 10 µM TPP-IOA over 48 
h. Cell viability was determined using the MTT assay. Values are presented as the mean of 
three independent experiments, ± SD. * represents p < 0.05, as determined through the 
paired t-test. 
 
4.3.4. Impact of TPP-IOA upon Artesunate-Induced Apoptosis 
 
The emergence of an apoptotic cell population was quantified through flow cytometry 
using the DNA intercalator PI. PI fluoresces strongly upon formation of adducts alongside 
nuclear DNA, with the intensity of emission being proportional to the cellular DNA content. 
Through consideration of the relative abundance of DNA across its stages, measurement of 
fluorescence may be used in order to determine the progression of a cell population along 
the cell cycle. As a cell moves through this sequence, the process of DNA replication, which 
occurs during the S-phase, doubles content from 2n found in the G0/G1-phase to 4n at the 
G2/M-phase. As a consequence of this growth, it is possible to infer from the plotting of 
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fluorescence intensity against cell count the relative proportion of cells present within each 
region (Fig. 4.7.). The apoptotic sub-G0/G1 population is characterised by its low apparent 
emission, which arises as a product of chromatin condensation and DNA degradation 
occurring during the enactment of programmed cell death. 
 
 
Figure 4.7. Representative histogram outlining fluorescence trace obtained in untreated 
cells upon PI staining. The locations of the regions which correspond to the sub-G0/G1, 
G0/G1, S and G2/M cell cycle phases are detailed.  
 
The accumulation of cells within the sub-G0/G1 region is indicative of the emergence of 
apoptotic death. Representative traces display alterations in PI fluorescence, stimulated 
through excitation at wavelength 488 nm, observed between vehicle control HL-60 cells 
(Fig. 4.8. A) and those treated with artesunate (Fig. 4.8. B) for a period of 24 h. The 
presence of drug leads to an increase in proportion of cells falling within this area, from 
4.0% to 29.6% of total. 
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Figure 4.8. Representative histograms outlining variation in PI fluorescence between 
control and drug-treated HL-60 cells. The proportion of the population falling within the 
sub-G0/G1 cell cycle region, as highlighted within the gated area, is shown within untreated 
control (A) and artesunate-dosed cells (B) following 24 h incubation. 
 
HL-60 cells were treated for 24 h with 5 µM artesunate. Co-administration of 1 µM TPP-IOA 
produced a mild but significant reduction in the proportion of cell appearing in the sub-
G0/G1 cell cycle phase (Fig. 4.9.), indicating that the compound possesses potential to 
impart anti-apoptotic effects. 
 
Figure 4.9. Impact of TPP-IOA upon artesunate-induced apoptosis. HL-60 cells were co-
treated with 5 µM artesunate and 1 µM TPP-IOA for a period of 24 h. The proportion of 
cells undergoing apoptotic death was determined through quantification of sub-G0/G1 
population using PI and flow cytometry. Results are presented as the mean of three 
independent experiments, ± SD. * represents p < 0.05, as determined through the paired t-
test. 
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4.3.5. Modulatory Impact of TPP-IOA upon Artesunate-Induced 
Mitochondrial Superoxide Formation 
 
The ability of TPP-IOA to impact upon levels of mitochondrial superoxide arising as an early 
feature of artesunate-induced toxicity was examined using MitoSOX. Specific detection of 
superoxide was facilitated through monitoring formation of the fluorescent 
hydroxyethidium product. Treatment of HL-60 cells with 1 µM TPP-IOA alongside 5 and 10 
µM artesunate imparted general increases in the levels of drug-induced mitochondrial ROS 
following 16 h (Fig. 4.10. A). These effects were mirrored within HeLa line upon co-
incubation for 24 h with 10 and 25 µM artesunate and 10 µM TPP-IOA (Fig. 4.10. B), but 
were less pronounced in the HeLa ρ0 variety following an identical dosing plan (Fig. 4.10. C).  
Figure 4.10. Modulatory impact of TPP-IOA upon artesunate-induced mitochondrial 
superoxide formation HL-60 cells (A) were co-treated with 5 and 10 µM artesunate and 1 
µM TPP-IOA for a period of 16 h. HeLa (B) and HeLa ρ0  cells (C) were co-incubated with 25 
– 50 µM artesunate and 10 µM TPP-IOA over 24 h. ROS levels were determined through 
measurement of MitoSOX fluorescence. Values are expressed as percentage of ROS 
detected relative to vehicle control, and are presented as the mean of three independent 
experiments, ± SD.  
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4.3.6. Effects of TPP-IOA upon Artemisinin Bioactivation 
 
The capacity of TPP-IOA to impact upon bioactivation of PFDHA was assessed using the LC-
MS method detailed in Section 3.2.10., Chapter 3. HL-60 cells were incubated with 5 µM 
PFDHA and 1 µM TPP-IOA for a period of 24 hours prior to organic extraction (Fig. 4.11. A), 
whilst HeLa (Fig. 4.11. B) and HeLa ρ0 cells (Fig. 4.11. C) were treated for 48 h with 25 µM 
PFDHA and 10 µM TPP-IOA. Across all cell lines, TPP-IOA was observed to have no 
significant impact upon the quantities of PFDHA and THF acetate recovered. 
 
Figure 4.11. Effects of TPP-IOA upon artemisinin bioactivation. HL-60 cells (A) were co-
treated with 5 µM PFDHA and 1 µM TPP-IOA for a period of 24 h. HeLa (B) and HeLa ρ0 cells 
(C) were co-incubated with 25 µM PFDHA and 10 µM TPP-IOA over 48 h. Values are 
expressed in terms of the quantity of PFDHA and THF acetate recovered as a percentage of 
starting material, and are presented as the mean of three independent experiments, ± SD.  
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4.4. Discussion 
 
The chemical synthesis of TPP-IOA proceeded broadly along the pathway outlined by 
Atkinson et al. (Atkinson et al., 2011). A key variation with regards to this existing method 
was in the employment of castor oil as the source of methyl ricinoleate. Approximately 90% 
of the fatty acid content of this mixture is composed of ricinoleic acid triglyceride, ensuring 
that the desired methyl ester derivatives can be furnished readily with good yield and high 
purity upon chromatographic separation (Yang et al., 2002). Although providing a further 
step to the synthetic pathway ahead of that reported in the literature, the use of 
inexpensive the castor oil circumvents the requirement for the employment of costly 
commercial sources of purified methyl ricinoleate and hence grants a greater cost-
effectiveness to production. The overall product yield, from castor oil through five stages to 
TPP-IOA, was 9.6% (Fig. 4.3.).  
The role of cardiolipin within the mechanism of artesunate-induced cytotoxicity was 
investigated through examining the impact of this inhibitor upon cell response to drug 
treatment. Studies into the effects of the compound were performed over three cell lines, 
with the HL-60 variety displaying greatest sensitivity towards its impact. A preliminary 
assessment of the activity of TPP-IOA alone within this line demonstrated an ability to 
induce cytotoxicity within the low micromolar range, with the upper concentration at which 
it could be used effectively limited to 1 µM (Table 4.1.). Increased resistance within the 
HeLa and HeLa ρ0 varieties ensured that the employment up to a maximum concentration 
of 10 µM was permissible. In order to fully elucidate the route through which TPP-IOA 
induces the emergence of cell death, additional study shall be required. The outcomes of 
the examinations performed assessing impact upon artesunate-induced mitochondrial 
superoxide levels suggest that the inhibitor possesses a capacity to enhance oxidative stress 
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within the organelle (Fig. 4.10.). It is believed that the anti-peroxidase activity of TPP-IOA is 
derived from the strong ligand affinity of its imidazole functionality towards the haem-Fe(II) 
situated within cytochrome c (Atkinson et al., 2011). Owing to the involvement of this unit 
within electron transport, it is feasible to hypothesise that disturbance to the coordination 
sites about the metal, arising from the presence of the additional ligand, might induce 
disruption to the redox processes mediated present and hence prevent passage through 
the electron transport chain. 
Rationale for investigation into the potential for artemisinin derivatives to function as 
oxidants of cardiolipin has been provided through the outcomes of  studies which have 
identified radical-initiated decomposition of the phospholipid as a key early stage in the 
progression of apoptosis (Fernandez et al., 2002). Biomimetic examinations have allowed 
for the characterisation of numerous products emerging from the oxidative degradation of 
the common cardiolipin forms, enabling elucidation of the routes through which such 
transformations arise in physiological and pathological settings (Kim et al., 2013; Kim et al., 
2011). The capacity of artemisinin to induce changes in the structures of related 
phospholipids has been demonstrated (Kumura et al., 2009). It is thus theorised that 
carbon-centred radicals, formed courtesy of Fe(II)-mediated bioactivation of the artemisinin 
endoperoxide bridge, might initiate such peroxidation through direct abstraction at the 
unsaturated lipid chain.  
Dose-dependent increases in levels of oxidised cardiolipin, as determined through use of a 
flow cytometric method reliant upon monitoring variation in NAO fluorescence, were 
witnessed following artesunate treatment across each of the three cell lines (Fig. 4.5.). The 
oxidation of cardiolipin, triggered through the induction of ROS formation, has been 
identified as a key stage mediating the release of cytochrome c and the progression of 
intrinsic apoptosis (Orrenius et al., 2005). With existing evidence strongly suggesting the 
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ability for artemisinin-derived compounds to impart toxic effects through enhancing levels 
of oxidative stress and stimulating the onset of apoptotic cell death, such a finding is 
consistent with current understanding regarding their mechanism of action (O'Neill et al., 
2010b). It is interesting to note that great similarities in extent of cardiolipin oxidation were 
witnessed across HeLa and HeLa ρ0 cells. Such an outcome serves to indicate that the 
influence held by an operational electron transport chain within the mediation of 
artemisinin-stimulated peroxidative effect is minimal.   
The co-administration of TPP-IOA alongside artesunate in HL-60 cells induced significant 
reductions in levels of oxidised cardiolipin, as assayed using NAO (Fig. 4.5.). According to 
this metric, the addition of 0.5 µM inhibitor was sufficient to reduce drug-induced 
cardiolipin oxidation levels by half following 24 h incubation. Such effects were not evident 
within the HeLa cells, where TPP-IOA was unable to impact significantly upon phospholipid 
oxidation following 48 h artesunate treatment. Doubts over the suitability of NAO to 
function as a reliable determinant of cardiolipin oxidation status have been raised owing to 
concerns regarding the impact of mitochondrial membrane potential upon uptake of the 
compound within the organelle (Fernandez et al., 2004; Rodriguez et al., 2008). Hence, a 
collaborative venture with Huiyong Yin has sought the development of a more reliable mass 
spectrometric protocol for the assessment and quantification of oxidised cardiolipin levels. 
Previous research within this group has facilitated the LC-MS characterisation of molecular 
species formed through the oxidative decomposition of common cardiolipin isoforms (Liu et 
al., 2011a; Yin et al., 2012). Accordingly, monitoring the relative prevalence of these 
products against selected parent cardiolipin varieties has allowed for examination into the 
ability of artesunate and TPP-IOA to impact upon the oxidation state of the phospholipid. 
Co-treatment of HeLa cells with 50 µM artesunate and 10 µM TPP-IOA was performed over 
a period of 24 h. LC-MS quantification of cardiolipin oxidation product abundance following 
incubation confirmed the capacity of the drug to induce peroxidation, whilst simultaneously 
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illustrating the potential for the inhibitor to impart protective effect (Fig. 4.12.). 
Interestingly, the results accrued through use of the LC-MS method, which indicate that 
TPP-IOA possesses the capability to reduce levels of drug-induced cardiolipin oxidation 
within these cells, contrast with the outcomes obtained following the use of NAO. It would 
seem apparent, therefore, that NAO functions as an imperfect metric of cardiolipin 
oxidation within this cell type. Whilst the time-course of the LC-MS assessment, at 24 h, 
varied from that which was employed in the NAO studies, comparison between the two 
outcomes can be made.  Extension of the scope of this study to include the HL-60 and ρ0 
HeLa lines would allow for the impact of TPP-IOA to be examined with much greater 
reliability, and would hence enable the validity of the both methods to be assessed more 
thoroughly.  
 
 
Figure 4.12. Impact of TPP-IOA upon artesunate-induced cardiolipin oxidation assayed 
using LC-MS. HeLa cells were co-incubated with 50 µM artesunate and 10 µM TPP-IOA for a 
period of 24 h. Ratio of oxidised to unoxidised cardiolipin was determined through an LC-
MS method. Results are expressed as the mean of three independent experiments, ± SD. 
 
In order to ascertain whether TPP-IOA exerted a cytoprotective effect against artesunate 
toxicity, the MTT assay was used in order to determine viability in co-treated cells. 
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Significant decreases in the levels of drug-induced cell death were apparent only within the 
HL-60 line, whilst no alteration in the susceptibility of both the HeLa and ρ0 HeLa cells was 
evident (Fig. 4.6.). The capacity of the inhibitor to protect against the toxicity of artesunate 
within HL-60 cells mirrors the apparent reductions in cardiolipin oxidation levels detected 
through NAO. This correlation would suggest that an ability to restrain the oxidation of 
cardiolipin is associated with a reduced sensitivity towards the drug within this line. 
Examination of cell cycle population distribution using PI following artesunate treatment 
demonstrated a moderately decreased tendency for HL-60 cells to fall within the sub-G0/G1 
region upon co-administration of the inhibitor (Fig. 4.9.). The mild anti-apoptotic effect 
would tally with the postulated relevance of cardiolipin oxidation within the progression of 
programmed cell death through the intrinsic pathway, whilst the continued impact of the 
endoperoxide upon viability indicates the inability of TPP-IOA to impart a complete 
suppression of peroxidation. Such observations stand in accordance with evidence derived 
from the early studies assessing the capacity of the inhibitor to mitigate the impact of pro-
apoptotic and cytotoxic stimuli across in vitro and in vivo systems (Atkinson et al., 2011). 
Through these investigations, it was witnessed that both radiation and rotenone-induced 
apoptotic cell death were diminished in mouse embryonic and lung epithelial cells upon 
administration of the compound, whilst the survival profiles of dosed, irradiated mice were 
further noted as favourable. However, concordant with the outcomes of the examinations 
performed within this chapter, whilst anti-apoptotic and cytoprotective effects were 
observed to be significant, in no system did they culminate in complete abrogation.  
When viewed alongside data accrued from both the NAO and the collaborative LC-MS 
investigations, it becomes apparent that TPP-IOA is incapable of suppressing the drug-
induced oxidation of cardiolipin in entirety. As such, the involvement of alternative 
pathways within the emergence of peroxidation becomes feasible. Direct, radical-mediated 
attack courtesy of the activated artemisinin derivative remains potentially a contributing 
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factor towards these effects. It is further acknowledged that, as in other phospholipids, 
peroxidase-independent modification of cardiolipin structure arises as a consequence of 
direct ROS-mediated attack occurring during instances of oxidative stress (Yin et al., 2012). 
A chemical pathway through which such an effect might be mediated, by means of the 
hydroxyl radical, is outlined in Figure 4.13. 
 
Figure 4.13. ROS-stimulated peroxidation of the unsaturated lipid chain. 
 
Outcomes of the LC-MS assessment the capacity of the inhibitor to prevent PFDHA 
bioactivation indicate that any protective influence of the compound is unrelated to an 
ability to suspend peroxidase-mediated reduction of the endoperoxide bridge (Fig. 4.11.). It 
therefore appears implausible to hypothesise that the cytochrome c-cardiolipin complex 
functions as a significant site for drug activation. 
The contrasting outcomes observed between cell models ensure that drawing definitive 
conclusions regarding the impact of TPP-IOA upon artesunate treatment is not possible in 
light of the evidence obtained. It is apparent that the inhibitor, which functions through 
suppressing the cytochrome c-peroxidase complex, is neither able to induce complete 
cessation in cardiolipin oxidation nor offer substantial cytoprotective effect. It follows that, 
168 
 
whilst investigation into the modulatory impact of the compound upon cell response to the 
drug has served to provide mechanistic insight into the activities of both, the precise 
mechanistic role of cardiolipin within the progression of artemisinin-induced cell death 
remains undetermined. 
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Examination into the Cytotoxic Profiles of 
Novel Endoperoxide Compounds 
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5.1. Introduction 
 
The great therapeutic efficacy of artemisinin derivatives has ensured that they have 
retained their role on the frontline of treatment against malaria. Whilst the value of the 
current set of clinically-employed compounds remains undoubted, the development of 
novel endoperoxide agents has continued to constitute an ongoing focus for research. In 
this chapter, a series of studies into the cytotoxic profiles of novel compounds from a host 
of recently developed synthetic and semi-synthetic endoperoxide classes is presented. 
Their number shall include both recently-developed antimalarial candidates and also 
experimental, anti-cancer drugs. 
The search for new endoperoxide antimalarial agents is spurred on by concerns regarding 
the activity profiles and sustainability of the semi-synthetic, artemisinin-derived 
compounds currently in use (Ridley, 2002). Clinically, both their poor bioavailability and 
their short half-life form unfavourable aspects of their pharmacokinetic profiles. Whilst 
instance of toxicity in man is generally held to be absent under dosing protocols routinely 
employed, evidence accrued from in vivo and in vitro studies has been sufficient to cast 
doubts regarding their universal safety (Efferth et al., 2010). An ability to induce the onset 
of embryotoxicity and neurotoxicity has been demonstrated consistently across animal 
models, influencing the WHO to recommend their contraindication in mothers during the 
opening trimester of pregnancy (WHO, 2006). 
Alongside the issues surrounding safety, a growing body of evidence exists to suggest the 
emergence of artemisinin resistance amongst a subset of parasite strains within South-east 
Asia (O'Brien et al., 2011). Although reduced susceptibility to drug effects has largely 
remained localised to regions surrounding the Thai-Cambodian border, a recent spread to 
neighbouring areas has been noted (Dondorp et al., 2009; Noedl et al., 2008). Whilst impact 
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upon the antimalarial efficacy of current combination therapy regimens has thus far 
remained minimal, it is conceivable that further extension might, with time, develop 
influence upon treatment outcomes. Additional concerns regarding drug affordability are 
derived from the costs associated with production of artemisinin (White, 2008). Extraction 
of the natural product from the leaves of Artemisia annua has remained the most 
economically viable route towards isolation, ensuring that supply has been dependent upon 
the commercial availability of the plant source. As a consequence of this, the typical market 
price for artemisinin derivatives has put them out of range in some of the world’s poorest, 
neediest regions, necessitating the employment of older, less effective drug classes (Yeung 
et al., 2008). 
The shortfalls associated with the present stock of artemisinin-based compounds have 
stimulated interest in the development of wholly synthetic endoperoxide analogues. 
Research has demonstrated that antimalarial efficacy of the endoperoxide unit can be 
maintained, and even improved, outside of the artemisinin molecular framework (Opsenica 
et al., 2009). A great number of peroxidic molecules, featuring a diverse array of structures, 
have been synthesised and examined for their activities, both in vitro and in vivo, over the 
preceding three decades (Jefford, 2007). Amongst these novel classes, compounds 
incorporating 1,2,4-trioxolane and 1,2,4,5-tetraoxane pharmacophores have displayed 
greatest promise regarding potential progression towards clinical use (Kumar et al., 2011). 
Examination into structure activity relationship has determined that optimal antimalarial 
performance is ensured through the protection of the peroxide with adamantyl and 
cyclohexyl groups. Alongside OZ277, introduced in Section 1.7., Chapter 1, compounds such 
as OZ439 (13), along with its tetraoxane isoform (14), have displayed antiparasitic activities 
greater than those of the artemisinin derivatives in pre-clinical testing (Charman et al., 
2011).  
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Whilst the cytotoxicity of endoperoxides within mammalian systems is an undesired feature 
of their activity profile during the course of antimalarial treatment, their enhanced 
sensitivity towards rapidly proliferating cancer cell lines in vitro has encouraged 
investigation into their potential for use as anticancer agents. A range of promising 
outcomes have been observed across a breadth of studies, with artemisinin derivatives 
including DHA and artesunate found to exert pro-apoptogenic and anti-proliferative effects 
against breast, prostate, lung, colon, and pancreatic cancer cells (Firestone et al., 2009). 
Aside from direct action against cell viability, the impediment of cell metastasis through 
mechanisms dependent upon the suppression of matrix metalloproteinase (MMP) has been 
demonstrated across several lines (Weifeng et al., 2011). It is theorised additionally that the 
ability of the drugs to initiate the downregulation of VEGF expression might lend them anti-
angiogenic properties (Wartenberg et al., 2003). Whilst evidence derived directly from 
clinical use remains limited, isolated studies attest to the therapeutic benefits of artesunate 
and artemether against a number of tumour types (Krishna et al., 2008). 
Research has thus sought the development of novel artemisinin derivatives providing 
enhanced potency and specificity towards rapidly proliferating cancer cells. Several 
strategies have been adopted in the design of these compounds, ranging from the creation 
of dimeric and trimeric artemisinin species to the construction of drug hybrids (Chaturvedi 
et al., 2010; Xie et al., 2011). Amongst these experimental classes, a number of which have 
been developed with the intention of offering improved activity against both the parasite 
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and against cancerous cells, there have been synthesised a variety of conjugates comprising 
DHA and an alternative active group. Within these categories have arisen combinations 
alongside thiazole, oxadiazole, caboxamide, spermidine and acridine moieties – the latter 
formed with the intention of enhancing toxicity through the provision of localisation 
towards DNA (Jones et al., 2009; Kumar et al., 2011). Many such derivatives have exhibited 
in vitro activities greater than that of DHA, and have hence been identified as promising 
potential leads for further trial. A further series of compounds, combining DHA with 
polypyrrole intercalators resembling those found upon antibiotics such a netropsin, have 
been designed rationally ahead of pre-clinical testing.   
An examination into the in vitro activity of several newly-developed endoperoxide classes is 
reported in this chapter. Studies shall be focused upon assessing the toxicity of novel 
synthetic antimalarial compounds and semi-synthetic hybrid artemisinin derivatives against 
cancer cell lines. The group of Paul O’Neill has developed 1,2,4-trioxolane and 1,2,4,5-
tetraoxane compounds which display great potency against parasite cultures (Ellis et al., 
2008; O'Neill et al., 2010a). Trioxolane FBEG-100 (15) and 1,2,4,5-tetraoxane RKA-182 (16) 
are a pair of synthetic antimalarial candidates which differ structurally only in their 
pharmacophores. Assessment of their cytotoxic properties in cancer cells, including 
investigation into their impact upon mitochondrial function, shall allow not only for an 
evaluation of their potential safety within mammalian systems, but also for direct 
comparison of the impact of any variations in activity arising from differences between the 
three-oxygen and four-oxygen peroxidic groups. The time-dependence of the activity of the 
novel tetraoxane E-209 (17) shall also be examined across several cell lines, so that a more 
complete image of its activity profile across a greater array of systems might be obtained. 
175 
 
 
Alongside these studies, the toxic profile of a series of anticancer artemisinin-polypyrrole 
hybrids is investigated. As alluded to earlier, it is intended that the conjugation of the DNA 
intercalator shall allow for the localisation of the compounds within the nucleus, where 
their proximity to DNA might enhance cell killing ability. Amongst the candidates examined 
shall be the related pair dipyrrole LLP-271 (18) and tripyrrole LLP-272 (19), the aryl-linked 
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NET-4, NET-5 and NET-6 (20-22) and non-ether linked NET-7 (23). Demonstration of 
enhanced cytotoxic activity within these compounds relative to established artemisinin 
derivatives shall provide indication of their potential suitability for progression into further 
trial.   Both the conjugates and the synthetic antimalarials will be compared against DHA for 
their performance.  
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5.2. Materials and Methods 
 
5.2.1. Materials 
 
TMRE was purchased from Sigma-Aldrich (Poole, Dorset, UK). All compounds tested were 
synthesised by the group of Prof. Paul O’Neill (University of Liverpool, Liverpool, UK). 
 
5.2.2. Cell Culture and Experimental Preparation 
 
HeLa and Hep G2 cells were cultured and maintained according to protocols outlined in 
Section 2.2.2., Chapter 2.  HL-60 cells were handled as in Section 4.2.2., Chapter 4. 
 
5.2.3. Analysis through Flow Cytometry 
 
Flow cytometric analysis was performed according to the parameters described in Section 
3.2.4., Chapter 3.  
  
5.2.4. Measurement of Mitochondrial Depolarisation using TMRE 
 
 
Tetramethylrhodamine ethyl ester (TMRE) is a fluorescent compound which is taken up into 
the mitochondrion to an extent proportional with the magnitude of the membrane 
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potential (Scaduto et al., 1999). Drug-treated HL-60 cells (2.5 x 105) were centrifuged 
(1000g) and washed with HBSS, before the cell pellet was resuspended in TMRE solution 
(50 nM in HBSS). Samples were incubated for 10 minutes at 37°C, prior to analysis 
(minimum 1 x 104 cells) through flow cytometry. Fluorescence was monitored following 
excitation at 488 nm. Parameters were assessed in non-quenching mode. 
 
5.2.5. Determination of Apoptotic Cell Population using Propidium 
Iodide 
 
The ability of drugs to exert influence upon the proportion of HL-60 cells falling within the 
sub-G0/G1 cycle phase was assessed using PI, following the protocol described in Section 
4.2.5., Chapter 4. 
 
5.2.6. Assessment of Cell Viability using the MTT Assay 
 
Cell viability within the HeLa and Hep G2 lines was ascertained through use of the MTT 
assay, as detailed in Section 2.2.4., Chapter 2. For HL-60 cells, the slightly modified protocol 
of Section 4.2.6., Chapter 4 was employed. 
 
5.2.7. Statistical Analysis 
 
Data is presented and analysed in line with the protocols described in Section 2.2.10., 
Chapter 2.  
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5.3. Results 
 
5.3.1. Cytotoxic Activities of Novel Endoperoxide Compounds against 
Cancer Cells 
 
5.3.1.2. 1,2,4-Trioxolane and 1,2,4,5-Tetraoxane Antimalarials 
 
5.3.1.2.1. FBEG-100 and RKA-182 
 
The cytotoxicity of the 1,2,4-trioxolane FBEG-100 and the 1,2,4,5-tetraoxane RKA-182 was 
assessed in HL-60 cells using the MTT assay. IC50 values, obtained following 24 h incubation, 
are listed in Table 5.1. Both compounds displayed activities within the low micromolar 
range, indicating reduced toxicity relative to the artemisinin derivative DHA. It is apparent 
that cell sensitivity towards the tetraoxane is greater than that towards the trioxolane.  
Compound IC50 (µM) 
    
DHA 0.39 ± 0.11 
FBEG-100 23.6 ± 1.57 
RKA-182 5.07 ± 0.72 
 
Table 5.1. IC50 values of HL-60 cells dosed with FBEG-100 and RKA-182. Cytotoxicity was 
measured using the MTT assay. Results are shown as the mean of three independent 
experiments, ± SD.  
 
 
5.3.1.2.2. E-209 
 
An assessment of the time-dependence of response towards tetraoxane E-209 was 
performed in HL-60 cells. Using the MTT assay, IC50 values were determined over time-
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courses ranging from 6 to 72 h (Table 5.2.).  A rapid onset of cytotoxicity was observed, 
with low micromolar activity evident after only 6 h treatment. 
T (h) IC50 (µM) 
    
6 13.7 ± 1.67 
16 4.63 ± 1.44 
24 2.85 ± 0.988 
48 1.59 ± 0.324 
72 1.28 ± 0.382 
 
Table 5.2. IC50 values of HL-60 cells dosed with E-209. Cytotoxicity was measured using the 
MTT assay. Results are shown as the mean of three independent experiments, ± SD.  
 
5.3.1.3. Artemisinin-Polypyrrole Anticancer Conjugates 
 
5.3.1.3.1. LLP 271 and LLP-272 
 
The activity of the artemisinin-dipyrrole conjugates LLP-271 and LLP-272 was examined in 
HL-60 cells. Following 24 h incubation, the MTT assay was employed in order to determine 
IC50 values for both the compounds and for an unconjugated control dipyrrole moiety (Table 
5.3.). Although LLP-271 displayed the greater potency of the two, neither possessed activity 
greater than that of DHA. The observed inertness of the dipyrrole unit (24) demonstrates 
that it exerts no cytotoxic effects in isolation. 
Compound IC50 (µM) 
    
LLP-271 2.16 ± 0.52 
LLP-272 15.5 ± 1.32 
Dipyrrole > 100 
 
Table 5.3. IC50 values of HL-60 cells dosed with LLP-271, LLP-272 and dipyrrole. 
Cytotoxicity was measured using the MTT assay. Results are shown as the mean of three 
independent experiments, ± SD.  
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5.3.1.3.2. NET-4, NET-5, NET-6 and NET-7 
 
A further selection of polypyrrole compounds were examined for their cytotoxic properties 
in HL-60 cells. Again, IC50 values were obtained following 24 h incubation using the MTT 
assay (Table 5.4). Activity was observed within the low micromolar range, but no compound 
exhibited cell killing ability greater than that possessed by DHA. 
Compound IC50 (µM) 
    
NET-4 6.35 ± 2.93 
NET-5 1.42 ± 0.66 
NET-6 4.60 ± 1.40 
NET-7 11.7 ± 4.38 
 
Table 5.4. IC50 values of HL-60 cells dosed with NET-4, NET-5, NET-6 and NET-7. 
Cytotoxicity was measured using the MTT assay. Results are shown as the mean of three 
independent experiments, ± SD.  
 
5.3.2. Mechanistic Aspects of Novel Endoperoxide Activity in Cancer 
Cells 
 
Having examined the cytotoxic potentials of the novel antimalarial and anticancer 
candidates, further investigations centred upon determining the mechanistic routes 
through which impact towards the viability of cells might potentially be mediated were 
performed with selected compounds. 
 
5.3.2.1. FBEG-100 and RKA-182 
 
5.3.2.1.1. Effects upon Mitochondrial Membrane Potential 
 
The impact of drug treatment upon mitochondrial membrane potential was determined 
through use of TMRE. TMRE is a fluorescent rhodamine derivative, which owing to its 
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lipophilic cationic properties, accumulates readily within the mitochondrion (Scaduto et al., 
1999).  The extent to which it is taken up into the organelle is determined by the magnitude 
of the membrane potential, with increased presence within the matrix correlating with 
greater fluorescence. It is the relationship between mitochondrial membrane potential, 
mitochondrial uptake and compound fluorescence which allows for assessment of 
membrane depolarisation. A fall in fluorescence, as measured following 488 nm excitation, 
is associated with diminished potential within non-quenching mode. Representative traces 
displayed in Figure 5.1. outline the variation between high-potential, untreated control cells 
(Fig. 5.1. A), and low-potential cells dosed for 24 h with 100 µM DHA (Fig. 5.1. B). The shift 
in distribution from upper to lower quadrants is readily apparent. 
 
Figure 5.1. Representative dotplots outlining variation in TMRE fluorescence between 
control and drug-treated HL-60 cells. TMRE fluorescence in control (A) and 100 µM DHA-
treated HL-60 cells (B) following 24 h incubation. 
 
HL-60 cells were treated for 24 h with 0 – 100 µM DHA, 0 – 30 µM FBEG-100 and 0 – 10 µM 
RKA-182.  Mitochondrial membrane potential was subsequently measured using TMRE.  A 
significant, dose-dependent increase in the proportion of depolarised cells was witnessed 
with each compound, with DHA exerting greater impact than either synthetic variety (Fig. 
5.2.).  
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Figure 5.2. Effects of trioxolane and tetraoxane antimalarials upon mitochondrial 
membrane potential. HL-60 cells were treated with 0 – 100 µM DHA 0 – 30 µM FBEG-100 
and 0 – 10 µM RKA-182 for a period of 24 h. Mitochondrial membrane potential was 
determined through flow cytometry using the TMRE dye. Results are shown as the mean of 
three independent experiments, ± SD. * represents p < 0.05, ** p < 0.01 and *** p < 0.001 
as determined through paired t-test. 
 
 
5.3.2.1.2. Ability to Induce Cell Death through Apoptosis 
 
The presence of apoptotic cells was detected using propidium iodide staining through the 
method described in Section 4.2.5., Chapter 4. HL-60 cells were treated with 0 – 100 µM 
DHA, 0 – 30 µM FBEG-100 and 0 – 10 µM RKA-182 for a period of 24 h, prior to flow 
cytometric analysis. Dose-dependent increases in the proportion of cells falling in the sub-
G0/G1 cycle region were apparent with each drug, with neither synthetic class displaying 
potency greater than DHA (Fig. 5.3.). 
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Figure 5.3. Ability of trioxolane and tetraoxane antimalarials to induce cell death through 
apoptosis. HL-60 cells were treated with 0-100 µM DHA 0 – 30 µM FBEG-100 and 0 – 10 µM 
RKA-182 for 24 h. The proportion of cells undergoing apoptotic death was determined 
through quantification of sub-G0/G1 population using PI and flow cytometry. Results are 
shown as the mean of three independent experiments, ± SD. * represents p < 0.05, ** p < 
0.01 and *** p < 0.001 as determined through paired t-test. 
 
5.3.2.2. E-209 
 
5.3.2.2.1. Further Impact upon the Viability of Cancer Cells 
 
Investigation into the cytotoxic impact of 1,2,4,5-tetraoxane E-209 was expanded to include 
assessment of its activity against cells belonging to both the HeLa and Hep G2 lines. Using 
the MTT assay, IC50 values were determined over time-courses ranging from 6 – 72 h in the 
former and 24 – 72 in the latter (Table 5.5.).  Whilst Hep G2 cells were shown to exhibit 
greater sensitivity towards the effects of the drug relative to those of the HeLa variety, 
neither line displayed responsiveness comparable to that observed within the HL-60 type 
(recorded in Table 5.2). 
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T (h) 
IC50 (µM) 
HeLa Hep G2 
      
6 445 ± 85.4  Not determined 
16 83.3 ± 7.60  Not determined 
24 57.3 ± 20.7 13.4 ± 1.70 
48 45.6 ± 8.90 10.5 ± 3.34 
72 38.2 ± 16.5 8.20 ± 3.72 
 
Table 5.5. IC50 values of Hep G2 and HeLa cells dosed with E-209. Cytotoxicity was 
measured using the MTT assay. Results are shown as the mean of three independent 
experiments, ± SD.  
 
 
5.3.2.3. LLP 271 and LLP-272 
 
5.3.2.3.1. Effects upon Mitochondrial Membrane Potential 
 
HL-60 cells were treated with DHA, LLP-271, LLP-272 and dipyrrole in concentrations 
ranging from 0 – 100 µM for a period of 24 h, before mitochondrial membrane potential 
was determined through flow cytometry using TMRE. Significant, dose-dependent increases 
in the proportion of depolarised cells were witnessed with each of the artemisinin-dipyrrole 
conjugates, although with neither exhibiting potency comparable to DHA at lower 
concentrations (Fig. 5.4.). Unconjugated dipyrrole displayed no activity. 
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Figure 5.4. Effects of artemisinin-dipyrrole conjugates upon mitochondrial membrane 
potential. HL-60 cells were treated with 0 – 100 µM DHA, LLP-271, LLP-272 or dipyrrole for 
24 h. Mitochondrial membrane potential was determined through flow cytometry using the 
TMRE dye. Results are shown as the mean of three independent experiments, ± SD. * 
represents p < 0.05, ** p < 0.01 and *** p < 0.001 as determined through paired t-test. 
 
 
5.3.2.3.2. Ability to Induce Cell Death through Apoptosis 
 
HL-60 cells were treated for 24 h with DHA, LLP-271, LLP-272 and dipyrrole in 
concentrations ranging from 0 – 100 µM. Apoptotic cell population was determined 
through PI staining. Significant, dose-dependent increases in the number sub-G0/G1 cells 
were witnessed through each compound, with DHA providing the greatest effect and the 
unconjugated dipyrrole appearing inactive (Fig. 5.5.). 
187 
 
 
Figure 5.5. Ability of artemisinin-dipyrrole conjugates to induce cell death through 
apoptosis. HL-60 cells were treated with 0 – 100 µM DHA, LLP-271, LLP-272 or dipyrrole for 
a period of 24 h. The proportion of cells undergoing apoptotic death was determined 
through quantification of sub-G0/G1 population using PI and flow cytometry. Results are 
shown as the mean of three independent experiments, ± SD. * represents p < 0.05, ** p < 
0.01 and *** p < 0.001 as determined through paired t-test. 
 
 
 
 
 
 
 
 
 
 
188 
 
5.4. Discussion 
 
The cytotoxic activities of novel endoperoxide derivatives belonging to several 
experimental drug classes were investigated within cancer cell lines. Broadly, the intentions 
of these assessments have been to determine the suitability of drug candidates for further 
development towards clinical use. 1,2,4-trioxolane and 1,2,4,5-tetraoxane antimalarial 
compounds were examined so that their toxicity in mammalian systems might be inferred 
ahead of their employment as therapy against parasitic infection. Similarly, study into the 
direct impact of the anticancer polypyrrole compounds upon cancer cell viability aimed to 
deduce the early feasibility for their potential use as disease treatment within a clinical 
setting. The model cell line employed across these investigations, the HL-60, has been 
chosen for its heightened sensitivity towards the effects of artemisinin derivatives and 
related endoperoxide compounds. 
Studies assessing the cytotoxic profiles of 1,2,4-trioxolane FBEG-100 and 1,2,4,5-tetraoxane 
RKA-182 have demonstrated that, whilst such synthetic agents display reduced levels of 
toxicity in HL-60 cells relative to that of the artemisinin derivative DHA, characteristic 
features of the mechanism through which death is imparted remain conserved across class. 
Dose-dependent collapse of the mitochondrial membrane, inferred through flow 
cytometric monitoring of TMRE fluorescence, is witnessed universally. This is accompanied 
by increases in the proportion of cells appearing in the sub-G0/G1 region of the cell cycle. 
Accordingly, it can be theorised that the route towards toxicity in the novel varieties 
proceeds, as it does in artemisinin derivatives, through induction of mitochondrial 
dysfunction and the emergence of apoptotic cell death.  
Further assessment of the activity of these compounds has provided additional mechanistic 
insight into the means by which such events might arise (Copple et al., 2012). These studies 
constituted an overall extension of the work reported within this chapter. In common with 
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the artemisinin-derived artesunate, it was revealed that toxicity proceeds through the 
induction of oxidative stress and the stimulation of caspase activation mediated courtesy of 
a mechanism reliant upon haem and cellular iron. In spite of these shared characteristics, it 
is apparent that there are variations in the manner by which the artemisinin-based and 
novel drug classes interact with cells. Onset of cytotoxicity is observed to occur rapidly in 
the synthetic compounds, with substantial impact upon the viability of cells evident within 
2 h of treatment. This contrasts greatly to the more delayed response to artesunate 
administration, by which significant levels of cell death are not noted until after 
approximately 12 h incubation. LC-MS studies have suggested key differences in the 
chemistry underpinning activity between classes, with the absence of observed structural 
degradation in the novel compounds, even following incubation periods at which cytotoxic 
effects are pronounced, contrasting with the well-characterised time-dependent and dose-
dependent fragmentation of PFDHA reported in other sources. Owing to the necessity of 
the endoperoxide bridge for pharmacological and toxicological functions, it has been 
suggested that bioactivation in these agents must proceed along an alternative route. 
 It is noted that, whilst cytotoxicity is dependent upon the presence of haem and cellular 
iron, sensitivity of FBEG-100 and RKA-182 to the effects of iron and haem content 
modulation differ relative to that of artesunate. Whilst imparting cytoprotective effects 
across all classes, haem synthesis inhibitors and free iron chelators were shown to exert a 
more pronounced effect in diminishing the toxicity of the artemisinin derivative. 
Alternatively, it was observed that iron loading through holotransferrin instead served to 
preferentially enhance the impact of the novel compounds. Findings such as this suggest 
that a differential in sensitivity towards iron concentration exists between the synthetic and 
semi-synthetic varieties, with the former possessing greater toxicity when levels are 
elevated to supra-physiological, and the latter being more active when content is closer to 
basal quantities. It is hypothesised that this relationship might offer explanation for the 
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greater toxicity of artesunate and DHA across cell lines studied, whilst simultaneously 
enabling rationalisation for the increased antiparasitic effects reported in FBEG-100 and 
RKA-182.  
Owing to their otherwise identical structures, explanation for the variation between the 
cytotoxic profiles of the 1,2,4,5-tetraoxane RKA-182 and the 1,2,4-trioxolane FBEG-100 
must be sought through reference to the properties of their respective pharmacophores. 
RKA-182 is witnessed to exhibit four-fold greater activity relative to its trioxolane 
counterpart within HL-60 cells (Table 5.1.), whilst simultaneously demonstrating greater 
mitochondrial liability (Fig. 5.2.) and enhanced stimulation of apoptotic death (Fig. 5.3.). It 
has been demonstrated previously, through studies assessing the activities of related 
compounds from both classes, that the presence of the four-oxygen 1,2,4,5-tetraoxane 
functional group imparts greater stability to the molecule compared to that which arises 
from incorporation of the three-oxygen 1,2,4-trioxolane equivalent (Ellis et al., 2008). As a 
consequence, it is noted that degradation of such compounds occurs at a greatly reduced 
rate, with lengthened half-lives and increased antimalarial potency following concurrently 
(Opsenica et al., 2009).  It is feasible that the greater toxicity of RKA-182 relative to FBEG-
100 might arise as a consequence its comparative resistance to decomposition. Accordingly, 
it has been demonstrated that the rate of recovery for the tetraoxane following 24 h 
incubation in cell-free media is greater than that of the trioxolane analogue (Copple et al., 
2012). In spite of the initial promise attributed to RKA-182 as a consequence of its 
performance in vitro, further progression towards clinical use was halted owing to the 
discovery of its potential to induce the acute onset of neurotoxicity upon administration in 
dogs. 
In light of the unfavourable activity of RKA-182 in vivo, the development of novel 1,2,4,5-
tetraoxane derivatives has proceeded. Attempts to improve metabolic stability have led to 
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the testing of a new generation of compounds which dispense with the requirement for 
incorporation of the potentially labile amide side linkage (Marti et al., 2011). One such 
candidate, E-209 was tested for its toxicity across HL-60, Hep G2 and HeLa cells (Table 5.2. 
and 5.5). As anticipated owing to the enhanced general sensitivity of the cells towards 
endoperoxide activity, the effects of the drug were most pronounced within the HL-60 line. 
It is generally believed that this greater susceptibility derives from the presence of elevated 
intracellular iron content (Mercer et al., 2011). The low micromolar activity of the drug 
observed within this system is comparable to that witnessed in RKA-182 and DHA. Similarly, 
a rapid onset of cell death in common with that witnessed upon treatment with FBEG-100 
and RKA-182 is shown to occur, suggesting that such activity is a feature shared across 
these synthetic classes (Copple et al., 2012). Interestingly, the cytotoxicity within Hep G2 
cells was witnessed to be more pronounced than that noted within the HeLa variety. This 
trend stands in contrast to the pattern observed across the studies reported in Section 
2.3.1., Chapter 2, where treatment with artesunate had greater impact upon the viability of 
the HeLa line. Whereas previous studies have identified correlations between the sensitivity 
of cancer cells towards artemisinin derivatives and their expression of genes involved in the 
regulation of areas such as cell cycle progression, antioxidant response, iron uptake and the 
performance of apoptosis, the scope of these assessments has included neither the novel 
synthetic compounds nor the lines in question. It is feasible, however, that relative 
susceptibility is dictated likewise through the unique pattern of gene expression 
characteristic to each cell type. The disparity in response between classes could arise as a 
product of suggested mechanistic variation between their modes of activity.  
The potential for clinical utility in E-209, and indeed all other novel endoperoxides 
compounds, cannot be reliably ascertained until both their antiparasitic activity and toxicity 
have been assessed further across more representative systems in vivo. As has been 
witnessed in the instance of RKA-182, reduced apparent toxicity relative to the artemisinin 
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derivatives in vitro does not necessarily translate to an improved safety profile within more 
complex settings. Nevertheless, the promise of these classes remains owing to their strong 
antiparasitic properties, and to the relative ease with which novel agents can be developed 
and functionalised.  
It was determined that conjugation of polypyrrole units to the DHA moiety did not have the 
effect of increasing cytotoxicity to levels exceeding that of the parent compound within HL-
60 cells. Dipyrrole LLP-271 and tripyrrole LLP-272 exhibited cell killing ability which was 
reduced five-fold and forty-fold respectively relative to the artemisinin derivative (Table 
5.3.). Cytotoxic effects were mediated through the common artemisinin mechanism of 
mitochondrial dysfunction (Fig. 5.4.) preceding apoptosis (Fig. 5.5.), and not, as the 
inactivity of (24) attests, through the specific actions of the polypyrrole unit. Investigation 
of the activities of the dipyrrole hybrids NET-5 and NET-7, and of the tripyrrole compounds 
NET-4 and NET-6, outlined that the attachment of the groups produced a similar diminution 
in the ability to induce toxic effects (Table 5.4.).  
Assessment of the properties of the NET series of conjugates formed one aspect of a larger 
study which aimed to ascertain the cytotoxic potential and mechanistic profiles of a 
broader range of related compounds (La Pensee et al., 2013). Rationale for the 
incorporation of the polypyrrole units was derived from the ability of these structures, as a 
consequence of their affinity for DNA conjugation, to impart the localisation of pyrrole-
amidine antibiotic agents, such as netropsin and distamycin, towards the nucleus. It is 
theorised that the presence of such groups would enhance the targeting of the artemisinin 
moiety towards DNA, hence aiding in the induction of fragmentation and the subsequent 
emergence of cell death. It was in fact revealed that the majority of the other compounds 
examined, in common with those assessed as part of the work presented within this 
chapter, exhibited reduced cytotoxicity relative to unmodified DHA. A single dipyrrole 
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compound, NET-2 (25), was found to exhibit preferable activity across both the HL-60 and 
intestinal HT-29 cell lines in which such effects were studied. The variability in the response 
imparted by the presence of the intercalators has been rationalised in terms of their 
structures, with the interplay between apparent binding affinity and the relevance of steric 
effects believed to be determinant of their ultimate impact upon the fate of cells. It is 
hypothesised that steric hindrance of the endoperoxide bridge, arising from occlusion of 
the group courtesy of the bulky polypyrrole chain, might inhibit drug bioactivation and 
hence reduce efficacy. It has thus been posited that the improved activity of NET-2 owes 
itself both to the apparent flexibility of the intercalator unit present, and to its proposed 
affinity towards the binding of DNA as inferred through molecular modelling studies. 
 
 
Further in vivo and clinical study would be required before the suitability of these 
compounds as anticancer agents could be adequately determined. Evidence for the anti-
tumour efficacy of traditional artemisinin derivatives in a clinical setting has been obtained 
in a small number of studies (Ho et al., 2014). Owing to the as yet limited scope of these 
assessments, it remains unclear precisely how performance against cell lines in vitro 
translates into a direct therapeutic utility. Artemisinin dimers have been shown to 
demonstrate improved activity relative to DHA in the reduction of breast tumour size in 
rats, in a manner which correlates with their cytotoxicity in vitro (Singh et al., 2011). Again, 
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studies would have to be extended to include a more diverse array of drugs and systems 
before the universality of such a relationship could be established.  
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Chapter Six 
 
 
Final Discussion 
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The capacity for endoperoxide antimalarial compounds to impart cytotoxic effects within 
mammalian systems is attested across an extensive body of literature. Studies have 
demonstrated that drugs belonging to both the semi-synthetic artemisinin-derived and 
rationally-designed synthetic drug classes possess an ability to stimulate the emergence of 
developmental and neurological toxicity across within animal models, whilst further 
initiating death in sensitive, proliferating cell lines (Crespo-Ortiz et al., 2012; Mercer et al., 
2010; O'Neill et al., 2010b). Although the evidence for the direct clinical relevance of these 
outcomes remains inconclusive, their persistence has prompted the WHO to recommend 
the contraindication of all routinely employed artemisinin-based therapies for use in 
mothers during the opening trimester of pregnancy (WHO, 2006).  
Prior mechanistic examinations into the routes through which these compounds induce cell 
death have elucidated aspects related both to the deficiencies in physiological functioning 
arising as a consequence of their administration, and to the chemical characteristics which 
underpin the emergence of such events (Lai et al., 2013; Mercer et al., 2011; O'Neill et al., 
2004). It is thus generally theorised that the activity of the drugs is derived from the Fe(II)-
dependent reduction of the endoperoxide bridge moiety, culminating in the formation of 
reactive carbon-centred radical species which proceed to impart structural modifications 
upon cellular proteins (Denisov et al., 2010; Mercer et al., 2007). Whilst the identity of 
relevant sites which may potentially function as targets for these products remain 
unknown, it has been demonstrated across studies performed in immortalised cancer lines 
that the generation of ROS and the initiation of mitochondrial dysfunction occur both as 
early phases in a cell death pathway which terminates with the stimulation of intrinsic 
apoptosis (Efferth et al., 2007; Mercer et al., 2011). Haem-iron has been associated with 
possessing an important role in the progression of this sequence, thus implicating proteins 
containing such units in functioning both as points of drug bioactivation and as targets for 
activity. 
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Whilst it is strongly implied that oxidative stress and mitochondrial dysfunction act as key 
stages in the route through which the endoperoxide compounds convey their cytotoxic 
impact, comparatively little has been determined regarding the mechanisms through which 
these occurrences arise following drug treatment, and of the relevance which they 
ultimately possess towards the progression of cell death. It has thus been the intention of 
the studies performed within this thesis to examine in greater detail the influence imparted 
by artemisinin derivatives upon the functioning of the mitochondrion, giving focus both to 
the characteristics of the deficits induced, and to the factors responsible for mediating their 
emergence. Accordingly, investigation into drug impact upon cellular bioenergetics has 
been supplemented by assessment into the importance of oxidative stress in affecting the 
progression of cytotoxicity. Accompanying examinations have focused upon assessing the 
potential capacity of the compounds to behave as direct phospholipid oxidants, and 
furthermore upon the activity profiles of novel, experimental derivatives.  
Primary examination into the capacity of the compounds to exert mitochondrial liability 
was performed utilising a method adapted from that developed by Marroquin et al. 
(Marroquin et al., 2007). The culturing of cancer cells in galactose-supplemented medium 
devoid of glucose has the effect of promoting oxidative ATP generation within the 
organelle, halting glycolysis and imparting cell sensitisation towards the effects of 
mitochondrially toxic agents (Dykens et al., 2008b). Whilst no significant variation in 
susceptibility towards artesunate was apparent between glucose and galactose-cultured 
Hep G2 lines following 24, 48 and 72 h treatment, substantial differences within the more 
sensitive HeLa cells were apparent upon identical periods of administration. The magnitude 
of this disparity is such that it is rational to suggest, in accordance with literature reports 
relating to alternative mitochondrially-active compounds, that the artemisinin derivatives 
exert toxicity through means which are at least partially reliant upon disruption to the 
functioning of the organelle (Swiss et al., 2013). Further assessment indicated that 
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decreases in ATP content within this line preceded falls in cell viability, providing evidence 
that interference with the machinery of oxidative phosphorylation forms an early stage in 
the pathway through which death is stimulated. A more thorough analysis of bioenergetic 
function, obtained through employment of the Seahorse XF analyser, revealed that the 
compound does indeed possess the ability to exert deleterious effects upon the efficiency 
of oxidative coupling, whilst simultaneously reducing the reserve respiratory capacity and 
enhancing reliance upon glycolytic ATP synthesis.  
In elucidating the factors associated with mediating artemisinin-induced impact upon the 
health of the mitochondrion, it was necessary to examine the contributory roles played by 
ROS and cellular Fe(II) in the emergence of any observed functional deficiencies. Reduction 
in artesunate-stimulated whole-cell and mitochondrial ROS levels through co-
administration of the mitochondrially-localised antioxidant tiron had the effect of 
substantially reducing the bearing of the drug upon the viability of HeLa cells, whilst 
simultaneously restoring bioenergetic capacity assayed through the Seahorse stress test. 
Such outcomes strongly indicate that oxidative damage to the mitochondrion forms a 
central facet of the respiratory dysfunction which is ultimately causative of cell death. 
Following on from these findings, the utilisation of the Fe(II) chelator DFO permitted 
mechanistic assessment of the influence of free iron upon the progression of cytotoxicity. 
Reduction in the content of the unbound metal was shown to produce partial diminution in 
the extent of PFDHA bioactivation, whilst further reducing artesunate-stimulated oxidative 
stress both across the whole-cell and within mitochondrion, imparting cytoprotective effect 
and precluding the onset of mitochondrial respiratory injury. It is apparent that the 
consequences of Fe(II) chelation regarding artemisinin toxicity are multifaceted, with the 
metal implicated in possessing contributions towards both the propagation of drug-induced 
oxidative stress and also in the potential formation of active radical species. Examinations 
performed within ρ0 HeLa line served to indicate that initial generation of ROS occurs 
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through mechanisms independent of the electron transport chain. Accordingly, 
investigation into the impact of the drug upon the complexes constituting this system 
revealed that it held only minimal bearing. Further attempts to establish the potential roles 
of the non-mitochondrial ROS-producing enzymes xanthine oxidase, NADPH oxidase, 
cytochrome c and COX in the routes towards oxidative stress arising from artesunate 
treatment produced results suggesting that inhibition of neither enzyme imparts 
substantial influence towards cell survival.  
Based upon the sum of this evidence, it would appear rational to hypothesise that damage 
towards the respiratory functioning of the mitochondrion, arising through means 
dependent upon the emergence of oxidative stress, acts as an essential stage in the 
pathway along which the endoperoxide antimalarials exert toxicity within cancer cells. It is 
apparent, therefore, that delineation of the source by which ROS formation is stimulated – 
be it as a function of carbon-centred radical formation, Fenton chemistry, lipid peroxidation 
or specific enzyme inhibition –   must constitute a central facet of any attempt to construct 
a thorough mechanistic understanding of the route through which these cytotoxic effects 
materialise. It is interesting to note that, whilst both prevalence of mitochondrial ROS and 
the susceptibility of cells towards the cytotoxic impact of artesunate are diminished within 
the ρ0 HeLa line, formation of superoxide continues to proceed in significant quantities. 
Such an outcome would suggest that, although a functioning electron transport chain holds 
a contributory role towards the enhancement of oxidative stress, its presence does not 
stand as a requirement for primary initiation. Investigations assessing the impact of 
artesunate upon the activity of the units constituting the electron transport chain within 
isolated mitochondria reveal that artesunate possesses no capacity to impart functional 
defects within the primary superoxide-generating sites at complex I and complex III. It is 
hence feasible that the presence of oxidative stress within the organelle might be 
attributable to damage sustained towards the body as a consequence ROS generated at 
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alternative sites within the cell. ROS-induced ROS release is a phenomenon whereby 
mitochondria subject to oxidative damage are liable to exhibit greatly enhanced ROS 
production, accompanied by permeability transition and collapse of membrane potential 
(Zorov et al., 2014). The release of ROS from impacted mitochondria may serve to initiate 
damage within neighbouring organelles, hence perpetuating a chain sequence capable of 
propagating injury throughout the cell. It follows naturally that the dysfunction of the 
respiratory chain, the oxidative degradation of phospholipids such as cardiolipin and the 
initiation of apoptotic death would form the consequences of this series of events. 
The possibility that oxidative stress stimuli located external to the electron transport chain 
might be of central importance within mediation of the mechanisms through which 
artemisinin derivatives initiate cytotoxic impact prompts consideration into the significance 
of alternative pathways upon which the drugs may have potential to exert influence. 
Outcomes of the assessments performed within this body of work indicate strongly that 
Fe(II) exerts substantial influence upon the progression of drug-induced deficiencies in 
cellular functioning. Chelation of free iron is associated with imparting reduction in levels of 
oxidative stress, whilst simultaneously exhibiting capacity to inhibit bioactivation of the 
endoperoxide bridge. Viewed from the perspective of the carbon-centred radical 
hypothesis, it is plausible to suggest that the prevention of iron activation leads to a 
curtailment in the generation of ROS as a function of the capacity to promote reduction in 
the formation of the reactive radical fragments postulated as having a central role within 
the induction of cellular injury (Mercer et al., 2011). The inability of the chelator to 
stimulate complete cessation of bioactivation would, however, appear to indicate that its 
protective influence extends beyond such a faculty. Accordingly, it follows that capacity to 
stimulate abrogation of oxidative stress and reduction in incidence of cell death is 
associated with the facility to bind labile iron. Thus, it can be reliably concluded that the 
contribution of the metal towards the procession of cytotoxicity is multifactorial.  
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Evidence has suggested that interaction with the lysosomal bodies, notable for possessing 
elevated content of labile iron, might potentially function as an early mediator both of 
mitochondrial and greater cellular response towards artemisinin administration (Hamacher-
Brady et al., 2011). Owing to the liability of the unbound metal towards participation in 
Fenton chemistry reactions, the often excessive concentrations of Fe(II) contained within 
the lysosome grant it particular relevance as a site for ROS formation (Kurz et al., 2008; 
Thomas et al., 2009). Associated closely with the emergence of oxidative stress within these 
bodies is the phenomenon of lysosomal membrane depolarisation – a process akin to that 
witnessed within the mitochondrion upon the induction of internal stress – whereby 
permeabilisation of the outer membrane culminates in the cytosolic release of cathepsins 
and related death-promoting factors (Aits et al., 2013). It is these which progress to 
stimulate depolarisation of the mitochondrion, promoting release of pro-apoptotic 
initiators ahead of subsequent cell termination. The impact of lysosomal dysfunction upon 
the progression of artemisinin-stimulated toxicity has been examined in detail (Hamacher-
Brady et al., 2011). In line with the outcomes of the assays reported within this thesis, 
depletion of free iron content was associated with an abrogation in drug impact upon ROS 
formation and subsequent cell survival. It is therefore rational to postulate that the capacity 
of the artemisinin derivatives to exert initial injury to the mitochondrion is at least partially 
upon reliant upon the influence of lysosomally-stimulated oxidative stress and resultant 
programmed cell death. A scheme outlining a hypothesised pathway along which 
artesunate-stimulated cell death might proceed is displayed in Figure 6.1. 
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Figure 6.1. Representation of the proposed route towards the induction of cell death 
through ROS-stimulated mitochondrial bioenergetic dysfunction. 
 
A further factor related to lysosomal functioning which may possess relevance towards the 
mechanism of artemisinin-induced ROS generation derives from the interplay which exists 
between iron pools located both within those bodies and within mitochondria. The motility 
of Fe(II) towards the mitochondrion is acknowledged to arise subsequent to the onset of 
damage to lysosome structural integrity (Uchiyama et al., 2008). It is plausible, therefore, 
that this loading of the organelle with the unbound metal might form a key determinant in 
the progression of response to drug treatment. Mechanisms through which such impact 
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might be mediated may be postulated as being related both to the increased potential for 
the body to operate as a site for generation of ROS, and furthermore to the enhancement 
in its capacity to serve as a location for drug bioactivation (Mercer et al., 2011; Thomas et 
al., 2009). Studies have indicated that bafilomycin and paracetamol-induced mitochondrial 
Fe(II) uptake might be inhibited through the co-administration of free iron chelators, 
abrogating ROS formation and imparting cytoprotective effect (Hung et al., 2013; Kon et al., 
2010). As such, so that it may be possible to discern the relevance of such a connection, it 
would be beneficial to monitor, in a similar manner, the occurrence of any redistribution of 
Fe(II) content related to artemisinin dosing. Repetition of the assessments performed 
monitoring the impact of mitochondrial iron transporter mitoferrin-2 knockdown upon the 
progression of cell response to the drugs would be greatly beneficial towards this end. 
Whilst iron-stimulated pathways towards the formation of ROS might appear to be of 
primary importance as regards to the activity of the drugs within cancer cells, it remains 
further plausible that enhancements in oxidative stress may have origins in alternative 
interactions occurring directly between the endoperoxide bridge and other cellular 
substituents. It has been posited, owing to outcomes obtained across a series of biomimetic 
examinations, that the artemisinin derivatives may, as a function of the chemistry of the 
endoperoxide bridge, possess capacity to behave as direct oxidants of reduced cofactors 
crucial for the maintenance of redox homeostasis (Haynes et al., 2012). It is held, 
specifically, that oxidation of FADH2, a molecule essential within the pathway mediating the 
generation of reduced glutathione equivalents, impairs the facility for cells to neutralise the 
emergence of ROS, and hence contributes towards the observed growth in the incidence of 
oxidative stress (Haynes et al., 2011). Such a sequence of reactions remains largely 
conserved within mammalian environments, ensuring the theoretical translatability of this 
hypothesised mode of action between pharmacological and toxicological settings. FAD, and 
related units, are identified as possessing roles within electron transport across a diverse 
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range of systems – including those related to the oxidative generation of ATP (Huttemann 
et al., 2008). It is feasible, therefore, that if such an oxidant capacity for the endoperoxide 
compounds holds relevance within living organisms, that the impact wrought upon cellular 
bioenergetic function could be substantial. The outcomes of the examinations performed 
within this body of work – particularly those detailing the importance of oxidative stress 
and mitochondrial respiratory dysfunction towards the progression of toxicity – are 
explicable in terms of a cofactor oxidation pathway. Nevertheless, despite the promise of 
this model, the paucity of evidence for its applicability outside of biomimetic chemical 
settings ensures that the nature of its clinical relevance remains undetermined. Extension 
of the scope of examination to include investigation into its presence across in vitro and in 
vivo cellular and parasitic environments shall constitute an essential stage in the 
establishment of its wider bearing, although owing to generality of the cofactors within the 
regulation of a varied selection of redox processes, elucidation of the precise pathways 
impacted as a consequence of drug treatment may prove experimentally challenging.  
Investigation into the capacity for endoperoxide compounds to function as direct oxidants 
of lipids focused upon assessing their influence upon the integrity of the mitochondrial 
phospholipid cardiolipin.  Studies were based around examining the impact of artesunate 
upon cardiolipin oxidation in HL-60, HeLa and HeLa ρ0 cells whilst in the presence of the 
cytochrome c-cardiolipin peroxidase inhibitor, TPP-IOA. Outcomes indicated that this 
inhibitor produced influences upon the prevalence of drug-stimulated oxidised cardiolipin, 
which were variable dependent upon the nature of the cell line examined, and also upon 
the method employed in the quantification of the parameter. Accordingly, owing to the 
inability of the compound to induce complete cessation in oxidation of the phospholipid, 
reliable conclusions as to the mechanism through which the artemisinin derivatives exert 
such effects cannot be drawn from the evidence accrued. It cannot be ruled out, therefore, 
that the lipid peroxidation emerges merely as factor secondary to the generalised increases 
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in ROS stimulated by the actions of the drugs. It is interesting to note that extent of 
oxidation is observed to be substantial across both the HeLa and the HeLa ρ0 lines. The 
apparent lack of dependence upon the electron transport chain within the mediation of 
such an effect acquires further significance when viewed alongside the data outlining the 
variation in ROS formation evident between the two cell varieties. It is feasible that this 
observation might function as indirect evidence supporting the relevance of a ROS-
independent pathway towards peroxidation emergence, and that this drug class might 
possess a role as a direct oxidant of the phospholipid. 
A primary aim of the research performed within this thesis has been to elucidate the 
mechanisms through which endoperoxide antimalarials impart cell death in mammalian 
systems, in order that a clearer understanding of the interactions underpinning drug 
activity might ultimately inform the development both of novel synthetic compounds which 
display cleaner safety profiles, and also of hybrid artemisinin derivatives which exhibit 
clinical utility as anticancer agents.  Assessments into the cytotoxic profiles of novel 
experimental synthetic antimalarial 1,2,4-trioxoloane and 1,2,3,5-tetraoxane compounds 
revealed apparent mechanistic commonality with the activities of the artemisinin 
derivatives across cancer cell lines, with similarities evident within both their capacity to 
impart mitochondrial dysfunction, and also within their ability to stimulate the emergence 
of apoptotic death. Semi-synthetic artemisinin-polypyrolle conjugates, functionalised with 
the intent of enhancing cytotoxic capacity for potential anti-cancer utility, were 
furthermore shown to exhibit a similar toxic capacity to that of their parent compound. 
Additional investigation has demonstrated that drugs belonging to the synthetic 1,2,4-
trioxoloane and 1,2,3,5-tetraoxane classes exert a series of developmental defects in vivo 
which closely mimic those reported to occur alongside the artemisinin agents (Copple et al., 
2012). The precise mechanism through which the emergence of mitochondrial dysfunction, 
as noted within the in vitro cancer studies, relates to the pattern of abnormalities 
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characteristic over embryonic maturity – namely the depletion of immature erythrocyte 
stock and the subsequent impacting of haematopoiesis, the onset of anaemia and the 
emergence of structural deficiencies within cardiovascular and skeletal growth – awaits 
definitive establishment (Efferth et al., 2010). It is pertinent to note that, at such a stage 
within their development, extrusion of the mitochondrial body from the growing 
erythrocytic cell has yet to occur (Mortensen et al., 2010). Studies have demonstrated that 
DHA possesses the capacity to produce significant anti-angiogenic impact, stimulating 
downregulation in VEGF receptor expression and furthermore promoting the arrest of 
growth in vascular endothelial cell lines (Chen et al., 2003; D'Alessandro et al., 2007). Such 
effects are witnessed to occur alongside an increased formation of ROS, and are further 
associated with death arising through apoptotic routes. Interestingly, it has been shown 
that the sensitivity of these systems towards the toxicity of the artemisinin derivatives may 
be enhanced under conditions of hypoxia (D'Alessandro et al., 2011). Whilst the 
mechanistic rational for this observation remains to be elucidated, it is notable that early 
embryonic development, particularly that which occurs during the relatively narrow 
window at which susceptibility towards the effects of the drugs is at its most heightened, 
proceeds under conditions of reduced oxygen tension (Dunwoodie, 2009). It is therefore 
rational to posit the existence of a relationship between the hypoxic nature of the 
environment present, the ensuing enhanced potency of artemisinin-stimulated toxicity, and 
the genesis of developmental dysfunction.  
Interestingly, evidence has indicated that, unlike their artemisinin-derived counterparts, the 
activity of the examined candidates FBEG-100 and RKA-182 does not bear correlation with 
extent of structural decomposition. It is further observed that the onset of impact towards 
cell viability imparted by drugs belonging to the novel classes proceeds at a rate which 
displays relative acceleration (Copple et al., 2012). Concordant discrepancies relating to 
pharmacokinetic parameters have been observed within related compounds, with 1,2,4-
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trioxoloane and 1,2,3,5-tetraoxane agents typically exhibiting enhanced elimination half-
lives in comparison with the traditional treatments (Wang et al., 2013). It would be 
beneficial in future study to examine in greater detail the origins of such variation, in order 
that further insight into relationships underpinning the functioning of all classes might be 
attained. It has been posited that the independence of the cellular toxicity of FBEG-100 and 
RKA-182 upon chemical degradation might stand in support of the aforementioned direct 
cofactor oxidation model (Haynes et al., 2012).  
Whilst the experimental outcomes obtained from the research performed within this body 
of work have attended to expand existing knowledge of the mechanistic routes through 
which endoperoxide compounds, both artemisinin-derived and synthetic, proceed to 
induce cellular dysfunction and toxicity, there remains substantial scope for further 
investigation into the nature of the interactions which underpin such observations. The 
practical applications of such improved understanding within the development of novel 
drug analogues and safer, more effective therapeutic routines are areas additionally in 
need of development. Although the evidence provided serves strongly to indicate the 
presence of a non-mitochondrial, iron-dependent source for the ROS ultimately causative 
of cell death, identification of the cellular substituents central to their emergence, and 
definition of the precise influence of endoperoxide chemistry upon the progression of 
response, remain both incomplete.  
Recognition of the importance of the lysosome within the initiation of oxidative stress 
occurring subsequent to the administration of these drugs has developed as a consequence 
of recent research. Despite such advancements, the process of characterising specific 
properties related to the impacts exerted upon the activity of constituent networks within 
these organelles remains grounded at an early phase. It would accordingly be beneficial to 
examine the factors underlying their sensitivity to the actions of the endoperoxides, with 
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focus given to aspects influencing the uptake and distribution of the compounds inside the 
bodies. Whilst it is plausible that their status as sites for iron accumulation might form the 
solitary factor responsible for their apparent roles in the stimulation of ROS generation, 
little has yet been ascertained regarding potential capacity of the drug to impart direct 
dysfunction or activation to proteins regulating pathways mediated within. As such, a 
further assessment into the facility of the artemisinin derivatives to induce alterations 
within processes such as iron motility, acidification, cathepsin-dependent apoptosis and 
membrane structural integrity would enable a more thorough understanding to be 
attained. 
Appreciation of the causative factors underlying the initiation of artemisinin-induced 
cytotoxicity would be incomplete without thorough distinction of the chemical mechanisms 
through which the activity of the compounds is mediated. Despite the existence of 
numerous plausible theories regarding the nature of the reactivity of the endoperoxide 
bridge, and the consequences which these ultimately possess towards the onset and 
progression of defective cell functioning, the identity of the definitive pathways relating 
drug activation to pharmacological and toxicological outcome has yet to be conclusively 
established. Observations that endoperoxide activity retains dependence upon interaction 
with iron sources, and that ROS generation is an essential feature for biological activity, 
remain explicable in terms of several common postulates. Accordingly, additional research 
would be required before the applicability of free radical and direct oxidant models could 
be applied with certainty to draw a complete image of the route through which cytotoxicity 
proceeds.  
In the functionalisation of endoperoxide hybrids for the enhancement of anticancer 
activity, it would appear that consideration of the outcomes obtained within this thesis 
might potentially prove beneficial towards the development of compounds displaying 
209 
 
enhanced activity over pre-existing artemisinin derivatives. Should the lysosomal action of 
the drugs be essential in mediating the progression of cytotoxicity, it is rational to theorise 
that targeting of the agents towards that body might enable a greater cell killing capacity. 
The influence of the lysosome upon the mediation of programmed cell death has led to its 
identification in the holding of roles contributory towards the abnormalities in cellular 
function characteristic of cancer (Kirkegaard et al., 2009). Accordingly, it has been 
suggested that the deployment of drugs exhibiting  lysosomal liability might constitute a 
focus for the development of future anticancer treatment (Fehrenbacher et al., 2005; Saftig 
et al., 2013). It is noted that molecules displaying a particular affinity towards accumulation 
within these bodies typically possess cationic amphiphilic properties, hence enabling 
sequestration as a function of ion trapping imparted due to the acidic nature of the 
environment therein. Owing to concerns regarding toxicity related to the lack of specificity 
of such compounds towards cancerous cells – and in light of further evidence detailing 
potential localisation issues related to acidification abnormalities in the lysosomes of 
selected cancer models – it is apparent that further investigation would be required before 
the functionalisation of artemisinin derivatives to display such characteristics would be 
feasible in regards to the enhancement of therapeutic benefit (Ndolo et al., 2012). Several 
strategies for the localisation of compounds towards the lysosome have instead been 
posited based upon the putative efficacy of experimental polymeric conjugate delivery 
systems (Binauld et al., 2013; Chiang et al., 2014). As a consequence of the relative novelty 
of such technology, it is yet not possible to assess with reliability its potential relevance 
towards improvement of artemisinin-based anticancer treatment outcome. 
By way of conclusion, it can be stated that the studies performed within this thesis have 
served to elucidate the essential contribution of mitochondrial dysfunction towards the 
progression of cytotoxicity induced through the endoperoxide class of antimalarial drugs. 
Defective respiratory and bioenergetic operation, emerging subsequent to damage 
210 
 
imparted through Fe(II)-associated oxidative stress, are identified as primary mechanisms 
through which cell death is stimulated. Consideration of these outcomes facilitates the 
identification of further pathways which might potentially be of relevance in informing 
understanding of the activity associated with the compounds. It is intended the 
establishment of such relationships shall enable eventual determination of the factors 
associated with the mediation of toxic impact, so that the development of safer treatment 
regimens might proceed with greater theoretical grounding. 
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